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Abstract 
Oncogenic activation of the Ras-ERK pathway is frequently observed in human cancers. 
Dual-specificity MAP kinase phosphatases (DUSPs or MKPs) are important negative 
regulators of this pathway and could therefore play an important role in modulating the 
oncogenic potential of signalling. DUSP5 and DUSP6/MKP-3 are ERK-specific MKPs, which 
are classical negative feedback regulators of pathway activity, but are differentially 
localised, with DUSP5 found in the nucleus and DUSP6/MKP-3 in the cytoplasm. However, 
to date their potential roles in modulating the oncogenic potential of the Ras-ERK 
pathway is unclear. This project aimed to use a range of biochemical and genetic 
techniques in order to determine whether these enzymes play functional roles in 
modulating the spatiotemporal regulation of ERK signalling and, in particular, to use 
murine cancer models to explore the effects of MKP deletion on the initiation and/or 
progression of mutant Ras-induced tumours.  
Here we show that DUSP5 is an essential regulator of nuclear ERK activity and gene 
expression in response to acute Ras/ERK pathway activation and this work provides a 
mechanistic underpinning for our observation that DUSP5 has a tumour suppressor 
function in the murine model of DMBA/TPA-induced skin carcinogenesis. We also show 
that the endogenous expression of mutant KRasG12D in murine fibroblasts induces the 
expression of both DUSP5 and DUSP6/MKP-3, suggesting these proteins are involved in 
the negative feedback response, which constrains ERK activity following constitutive 
pathway activation. Finally, using mouse models of KRasG12D-driven pancreatic cancer, we 
demonstrate that the deletion of either DUSP5 or DUSP6/MKP-3 accelerates the initiation 
of acinar-to-ductal metaplasia (ADM) and pancreatic intra-epithelial neoplasia (PanINs). 
However, with respect to the development of invasive pancreatic ductal adenocarcinoma 
(PDAC), loss of DUSP6/MKP-3 seems a more potent driver. Our data confirm that these 
MKPs do play an important role in modulating the initiation and development of Ras-
induced tumours in this clinically relevant murine cancer model. The variable penetrance 
of the pancreatic phenotypes observed following the loss of either DUSP5 or DUSP6/MKP-
3 could reflect either the differing ability of these MKPs to regulate the strength of ERK 
activity or differential effects on the nuclear and cytoplasmic fractions of ERK 
respectively.  
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Chapter 1 Introduction 
1.1 Signal transduction and protein phosphorylation 
To enable optimal survival and functional activity a cell needs to be able to adapt to 
changes in its external environment or intracellular conditions. A cells ability to adapt to 
changing conditions depends on its capacity to transduce signals from such stimuli to 
initiate an appropriate physiological response. As well as enabling individual cells to 
respond to their environment, such communication is essential to enable cells to act in 
unison to form functioning tissues as part of multicellular organisms. 
Cell surface receptors enable cells to detect changes in their external environment. These 
include transmembrane proteins such as receptor tyrosine kinases (RTKs), G-protein 
coupled receptors (GPCRs) or integrin receptors, which are activated by the binding of 
extracellular ligands initiating an intracellular signalling cascade to alter cellular activity or 
cell fate. Changes in intracellular homeostasis, such as nutrient shortages, the 
accumulation of reactive oxygen species (ROS) or the presence of deoxyribonucleic acid 
(DNA) damage can be detected by specialised intracellular receptors leading to signal 
transduction to initiate a response in order to oppose these perturbations or stresses. The 
cellular response to these signals or stresses can be mediated by processes, which 
operate at both the gene and protein level, including: changes in gene expression, rates 
of protein degradation and alterations in the activity or subcellular localisation of 
proteins. 
In most cases signal transduction involves the stepwise amplification of a small initial 
signal, to generate a response of a greater magnitude that is able to cause significant 
changes in cellular activity. This occurs by the signalling molecule at each step of the 
signalling cascade activating more than one molecule of its downstream target, thereby 
gradually building up the signal magnitude to ensure a robust response. Signal 
transduction is predominantly enabled through post-translational modifications of the 
amino acid side-chains of signalling proteins and effectors. Post-translational 
modifications can alter the structural conformation and thus enzymatic activity of a 
protein, block or enable the binding of proteins to their substrates or target proteins for 
degradation. These modifications include acetylation, nitrosylation, O-GlcNAcylation, 
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SUMOylation, ubiquitination, phosphorylation and others. This project is focused on the 
activity of signalling pathways, which are driven by sequential phosphorylation and 
dephosphorylation. 
Protein phosphorylation is a rapid and reversible process, making it an ideal molecular 
switch to enable signal transduction (Fig. 1.1). Protein kinases are enzymes that catalyse 
the covalent addition of a phosphate group, from adenosine triphosphate (ATP), to a free 
hydroxyl group on the side chain of an amino acid residue within the target protein. This 
is an anabolic process requiring energy from the breakdown of ATP. Proteins can be 
phosphorylated on nine amino acids: tyrosine, serine, threonine, cysteine, arginine, 
lysine, aspartate, glutamate and histidine (Manning et al., 2002). However, serine, 
threonine and tyrosine phosphorylation are predominant in eukaryotic cells, giving rise to 
the two major classes of protein kinases named after the amino acid residues they target 
for phosphorylation, the serine/threonine or tyrosine protein kinases. Most protein 
kinases were first described as putative amino acid sequences deduced from the coding 
nucleotide sequences of cloned cDNA’s rather than the traditional biochemical approach 
of enzyme assays using purified protein (Hanks et al., 1988). These two families were 
initially thought to be mutually exclusive, however a group of protein kinases have been 
discovered that would have been classified via their primary structure as serine/threonine 
kinases but are actually able to phosphorylate tyrosine residues (Lindberg et al., 1992). 
Furthermore, a number of kinases have been shown to be dual-specificity protein kinases, 
that are capable of phosphorylating both tyrosine and serine/threonine residues, thus 
constituting a further subfamily of protein kinases (Lindberg et al., 1992). 
Phosphorylation can regulate protein function and cell signalling by two mechanisms. The 
addition of a negatively charged phosphate group is able to induce conformational 
changes in the phosphorylated protein, as this alters the surface charge and thus 
hydrophobicity of a region of the protein, which helps to determine the tertiary (globular) 
structure of a protein. Conformational changes can alter the enzymatic activity and 
binding ability of a protein therefore altering its function in a signalling system. Secondly, 
phosphorylation can alter the ability of a target protein to associate with its binding 
partners through the generation or disruption of charge-based interactions, without the 
requirement for any conformational change (Johnson and O’Reilly, 1996).  
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Figure 1.1 Protein Phosphorylation. The reversible modification of proteins by phosphorylation is 
mediated by two classes of enzyme, protein kinases and protein phosphatases. Protein kinases 
transfer the terminal phosphate of adenosine triphosphate (ATP) to a hydroxyl group on an amino 
acid side chain of the protein, typically on serine, threonine or tyrosine residues. In the reverse 
process protein phosphatases catalyse the removal of the phosphate by hydrolysis. Protein 
phosphorylation is able to regulate the activity or binding ability of a protein through the induction of 
conformational changes in the protein’s globular structure. 
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The reverse reaction of protein dephosphorylation is carried out by a class of enzymes 
known as protein phosphatases, which catalyse the removal of the phosphate group by 
hydrolysis (Fig. 1.1). These can be broadly classified into two main families, the protein 
tyrosine phosphatases (PTPs) and the serine/threonine protein phosphatases (Barford, 
1996; Mustelin, 2007). The latter group is comprised of three structurally distinct families 
i) The Mg+-dependent protein phosphatases (PPM) group of exemplified by PP2C ii) The 
Mg+-dependent FCP (F-cell production) phosphatases, which act on the C-terminal 
domain of RNA polymerase 2. iii) PPP (protein phosphatase P) family phosphatases which 
comprise the largest group of ser/thr phosphatases and include PP1, PP2A, PP2B 
(calcineurin), PP5 and many others (Cohen, 2004; Mustelin, 2007).  
Like the ser/thr phosphatases, PTPs, which are defined as phosphatases with some 
degree of structural homology to known enzymes with bona fide PTP activity, can also be 
broken down into four evolutionarily distinct groups (Table 1.1) (Tonks, 2006). The class 1 
cysteine-dependent protein tyrosine phosphatases comprise the largest of these and 
includes the transmembrane (receptor type) PTPs such as PTPalpha and CD45, the non-
receptor type PTPs exemplified by PTP1B, T-cell PTP and Shp1, but also a very large and 
diverse group of dual-specificity protein phosphatases or DUSPs (Alonso et al., 2004; 
Mustelin, 2007). The latter includes the thr/tyr dual-specificity MAP kinase phosphatases 
(MKPs), but also atypical DUSPs (VHR, PIR, Laforin), slingshot phosphatases (SSH1-3), 
phosphatases of regenerating liver (PRLs), CDC14 phosphatases, the PTENs (PTEN, TPIP, 
Tensin) and myotubularins. The latter two groups are not protein phosphatases, but 
instead act on inositol phospholipids (Patterson et al., 2009). The class 2 PTPs comprise a 
small family of CDC25 cell cycle regulatory phosphatases while class 3 PTPs, although 
widely distributed in nature, contain only one mammalian member in the low molecular 
weight PTP (LMWPTP). The final class of PTPs are the eyes-absent (EyA) PTPs, which use 
an aspartate residue as a nucleophile, require a divalent metal ion in the active site to 
catalyze phosphate hydrolysis and have some structural similarity to haloacid 
dehalogenases (HAD) (Mustelin, 2007; Tonks, 2006). The subjects of this thesis are the 
members of the MKP subfamily of DUSPs and as such the cellular consequences of their 
phosphatase activity are determined by the functions of their target kinase(s), in this case 
the MAPKs.  
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Table 1.1 Classification and substrate specificity of protein tyrosine phosphatases (PTPs). 
The PTPs are divided into four groups: the Class I, II and III Cys-based PTPs and the Asp-based 
PTPs. These groups are further divided into additional sub-groups and families, of which the 
number of phosphatases and their substrate specificities are outlined. The subject of this thesis is 
the Dual-specificity MAP kinase phosphatases (MKPs), which are highlighted in red. PRL 
(phosphatases of regenerating liver), PTEN (Phosphatase and tensin homolog), LMWPTP (low 
molecular weight PTP), EyA (eyes-absent). Compiled from: Alonso et al., 2004; Patterson et al., 
2009; Tonks, 2006. 
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1.2 Mitogen-activated protein kinase (MAPK) signalling 
1.2.1 MAPK pathways 
The mitogen-activated protein kinase (MAPK) cascades constitute a group of highly 
conserved signal transduction pathways which regulate numerous cellular functions 
including proliferation, differentiation, survival, migration and inflammation, as well as 
stress responses such as growth arrest or apoptosis (Chang and Karin, 2001; Kyriakis and 
Avruch, 2012; Wada and Penninger, 2004). MAPK cascades can be activated by a diverse 
range of extracellular and intracellular stimuli including growth factors, cytokines, 
metabolic state, DNA damage and other cellular stresses (Raman et al., 2007). The core 
MAPK signalling module is comprised of three kinases, which sequentially activate each 
other. Active MAPK kinase kinase (MAPKKK) phosphorylates and activates MAPK kinase 
(MAPKK), a dual-specificity protein kinase, enabling the phosphorylation of both the 
threonine and tyrosine residues of a conserved T-X-Y motif within the kinase activation 
loop which is required to activate the MAPK itself (Marshall, 1994; Ray and Sturgill, 1988). 
Following activation the terminal MAPK is able to directly phosphorylate cytoplasmic 
targets in a wide range of cellular compartments or shuttle into the nucleus to 
phosphorylate nuclear targets including transcription factors to induce changes in gene 
expression (Pearson et al., 2001; Wortzel and Seger, 2011). 
There are four major groups of MAPK signalling cascades in mammalian cells (Fig. 1.2). 
These are the prototypical Ras-activated extracellular signal-regulated kinases 1 and 2 
(ERK1/2), the three stress activated c-Jun N-terminal kinases (JNK1, 2 & 3), the four p38 
MAPKs (p38α, β, δ and γ) and ERK5 (Pearson et al., 2001). In addition to these 
conventional MAPKs there are less well-characterised atypical MAPKs including ERK3/4, 
NEMO-like kinase (NLK) and ERK7. Atypical MAPKs are unable to be phosphorylated by 
MAPKK proteins, and hence lack the classical three tiered-cascade organisation shared by 
conventional MAPKs (Coulombe and Meloche, 2007). The ERK1/2, JNK and p38 pathways 
are the best characterised MAPK pathways, with the most known about their negative 
feedback regulation and involvement in human cancer progression. 
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Figure 1.2 The major MAPK signalling pathways and their functions. Schematic outlining the 
components of the major MAPK modules in mammalian cells, some of the biological endpoints 
associated with pathway activity and a description of their characterised roles in cancer. For detail 
see text.  
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1.2.2 The classical ERK pathway 
The classical ERK pathway is the prototypical MAPK cascade (Boulton et al., 1990). The 
MAPK components of this pathway, ERK1 and ERK2, are closely related isoforms which 
exhibit 83% amino acid identity and are coexpressed in most cell types (Boulton et al., 
1991). Consequently it was proposed that these isoforms have overlapping, potentially 
redundant, functions (Cobb and Goldsmith, 2000). This interpretation is supported by 
RNAi silencing experiments, which demonstrated that the combined expression level of 
ERK1 and ERK2 determines the biological outcome of ERK signalling both in vitro and in 
vivo, although ERK2 is expressed at a much higher level in most cell types. Furthermore, 
the kinase activities of ERK1/2 against known targets appear indistinguishable in vitro 
(Lefloch et al., 2008). Overexpression and knockout studies had previously demonstrated 
differential effects of ERK1 and ERK2 in mice (Pagès et al., 1999; Vantaggiato et al., 2006; 
Yao et al., 2003). However, these studies usually observed a greater effect of the loss of 
ERK2 than of ERK1, which could be explained by the more significant effect of ERK2 
ablation would have on total ERK1/2 levels due to its higher level of expression. A recent 
study has convincingly demonstrated functional redundancy between ERK1 and ERK2 by 
rescuing the embryonic lethality of ERK2 null mice using transgenic ERK1 expression 
(Frémin et al., 2015). The developmental consequences of ERK1 expression correlated 
with global ERK1/2 activity in a dose-dependent manner, supporting the conclusions of 
Lefloch and colleagues (2008) that ERK1 and ERK2 are totally redundant and that it is the 
combined expression level and activation state of ERK1 and ERK2, which determines the 
biological outcome of ERK1/2 (hereafter referred to as ERK) signalling. 
The ERK pathway is classically activated via growth factor signalling through RTKs, 
stimulating sequential activation of the small G-protein Ras, and the Raf, MAPK/ERK 
Kinase (MEK), ERK kinase cascade (Fig. 1.3) (Shaul and Seger, 2007). Growth factor 
ligands, such as epidermal growth factor (EGF), bind to their respective RTKs inducing 
receptor dimerization, activation and autophosphorylation of intracellular tyrosine 
residues. These phosphorylated residues allow the binding of Src homology 2 (SH2) or 
phosphotyrosine-binding domain-containing proteins, to initiate intracellular signalling 
cascades including the MAPK and Phosphoinositide 3-kinase (PI3K) pathways amongst 
many others. The MAPK pathway is initiated by the binding of the SH2 protein Grb2 to a 
phosphorylated tyrosine residue, allowing the recruitment of the guanine nucleotide 
26 
 
exchange factor (GEF) Son of Sevenless (SOS). SOS sequesters GDP from Ras GTPases 
(KRas, NRas, and HRas) enabling GTP binding, causing a conformational change and 
activating Ras (Cargnello and Roux, 2011; English et al., 1999; Greene and Kaplan, 1995). 
Active Ras functions as an adaptor protein which is able to bind and activate multiple 
downstream effectors initiating signalling systems including the ERK, PI3K, Ral and 
phospholipase C pathways (Rajalingam et al., 2007). With regard to the ERK pathway 
active Ras is able to bind and activate multiple MAPKKKs, including A-Raf, B-Raf, and Raf-1 
(cRaf) through the induction of dimer formation (Moodie et al., 1994; Morrison et al., 
1988; Reuter et al., 1995). Activated Raf is then able to promote the activation of the 
MAPKK isoforms MEK1 and MEK2 by phosphorylation of dual serine residues (Zheng and 
Guan, 1994), this is followed by the sequential activation of ERK by phosphorylation of its 
T-E-Y motif (the dually phosphorylated and activated (p-T-E-p-Y) form of ERK will be 
subsequently referred to as p-ERK) (Ray and Sturgill, 1988).  
Hundreds of proteins with diverse biological functions have been characterised as ERK 
substrates or binding partners, these include direct targets such as transcription factors, 
and also other protein kinases (Ramos, 2008; Yoon and Seger, 2006). Cytoplasmic targets 
of ERK include: members of the apoptotic regulatory B-cell lymphoma 2 (BCL-2) family 
that regulate cell survival (Balmanno and Cook, 2009), myosin light chain kinase (MLCK), 
which regulates migration (Klemke et al., 1997) and paxillin/focal adhesion kinase (FAK), 
that regulates microtubule formation (Ishibe et al., 2004). Nuclear targets are primarily 
transcription factors, including ELK-1, c-Fos, NF-AT, c-Myc and STAT3, which alter gene 
expression to induce diverse biological outcomes, including the promotion of 
proliferation (Pearson et al., 2001; Ramos, 2008). The kinase targets of ERK include the 
p90 ribosomal S6 kinases (RSKs), mitogen- and stress-activated kinases (MSKs), and 
MAPK-interacting kinases (MNKs) (Cargnello and Roux, 2011). These downstream kinases 
constitute an additional amplification step within the ERK cascade, enabling them to 
influence a wider range of biological processes. Furthermore, ERK has also been shown to 
have the ability to regulate some target proteins through non-catalytic mechanisms, for 
example it is able to activate topoisomerase-2a in a phosphorylation-independent 
process to cause DNA unwinding (Rauch et al., 2011; Shapiro et al., 1999). 
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Given such a diverse spectrum of functions it is not surprising that aberrations in ERK 
signalling have been revealed in a broad range of pathologies including multiple cancers, 
diabetes, inflammation, and cardiovascular disease (Ramos, 2008). This thesis is 
concerned with the influence of altered feedback regulation within the MAPK cascades on 
cancer development. 
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Figure 1.3 The Ras-ERK MAPK cascade and the major mechanisms of oncogenic activation 
of this signalling pathway. Schematic showing the architecture of the core components of the 
Ras- extracellular signal regulated kinase (ERK) pathway from the receptor tyrosine kinase (RTK) 
at the plasma membrane, through the adaptor protein GRB (growth receptor bound protein), the 
guanine nucleotide exchange factor SOS (son of sevenless) to the small GTPase Ras. Once GTP 
bound and activated, Ras activates the Raf MAPK kinase kinase (MAPKKK), the initial component 
of the MAPK module. Raf activity induces the sequential phosphorylation and activation of the 
remaining MAPK module consisting of, MEK (MAPKK) and ERK itself. Once activated in the 
cytoplasm, ERK can phosphorylate regulate a large number of cytoplasmic proteins. Additionally, 
activated ERK is also able to translocate to the cell nucleus where it can phosphorylate and 
activate transcription factors (TF) and induce the expression of ERK target genes. These encode 
many proteins involved in the regulation of cell proliferation and/or differentiation, as well as many 
other cellular processes. Oncogenic activation of the Ras-ERK pathway can occur by 
overexpression or mutation of a number of components. Commonly occurring mutations are 
indicated with asterisks, along with the identification of the major cancer types in which these 
mutations are found to occur at a high frequency. 
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1.2.3 The classical ERK pathway and cancer 
Due to the ability of ERK to influence many of the hallmarks of cancer (Hanahan and 
Weinberg, 2000, 2011), it is no surprise that ERK deregulation has been implicated in the 
initiation, progression and maintenance of approximately a third of human cancers. 
Oncogenic activating mutations or overexpression are commonly found upstream of ERK 
in genes encoding RTKs, Ras, BRaf and CRaf (Fig. 1.3) (Dhillon et al., 2007; Downward, 
2003). In contrast, mutations in MEK and ERK itself are rarely seen in human cancers. This 
is likely to be due to these proteins requiring dual phosphorylation for their activation, 
therefore multiple nucleotide base changes would be necessary for their oncogenic 
activation reducing this probability of this occurring in nature to drive human 
tumourigenesis (Cowley et al., 1994). RTK or Ras mutations can activate multiple 
downstream signalling cascades as well as the ERK pathway, making their relative 
contribution to tumourigenesis somewhat difficult to fully assess (as discussed for 
pancreatic cancer below). However, the importance of the ERK pathway in human 
malignancy can be clearly demonstrated by the finding that the MAPKKK BRaf is the 
driving oncogene in 40-60% of malignant melanomas as well as in a number of other 
cancer types to a lesser degree. BRafV600E is the most common mutation, leading to 
increased kinase activity and hence activation of MEK and ERK (Wan et al., 2004). The 
development of the BRafV600E-specific inhibitor vemurafenib, and its efficacy in inhibiting 
ERK activation and tumour cell proliferation in preclinical models, as well as to elicit 
clinical responses in BRafV600E-positive melanoma patients, demonstrates the dependency 
of these tumours on Raf-ERK signalling (Bollag et al., 2010; Joseph et al., 2010; Lito et al., 
2012).  
Many Ras or BRaf mutant cancer cell lines are sensitive to MEK inhibition (MEKi) in vitro 
and in vivo (Roberts and Der, 2007), however these initial responses have failed to 
translate into sustained clinical success due to a variety of drug resistance mechanisms. 
Some tumour cells can display intrinsic resistance to MEKi through parallel oncogenic 
pathways active in the tumour. This explains why within a panel of human cancer cell 
lines BRaf mutant cells have been shown to be far more sensitive to MEKi (addicted to 
ERK signalling) than those driven by Ras mutations (Solit et al., 2006). Alternatively, the 
limited success of MEKi in Ras mutant cells could also be due to the loss of ERK-
dependent negative feedback systems within the ERK signalling cascade, leading to 
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reactivation of MEK-ERK following MEKi treatment. ERK signalling is also required to 
inhibit many RTKs; therefore MEKi induces the rapid activation of an array of RTKs, which 
would usually be suppressed. This adaptive kinome reprogramming initiates additional 
oncogenic signalling to compensate for the inhibition of the ERK pathway and minimise 
the efficacy of MEKi. Finally, tumour cells can evolve acquired resistance to MEKi through 
a range of mechanisms including the amplification of upstream driving-oncogenes such as 
Ras or Raf or the accumulation of additional gain of function mutations for example in 
MEK (Caunt et al., 2015; Little et al., 2011; Poulikakos and Rosen, 2011). 
Oncogenic mutations in the ERK pathway lead to sustained ERK activation, which is able 
to promote cell proliferation, survival, motility and other tumour phenotypes. However, 
the magnitude of ERK activation is also important in determining its tumourigenic effects. 
It has been known for a long time that excessive hyperactivation of the ERK pathway in 
vitro elicits cell cycle arrest and senescence by inducing the accumulation of cyclin-
dependent kinase inhibitors including CDKN2A and p21 (Meloche and Pouysségur, 2007; 
Serrano et al., 1997). The can be demonstrated by the fact that although Ras and BRaf 
mutations are amongst the most frequently mutated oncogenes in human cancers 
(present in around 30% and 7% of cancers respectively), and both overlap as driver-
mutations for colon and lung cancer they are almost never identified in the same tumour 
(Borràs et al., 2011; Goydos et al., 2005; Karnoub and Weinberg, 2008; Kinno et al., 2014; 
Pylayeva-Gupta et al., 2011; Sensi et al., 2006). This mutual exclusivity has been 
experimentally demonstrated by that fact that the co-activation of BRrafV600E and KRasG12D 
markedly reduced tumour initiation in a mouse model of lung cancer due to elevated 
oncogene-induced senescence (OIS) (Cisowski et al., 2015). Therefore, for optimal tumour 
promotion a sustained elevated level, but not excessive hyperactivation, of ERK signalling 
is required. This conclusion can be further validated by the observation that epidermal 
growth factor receptor (EGFR) and KRas mutations are mutually exclusive in human lung 
adenocarcinoma and that their forced co-activation human lung cancer cell lines results in 
synthetic lethality. Subsequent co-activation of EGFR and KRas mutations in a mouse 
model of lung cancer results in tumours with only a single mutation, reinforcing the 
conclusion that their co-expression is deleterious to tumour development (Unni et al., 
2015). 
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1.2.4 The Stress-activated MAPK pathways 
The stress-activated protein kinase (SAPK) group of MAPKs comprise the JNK and p38 
MAPK families. They display more complex signalling cascade than the prototypical ERK 
pathway, due to the presence of a large number of MAPKKK proteins which are known to 
activate these pathways. Both the JNK and p38 pathways can be activated by a variety of 
environment and cellular stresses, including oxidative stress, DNA-damaging agents, 
ultraviolet (UV) irradiation, and inflammatory cytokines amongst other stimuli (Cargnello 
and Roux, 2011; Pearson et al., 2001). Such stimuli induce the activation of an array of 
MAPKKK proteins including MEKK1-4, MLK1-3, ASK1, TPL2, TAK1 and TAO1/2. It remains 
unresolved whether MAPKKKs simultaneously regulate the JNK and p38 pathways or 
whether one pathway is pre-selected through targeting of the activated MAPKKK to a 
particular substrate (Rincón and Davis, 2009). Signalling specificity becomes apparent at 
the MAPKK level, with MKK4/7 being responsible for JNK activation (Dérijard et al., 1995; 
Tournier et al., 1997) and MKK3/6 for p38 activation (Dérijard et al., 1995; Han et al., 
1996), although MKK4 has also been shown to possess limited activity towards p38 
(Meier et al., 1996). 
The first JNK family member was identified as a cycloheximide-activated hepatic protein 
kinase that phosphorylates MAP-2 on serine and threonine residues, then subsequently 
as a UV-responsive protein kinase that binds and activates the transcription factor c-Jun 
(Hibi et al., 1993; Kyriakis and Avruch, 1990; Pulverer et al., 1991). There are three 
isoforms of JNK (JNK1, 2, 3), encoded by three distinct genes with greater than 85% 
homology. These genes give rise to 10 alternatively spliced isoforms of JNK, which display 
different activities towards their target proteins, including the transcription factors c-jun, 
activating transcription factor 2 (ATF-2) and Elk-1 (Gupta et al., 1996). JNK1 and JNK2 are 
expressed in a broad range of human tissues, whereas JNK3 expression is localised to 
neuronal and cardiac tissue as well as the testis (Mohit et al., 1995). The deletion of a 
combination of JNK1/2, in mice results in embryonic lethality due to defects in patterns of 
apoptosis during brain development, whereas single JNK knockout or combinations of 
JNK1/3 or JNK2/3 do not (Kuan et al., 1999). This experiment demonstrates that there is 
some functional redundancy between JNK1 and JNK2, although this is not always the case 
in other tissues or in response to different stimuli. Furthermore, it helps to demonstrate 
the important roles JNKs can play in the control of apoptosis in response to many cellular 
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stresses (Dhanasekaran and Reddy, 2008). Mouse embryonic fibroblasts (MEFs) isolated 
from JNK1/2 or MKK4/7 knockout mice are resistant to UV irradiation induced apoptosis. 
This loss of JNK signalling prevented cytochrome c release, indicating a requirement for 
JNK in promoting the intrinsic apoptotic pathway in response to genotoxic stress 
(Tournier et al., 2000). Furthermore, the targeted activation of JNK1/2 protects cells from 
apoptosis following serum starvation (Molton et al., 2005). JNK1 and JNK2 have also been 
shown to play important and differential roles in the control of cell proliferation. JNK2-/- 
MEFs proliferate faster than wild-type littermates, whereas JNK1-/- and JNK1-/-/JNK2-/- 
MEFs proliferate slower (Tournier et al., 2000). JNK1 activity promotes c-Jun activation, 
AP-1 complex formation and induction of AP-1-target genes, including genes such as 
cyclin D1, which are responsible for cell cycle progression. Whereas, JNK2 was shown to 
primarily bind c-Jun in its inactive state and target c-Jun for degradation (Sabapathy et al., 
2004). Finally, JNKs also have important roles in the development of and regulation of 
immune cell function  (Rincón and Davis, 2009). 
p38α was discovered simultaneously by three groups in 1994 as a MAP kinase activated in 
response to various stresses including heat shock, osmotic stress and lipopolysaccharide 
(LPS) (Han et al., 1994; Lee et al., 1994; Rouse et al., 1994). The p38 MAP kinase family 
consists of four isoforms: p38α, β, δ and γ, of which the archetypal member p38α is the 
most studied. p38α and p38β are expressed ubiquitously in all tissues, whereas p38δ and 
p38γ exhibit more localised expression (Kyriakis and Avruch, 2012). Genetic deletion of 
p38α results in embryonic lethality in mice due to incomplete placental development 
(Adams et al., 2000; Mudgett et al., 2000), and conditional deletion in the embryo, to 
bypass these placental defects, also results in death shortly after birth due to lung defects 
(Hui et al., 2007). p38 signalling plays an important role in immune and inflammatory 
responses (Cuadrado and Nebreda, 2010). In response to extracellular mediators of 
inflammation, such as cytokines, chemokines and LPS, p38 signalling can induce the 
production of pro-inflammatory cytokines to intensify the immune response. p38 
signalling regulates pro-inflammatory cytokine expression is through the modulation of 
transcription factors including NF-κB (Rincón and Davis, 2009), and at the post-
transcriptional level through the regulation of mRNA stability (Clark et al., 2009; Gaestel, 
2013).  MAPK-activated protein kinase 2 (MK2) deficient mice demonstrate a significant 
reduction in TNFα protein production, despite no change in the mRNA expression, 
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following an LPS challenge showing MK2 to be the major kinase downstream of p38 
responsible for the  post-transcriptional regulation of cytokine biosynthesis (Kotlyarov et 
al., 1999). Furthermore, p38α has been associated with the regulation of cell proliferation 
and apoptosis. p38α signalling activates the G1/S and G2/M checkpoints to inhibit 
proliferation and it has been implicated with the induction of apoptosis following cellular 
stress (Thornton and Rincon, 2008).  
1.2.5 The JNK pathway and cancer 
Sequencing of human tumour samples has revealed that components of the JNK pathway 
are frequently mutated in a diverse range of cancers including pancreatic, lung and 
colorectal (CRC). Genes mutated include MKK4, MKK, JNK1 and JNK2 and the mutations 
were typically truncating or mis-sense mutations indicating that loss of JNK signalling 
might contribute to tumorigenesis  (Davies et al., 2005; Greenman et al., 2007; Jones et 
al., 2008). However, the role of the JNK isoforms in cancer appears complex, with JNK1 
and JNK2 exhibiting both oncogenic and tumour suppressive functions across a range of 
in vitro and in vivo model systems (Wagner and Nebreda, 2009; Weston and Davis, 2007).  
Initial in vitro experiments demonstrated JNK signalling promoted Ras, c-Abl or Met-
induced cell transformation, suggesting an oncogenic role for JNK activity (Clark et al., 
1997; Raitano et al., 1995; Rodrigues et al., 1997). However, strikingly this is not the case 
for transformation assays performed in vivo. Injection of Ras-transfected JNK1/2 null cells 
into athymic, immunocompromised mice caused a significant increase in the number and 
size of Ras-induced tumour nodules compared to wild-type Ras-transfected cells, even 
though these same JNK1/2 null cells were found to be resistant to Ras-induced 
transformation in vitro (Kennedy et al., 2003). This observation correlates with the 
occurrence of loss of function mutations in the JNK pathway in human tumours in 
suggesting that JNKs are tumour suppressive. This is further supported by evidence that 
mice lacking JNK signalling, through ablation of MKK4 and MKK7, show increased 
sensitivity to KRasG12D-driven pancreatic carcinogenesis (Davies et al., 2014). However, 
experiments utilising mice lacking individual JNK isoforms demonstrate a more complex 
role of JNK signalling in cancer, possibly reflecting their divergent functions elucidated in 
vitro. Furthermore, the same JNK isoform has the ability to act as an oncogene in some 
cancer types, but a tumour suppressor in others, demonstrating potential tissue-specific 
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roles of the JNK isoforms. For instance, JNK1-/- mice show increased sensitivity to 7,12-
Dimethylbenz[a]anthracene/12-O-tetradecanoylphorbol-13-acetate (DMBA/TPA)-induced 
skin carcinogenesis, whereas JNK2-/- mice were protected. The differential effects of JNK1 
or JNK2 ablation were mediated by the opposing abilities of JNK1 and JNK2 to influence 
ERK and AKT activity, with JNK1 loss promoting their activity and JNK2 loss inhibiting it 
(Chen et al., 2001; She et al., 2002). Whereas, in the diethylnitrosamine (DEN)-induced 
liver cancer model JNK1-/- , but not JNK2-/-, mice show decreased sensitivity to 
tumourigenesis. JNK1 was shown to promote the growth and proliferation of liver 
tumours and cell lines through its ability to inhibit p53-dependent pro-apoptotic signalling 
(Hui et al., 2008; Sakurai et al., 2006).  
1.2.6 The p38 MAPK pathway and cancer 
Unlike the ERK and JNK pathways, there is very limited evidence for mutations within the 
p38 pathway in human cancers. As mentioned above, MKK4 inactivating mutations have 
been discovered in a range of human cancers (Greenman et al., 2007), and although it is 
able to activate p38 it is primarily thought to target JNK, therefore it is unclear whether 
alterations in p38 signalling would occur or have any functional role in these cancers. The 
only other link to p38 signalling of any significance is the amplification of the p53-
inducible phosphatase WIP1/PPM1D in around 11% of breast cancers, and some ovarian 
cancers (Bulavin et al., 2002; Lu et al., 2008). WIP1/PPM1Ds oncogenic function has been 
linked to its ability to dephosphorylate p38α, inhibiting p38α’s ability to negatively 
regulate tumour cell proliferation (Bulavin et al., 2004). However, WIP1/PPM1Ds is also 
capable of negatively regulating the activity the tumour suppressors p53, ATM and 
CDKN2A, therefore the relative importance of p38α signalling to the pro-oncogenic 
effects of WIP1/PPM1D  is unclear (Lu et al., 2008). 
In experimental systems the role of p38 isoforms appears complex. Both in vitro and in 
vivo studies demonstrate a tumour suppressive role for p38α. Immortalised p38α-/- MEFs 
show increased sensitivity to HRasV12-driven transformation in culture and generate an 
elevated tumour burden following their injection into athymic mice (Dolado et al., 2007). 
Fetal haematopoietic cells and MEFs from p38α-/- mice demonstrate increased 
proliferation, which is dependent on the ability if p38α loss to induce the hyperactivation 
of the JNK pathway (Hui et al., 2007). In murine models the conditional deletion of p38α 
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has been shown to sensitise mice to KRasG12V-induced lung tumours (Ventura et al., 2007) 
and DEN-induced liver cancer (Hui et al., 2007). Although the majority of evidence 
supports a tumour suppressive role for p38α, there is some evidence that in certain 
contexts it could be oncogenic. p38α may promote tumour development through the 
upregulation of autophagy (Comes et al., 2007), the promotion of tumour cell invasion 
(Rousseau et al., 2006) and the induction of pro-inflammatory cytokines and thus an 
elevated inflammatory response, which is known to be a causative factor in many cancer 
types (Kumar et al., 2003; Schieven, 2009). 
More recently, the roles of other p38 isoforms in cancer development have begun to be 
elucidated. Evidence from MEFs lacking p38γ and p38δ suggests that loss of either 
isoform promotes increased migration, whereas only p38δ loss impaired cell contact 
inhibition and only p38γ loss promotes KRasV12-driven proliferation, transformation and 
tumour formation in athymic mice (Cerezo-Guisado et al., 2011). In murine models the 
loss of p38δ has been shown to protect mice from DMBA/TPA-induced skin tumours and 
KRasG12D-driven lung tumours (Schindler et al., 2009), whereas conditional p38γ ablation 
attenuates colitis-associated tumourigenesis (Yin et al., 2016). Furthermore the dual-
deletion of p38γ and p38δ protects mice from DMBA/TPA-induced skin tumourigenesis 
and colitis-associated tumourigenesis (Reino et al., 2014; Zur et al., 2015). In summary, 
although both p38γ and p38δ appear to show a tumour suppressive phenotype in vitro 
and in immunocompromised mice, they demonstrate strong oncogenic phenotypes 
across multiple cancer models, including most strikingly in inflammation-associated 
cancer. This highlights the key role of p38γ and p38δ in the regulation of the 
inflammatory response as well as the importance of this process in cancer development. 
Within both the JNK and p38 families’ individual isoforms have shown diverse roles in 
cancer development and additionally specific isoforms have demonstrated opposing 
functions in different tumour contexts. This contrasts with the ERK pathway where both 
isoforms appear functionally redundant (Frémin et al., 2015) and are primarily known to 
act in an oncogenic manner. The roles of the JNK and p38 isoforms are likely to be both 
cell context and cell-type dependent due to many factors including: the wide range of 
stimuli which are able to activate these pathways, their range of tissue specific 
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expression, the fact that many stimuli will activate both pathways simultaneously and the 
crosstalk which occurs between them (Wagner and Nebreda, 2009).  
1.2.7 Spatiotemporal regulation of MAPK signalling 
The duration, magnitude and subcellular localisation of MAPK activation are all crucial 
parameters, which determine the biological outcome of signalling. These factors can be 
modulated in a variety of ways to determine the dynamics of MAPK signalling, including 
through alterations in the kinetics and magnitude of the stimuli that initiate signalling 
activity, post-translational modifications of the MAPK itself, the binding of MAPKs to 
scaffold proteins or the influence of negative feedback regulation within the MAPK 
pathway (Ebisuya et al., 2005; Kholodenko et al., 2010; Marshall, 1995). This section will 
outline evidence for how many of these factors can cooperate in regulating the 
spatiotemporal activity of the ERK pathway, as this pathway is the primary focus of this 
thesis. 
The importance of temporal control of ERK activity was first revealed when it was 
demonstrated to be a critical factor in the regulation of cell fate decisions. EGF 
stimulation of rat pheochromocytoma (PC12) cells was shown to induce transient ERK 
activation and to induce cell proliferation, whereas nerve growth factor (NGF) stimulation 
generated sustained ERK activation, increased nuclear p-ERK accumulation and induced 
neural differentiation (Marshall, 1995; Traverse et al., 1992). The EGF receptor undergoes 
rapid internalisation and degradation following activation in comparison to other 
receptors, explaining its more transient signalling (Countaway et al., 1992). However, the 
overexpression of the EGFR is able to convert this transient response to a more sustained 
activation of ERK and mimic the effects of NGF in causing neuronal differentiation 
(Traverse et al., 1994). Therefore, differences in signalling dynamics are one factor that 
can determine the spatiotemporal effects of different growth factor stimuli on ERK 
activation and thus signalling outcome. Similar effects have also been demonstrated in 
the balance between continued cell proliferation or apoptosis in developing T cells 
(Werlen et al., 2003).  
One of the principle mechanisms controlling ERK subcellular localisation is the regulation 
of ERK targeting to the nucleus. Nuclear translocation of ERK was initially thought to 
37 
 
require phosphorylation-dependent dimerization of ERK (Cobb and Goldsmith, 2000; 
Khokhlatchev et al., 1998). However, subsequent studies have shown that ERK nuclear 
translocation can occur by the passive diffusion of ERK monomers or the active transport 
of dimers (Adachi et al., 1999), and can in fact be dimerization independent (Casar et al., 
2008; Lidke et al., 2010). Nuclear translocation of ERK requires phosphorylation of ERK by 
MEK, as MEK is able to anchor inactive ERK in the cytoplasm (Adachi et al., 2000; 
Rubinfeld et al., 1999), and the MEK‐mediated phosphorylation of ERK is necessary for 
the dissociation of ERK from MEK (Adachi et al., 1999). Furthermore, a 3 amino acid 
sequence (SPS) has been identified that when phosphorylated induces nuclear 
translocation of ERK. This could be a mechanism which targets activated ERK to the 
nucleus (Chuderland et al., 2008; Zehorai et al., 2010). Finally, it has been shown that ERK 
homodimers are essential for binding to many cytoplasmic substrates and scaffolds, but 
nuclear substrates almost exclusively associate with ERK monomers (Casar et al., 2008). 
Together these findings establish dimerization and nuclear translocation signal activation 
as key determinants of the spatial specificity of ERK signalling. 
Scaffold proteins can also regulate the spatial distribution of MAPKs, by targeting MAPKs 
to specific subcellular organelles and substrates, to modulate the signalling outcome. 
Cytoplasmic scaffold proteins such as PEA-15 can sequester ERK in the cytosol, to 
constrain ERK-dependent transcription (Formstecher et al., 2001). Other scaffold proteins 
can localise ERK to precise subcellular localisations to promote a specific biological 
response. For example, following hepatocyte growth factor stimulation of epithelial cells 
the multidomain scaffold protein paxillin facilitates the localisation of Raf-MEK-ERK 
complexes at focal adhesions. ERK-dependent phosphorylation of paxillin induces the 
recruitment of focal adhesion kinase (FAK) to stimulate microtubule formation and cell 
migration (Ishibe et al., 2004). Furthermore, scaffold proteins such as Kinase suppressor 
of Ras (KSR) and MEK partner-1 (MP1), have been shown to sequester ERK pathway 
components together to facilitate more efficient sequential activation, thereby increasing 
the magnitude of ERK signalling (Kolch, 2005). The magnitude of ERK signalling can 
regulate the ensuing biological outcome. In most cell types ERK activation is necessary for 
cell cycle progression. However, ERK hyperactivation, induced by cellular stress or 
oncogenic transformation, elicits cell cycle arrest through the induction of cell cycle 
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inhibitory proteins including the p53, p21, p16Ink4a and retinoblastoma (Rb) (Meloche 
and Pouysségur, 2007; Serrano et al., 1997). 
The opposing action of upstream pathway activators and negative regulatory mechanisms 
can modulate the duration and magnitude of MAPK activation (Caunt and Keyse, 2013) 
(Fig. 1.4 outlines many of the key negative feedback systems within the ERK pathway). 
Negative regulatory mechanisms can be induced as classical negative feedback systems or 
as crosstalk from alterative signalling pathways and can act at multiple levels within the 
MAPK pathway (Fey et al., 2012; Shin et al., 2009). Negative feedback systems within the 
ERK pathway can be controlled through post-translational modifications of pathway 
components or regulators or through transcriptional activation of negative regulators. 
ERK-mediated feedback phosphorylation of the upstream pathway components MEK 
(Catalanotti et al., 2009; Eblen et al., 2004), Raf (Dougherty et al., 2005), the Ras-
activating GEF SOS (Douville and Downward, 1997) or some RTKs (Ramos, 2008) can 
inhibit their activity generating rapid negative feedback loops to dampen and constrain 
ERK pathway activation. ERK signalling can also induce transcriptional negative feedback 
through the de novo expression of immediate early genes such as sprouty proteins and 
phosphatases which target ERK, primarily MKPs. Sprouty proteins are also regulated 
through phosphorylation in response to ERK activation and inhibit ERK signalling at the 
level of RTKs, SOS and Raf (Hanafusa et al., 2002; Mason et al., 2006; McKay and 
Morrison, 2007). The interplay of fast and delayed feedback loops allows complex 
signalling responses to be generated in response to a constant stimulus. Computational 
modelling has demonstrated the ability of tuneable combinations of these feedback 
systems to generate a variety of temporal responses in ERK signalling following a constant 
stimulus, including sustained, bistable switch-like or oscillating responses, allowing ERK to 
signal for distinct biological outcomes (Kholodenko et al., 2010; von Kriegsheim et al., 
2009). 
Dephosphorylation and inactivation of MAPKs themselves constitutes a major negative 
feedback system within MAPK cascades. This can be performed by 3 classes of protein 
phosphatases: serine/threonine-specific phosphatases, tyrosine-specific phosphatases or 
dual-specificity phosphatases (DUSPs) (Fig. 1.5) (Keyse, 2000). The focus of this thesis are 
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the MKPs, a sub-family of cysteine-dependent phosphatases within the DUSPs, which 
specifically target the MAPKs. 
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Figure 1.4 Spatiotemporal regulation of the Ras-ERK MAPK pathway. Schematic showing the 
architecture of the core components of the Ras- extracellular signal regulated kinase (ERK) 
pathway (Blue), as well as major negative feedback systems (Red) and scaffold proteins (green) 
which can regulate ERK pathway activity and localisation. The Ras-ERK pathway is classical 
activated through ligand-induced receptor tyrosine kinase (RTK) activation at the plasma 
membrane, inducing binding of the adaptor protein GRB (growth receptor bound protein) and the 
guanine nucleotide exchange factor SOS (son of sevenless). SOS promotes GTP binding to the 
small GTPase Ras. Active, GTP-bound Ras induces the sequential activation of the MAPK module 
consisting of, Raf, MEK and ERK itself. Once activated in the cytoplasm, ERK can phosphorylate 
and regulate a plethora of cytoplasmic proteins, including inhibitory phosphorylation of upstream 
Ras-ERK pathway components such as RTKs, SOS or Raf, thus exerting negative feedback 
control over pathway activation. Additionally, activated ERK is also able to translocate to the cell 
nucleus where it phosphorylates and activates transcription factors (TF) and induces the 
expression of ERK target genes. These encode many proteins involved in the regulation of cell 
proliferation and/or differentiation, as well as many other cellular processes. One major class of 
ERK target genes are negative feedback regulators of the ERK pathway itself, including the 
Sprouty proteins and MAPK phosphatases (MKPs). The scaffold protein KSR1 is able to localise all 
components of the ERK MAPK module together, facilitating efficient sequential activation, thereby 
increasing the magnitude of ERK signalling. Other scaffold proteins sequester active or inactive 
ERK to particular subcellular compartments to either promote ERK activation of specific targets, or 
to sequester ERK prior to subsequent activation. 
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Figure 1.5 Regulation of MAPK phosphorylation and activity. Phosphorylation of the threonine 
and tyrosine residues in the T-X-Y motif of the MAPK activation loop are critical for kinase 
activation.  Dual phosphorylation of these residues by upstream MAPKKs such as MEK or MKK 
facilitates MAPK activation. Three groups of phosphatase can mediate the dephosphorylation of 
the T-X-Y motif resulting in MAPK inactivation. Ser/Thr protein phosphatases such as PP2A can 
act upon the Thr residue, whilst tyrosine phosphatases such as PTPase family target the Tyr 
residue.  DUSPs/MKPs have the ability to inactivate MAP kinases through dephosphorylation of 
both of these phosphorylated residues. 
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1.3 Dual-specificity MAP kinase phosphatases 
(MKPs/DUSPs) 
1.3.1 MKP classification, structure & function  
MKPs are DUSPs with the ability to specifically dephosphorylate both the threonine and 
tyrosine residues of the T-X-Y motif within the kinase activation loop of MAPKs and which 
are required for MAPK activation (Fig. 1.5) (Patterson et al., 2009). There are ten 
catalytically active MKPs in mammalian cells. The MKPs share a common structure 
consisting of an N-terminal non-catalytic domain and a conserved C-terminal catalytic 
domain, containing the conserved cysteine-dependent PTPase consensus active site 
sequence C(X)5R (Dickinson and Keyse, 2006). All classical PTPases employ a common 
catalytic mechanism in which the cysteine residue of the active site initiates nucleophilic 
attack on the substrate phosphorous atom (Tonks, 2006). At the same time as the ester 
bond is cleaved, a conserved aspartic acid residue acts as a general acid to protonate the 
oxygen of the tyrosine leaving group. The resulting phospho-cysteine intermediate is 
resolved by the activation of water by the same aspartic acid residue (now acting as a 
general base) and its hydrolysis to yield the restored enzyme and inorganic phosphate 
(Labbé et al., 2012; Tonks, 2006). Structural studies reveal that DUSPs such as the MKPs 
have a very shallow active site cleft when compared with classical PTPs and it is this 
feature, which is thought to underpin the ability of these enzymes to dephosphorylate 
both tyrosine and Ser/Thr residues (Stewart et al., 1999; Yuvaniyama et al., 1996). The N-
terminal non-catalytic domain has been shown to be a regulatory region, containing a 
kinase interaction motif (KIM), which facilitates the specific binding of MKPs to their 
target MAPKs. Many MKPs also contain either nuclear localisation signals (NLS) or nuclear 
export signals (NES) that determine their subcellular localisation (Caunt and Keyse, 2013; 
Owens and Keyse, 2007). 
The MKPs have been divided into three subfamilies based on their gene structure, amino 
acid sequence homology, substrate specificity and subcellular localisation (Table 1.2) 
(Camps et al., 1998; Keyse, 2000; Theodosiou and Ashworth, 2002). One group comprises 
of the mitogen or stress-inducible, nuclear MKPs, DUSP1/MKP-1, DUSP2, DUSP4/MKP-2 
and DUSP5. These inducible MKPs exhibit nuclear localisation and the ability to bind and 
dephosphorylate all three major classes of MAPK (ERK, JNK and p38), with the exception 
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of DUSP5 which is highly ERK-selective. A second group consists of the cytoplasmic ERK-
selective MKPs: DUSP6/MKP-3, DUSP7 and DUSP9/MKP-4. Finally, a third group contains 
the JNK/p38-specific MKPs DUSP8, DUSP10/MKP-5 and DUSP16/MKP-7, which are found 
in both the nucleus and the cytoplasm. 
MKPs are predominantly expressed at relatively low levels in unstimulated cells and are 
transcriptionally induced as immediate early genes following mitogenic or stress 
stimulation and MAPK pathway activation. Following the removal of a transient stimulus 
MKP transcription is reduced, allowing ubiquitination and protein degradation to restore 
MKP expression to basal levels (Bermudez et al., 2010). Therefore, MKPs were first 
thought to solely act as classical negative feedback regulators of MAPK signalling. 
However, subsequently a range of other pathways which are able to induce MKP 
expression have been identified. For example, Wnt-β-catenin signalling has been 
demonstrated to induce DUSP6/MKP-3 expression during zebrafish development and in 
murine hepatoma cells (Tsang et al., 2004; Zeller et al., 2012). Furthermore, DUSP1/MKP-
1 is transcriptionally regulated by p53 during responses to oxidative stress (Liu et al., 
2008), and transforming growth factor-β (TGFβ) can induce DUSP4/MKP-2 expression in a 
SMAD3-dependent manner in lymphocytes (Ramesh et al., 2008). Thus as well as acting 
as negative feedback regulators of MAPK activity MKPs can mediate crosstalk between a 
variety of other signalling pathways and the MAPK cascades in a range of different 
contexts. It is likely that the full extent of MKP mediated crosstalk is yet to be discovered. 
Post-translational modification of MKPs also plays a key role in the control of their 
expression levels and activity. Phosphorylation by MAPKs has been shown to mediate 
either MKP protein stability or to increase the rate of degradation. For example, ERK-
mediated phosphorylation of Ser359/364 in DUSP1/MKP-1 increases protein stability and 
thus the strength of negative feedback (Brondello et al., 1999), whereas phosphorylation 
of Ser296/323 results in ubiquitin ligase recruitment and increased DUSP1/MKP-1 
degradation (Lin and Yang, 2006; Lin et al., 2003). ERK-mediated phosphorylation of 
Ser159/197 on DUSP6/MKP-3 promotes its ubiquitin-mediated degradation (Marchetti et 
al., 2005), this occurs to such an extent that DUSP6/MKP-3 expression is lost immediately 
following platelet-derived growth factor (PDGF) stimulation, before being restored 
through ERK-mediated transcriptional activation (Jurek et al., 2009). This demonstrates 
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how reductions in MKP expression can also be essential for optimal MAPK activation 
following a stimulus and that MKPs have a more complex role in modulating MAPK 
activity than solely as negative feedback regulators. This can also be demonstrated by the 
observation that protein kinase-A (PKA) is able to phosphorylate the KIM motif of 
DUSP9/MKP-4, preventing the phosphatase from binding and inactivating ERK and p38 
substrates (Dickinson et al., 2011). This post-translational regulation of an MKP by a non-
MAPK pathway highlights another mechanism by which MKPs can facilitate crosstalk 
between distinct signalling pathways.  
Finally, whilst some MKPs are intrinsically active, others including DUSP1/MKP-1, 
DUSP4/MKP-2 and DUSP6/MKP-3 undergo “catalytic activation”, a process in which 
binding of the MAPK substrate to the amino-terminal non-catalytic domain of the 
phosphatase induces an allosteric change within the catalytic domain of the MKP. This 
causes several residues within the active site of the enzyme, and particularly the 
conserved aspartic acid “general acid” residue, to adopt an optimal conformation for 
catalysis. (Camps et al., 1998; Slack et al., 2001). This catalytic activation is thought to 
further reinforce the substrate selectivity of MKPs, which is already determined by the 
ability of the KIM to recognise and specifically bind particular MAPKs, and thus to further 
prevent any promiscuous activity against non-MAPK substrates (Caunt and Keyse, 2013). 
Other MKPs such as DUSP5 and DUSP10/MKP-5 do not have the ability to undergo 
catalytic activation, as binding to their substrates does not increase their basal activity 
(Mandl et al., 2005; Tanoue et al., 1999). The crystal structures of the catalytic domains 
for DUSP5 and DUSP10/MKP-5 show the general acid-containing loop to already be in the 
optimal position for catalysis, unlike that of DUSP6/MKP-3 (Jeong et al., 2006, 2007; 
Stewart et al., 1999). This provides an explanation for the lack of catalytic activation of 
DUSP5 and DUSP10/MKP-5. However, at the present time it is unclear as to why some 
MKPs undergo catalytic activation while others do not. 
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Table 1.2 MAP kinase phosphatase (MKP) structure, function and classification. The 10 
mammalian dual-specificity MKPs divided into three groups based on their similarity, subcellular 
localisation and substrate specificity. The schematics in the final column demonstrate the domain 
structures of the MKPs, highlighting the localisation of the kinase interaction motif (KIM) within the 
N-terminal non-catalytic domain and the catalytic site within the C-terminal domain. N/D, not 
determined. 
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1.3.2 Spatiotemporal regulation of MAPK signalling by MKPs 
Through their ability to specifically regulate the phosphorylation status, activity and 
subcellular localisation of MAPKs, MKPs are able to modulate the magnitude, duration 
and spatial limits of MAPK activity. In addition to this, MKPs bind MAPK substrates in a 
phosphorylation-independent manner, so are also able to anchor substrate MAPKs in 
distinct subcellular compartments following dephosphorylation (Caunt and Keyse, 2013; 
Karlsson et al., 2004; Mandl et al., 2005). Furthermore, due to the differing mechanisms 
and kinetics of induction, substrate specificity and subcellular localisation of each 
individual MKP, the family as a whole is able to precisely influence MAPK activity in in a 
context-dependent manner. Together these properties indicate that MKPs have a greater 
role than simply acting as negative feedback regulators of MAPK activity and are able to 
regulate MAPK kinetics, substrate targeting and crosstalk (Caunt and Keyse, 2013). 
The temporal regulation of MAPK signalling by MKPs can mediate multiple functional 
responses including autoregulation, a signalling “memory” and crosstalk between 
signalling pathways (Caunt and Keyse, 2013). Following a mitogenic stimulation 
transcriptional activation of the ERK-specific MKPs DUSP5 and DUSP6/MKP-3 is induced in 
an ERK-dependent manner (Ekerot et al., 2008; Kucharska et al., 2009). This forms a 
delayed auto-regulatory negative-feedback loop; therefore such MKP expression would 
constrain sustained, but not transient, ERK activation. However, if cells are quickly 
exposed to a subsequent stimulus and the MKP protein is still present, it will modulate 
the initial response to this signal potentially constraining transient ERK activation. 
Consequently, the cell will have retained a temporal memory from the initial signal which 
will affect the biological response to subsequent stimuli (Caunt and Keyse, 2013). 
Furthermore, MKPs can facilitate crosstalk between discrete MAPK pathways. This can 
occur through the induction of MKPs with a broad MAPK-specificity, for example the 
MKPs DUSP1/MKP-1 and DUSP4/MKP-2 are transcriptionally induced by the ERK pathway 
yet can target the ERK, JNK and p38 or ERK and JNK pathways respectively (Brondello et 
al., 1997; Chu et al., 1996), thus enabling ERK activation to regulate JNK and p38 signalling 
output (Staples et al., 2010). Finally, any non-MAPK signalling pathways which are able to 
induce MKP expression, such as p53, β-catenin or TGFβ, are able to modulate MAPK 
signalling. This places MKPs as key regulators of MAPK crosstalk to consolidate multiple 
signalling inputs.  
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The ability of MKPs to anchor dephosphorylated MAPKs in a precise subcellular location 
could perform a capacitor-like function, whereby the accumulation of inactive MAPKs  
would facilitate rapid reactivation in this location in response to upstream signalling 
(Caunt and Keyse, 2013). By such a process you could conceive how the physiological 
levels of the ERK-specific MKPs such as DUSP5 and DUSP6/MKP-3 could mediate the 
kinetics of ERK activation. High levels of DUSP6/MKP-3 protein would induce the 
cytoplasmic accumulation of dephosphorylated ERK, facilitating rapid reactivation of this 
ERK store by active MEK. Conversely, the nuclear MKP DUSP5 would sequester inactive 
ERK in the nucleus, possibly restricting it’s assess to MEK and preventing rapid 
reactivation. However, such a role for DUSP5 might not be the case as, although primarily 
a cytoplasmic protein, MEK has been shown to have the ability to translocate to the 
nucleus and ERK activation in the nucleus has been observed (Chuderland et al., 2008; 
Mandl et al., 2005; Zehorai et al., 2010). Alternatively, dephosphorylated, anchored 
MAPKs may have the ability to modulate specific sets of substrates in a non-catalytic 
manner to generate unique signalling outcomes, and thus specific localisation by MKPs 
could promote such outcomes (Caunt and Keyse, 2013; Rauch et al., 2011). 
A more detailed understanding of MKP regulation could help elucidate how mechanisms 
of autoregulation within MAPK pathways and systems of crosstalk with other pathways 
modulate the signalling outcome. This thesis is focused on the ERK-specific MKPs DUSP5 
and DUSP6/MKP-3, in particular any differences in their ability to modulate the ERK 
pathway activity resulting from their differential localisation and their roles in cancer 
development and progression. See Kidger and Keyse, (2016a) for a comprehensive review 
on the roles of all the MKPs in cancer. 
1.3.3 DUSP5 
DUSP5 (also known as B23, hVH3) was first identified through screening a mammary 
epithelial cell cDNA library for sequences encoding putative protein tyrosine 
phosphatases using low-stringency hybridisation probes for the catalytic domains of the 
human VHR and mouse 3CH134 phosphatases (Ishibashi et al., 1994). DUSP5 mRNA was 
shown to be induced in response to mitogenic signalling (including serum, EGF and TPA) 
and some cellular stresses such as heat shock (Ishibashi et al., 1994; Kwak and Dixon, 
1995). The DUSP5 gene was subsequently shown to be located on human chromosome 
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10 (Martell et al., 1994). Through its amino acid sequence homology and subcellular 
localisation, DUSP5 can be classified as a member of the nuclear-inducible group of MKPs 
(Kwak and Dixon, 1995), although unlike other members of this subgroup of MKPs it 
shows a substrate specificity for ERK and does not interact with JNK and p38 MAPK 
isoforms (Mandl et al., 2005). DUSP5’s N-terminal non-catalytic domain contains a KIM 
motif to allow specific binding to ERK and an NLS, which facilitates its nuclear localisation. 
These features combined with its catalytic activity allow DUSP5 to specifically 
dephosphorylate nuclear p-ERK, and then anchor this inactive ERK in the nucleus (Mandl 
et al., 2005). 
The induction of DUSP5 mRNA and protein in response to growth factor stimulation is 
dependent on ERK activation (Kucharska et al., 2009), demonstrating that DUSP5 can act 
as a classical negative feedback regulator of the ERK pathway. Recently, the transcription 
factors serum response factor (SRF) and ELK1 have been shown to be essential for the 
EKR-mediated induction of DUSP5 (Buffet et al., 2015). DUSP5 protein has a short half-life 
and is rapidly downregulated by ubiquitination and proteasomal degradation (Kucharska 
et al., 2009). DUSP5 is also phosphorylated in vitro and in vivo on three sites (Thr321, 
Ser346 and Ser376) in its N-terminal regulatory domain by ERK in a manner that is 
dependent on the KIM-mediated binding of DUSP5 to ERK. However, mutation which 
abrogate this phosphorylation does not seem to affect the stability of DUSP5 protein 
(Kucharska et al., 2009), in a similar manner to the ERK-dependent phosphorylation of 
other MKPs such as DUSP1/MKP-1 and DUSP6/MKP-3 (Brondello et al., 1999; Lin and 
Yang, 2006; Marchetti et al., 2005). In fact further analysis could not reveal any function 
for the ERK-mediated phosphorylation of DUSP5 in terms of effects on substrate 
specificity, cellular localisation, or its ability to anchor ERK in the nucleus (Kucharska et al., 
2009). However, DUSP5 was found to be stabilised by complex formation with ERK 
independently of any phosphorylation events, indicating that substrate binding by DUSP5 
may prolong its ability to dephosphorylate and act as a nuclear anchor for ERK (Kucharska 
et al., 2009).  
DUSP5 is one of the least studied of the MKPs. This is probably because for many years it 
was assumed to behave similarly to DUSP1/MKP-1 and DUSP4/MKP-2, and also due to a 
lack of reagents, in particular commercially available DUSP5-specific antibodies. However, 
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despite this a number of physiological roles have been proposed for DUSP5. These 
include, a role in p53-dependent suppression of cell proliferation, as DUSP5 was revealed 
to be a direct transcriptional target of p53 (Brynczka et al., 2007; Ueda et al., 2003). 
DUSP5 is also proposed to play a role in T-cell development due to the observation that it 
was highly induced following IL-2 stimulation of T-cells, where it was assumed to be 
involved in regulating ERK activity (Kovanen et al., 2003). The same group subsequently 
demonstrated that in transgenic mice overexpressing DUSP5 in the lymphoid 
compartment thymocyte development was arrested at the double positive stage and that 
these animals went on to develop autoimmune symptoms. Furthermore, DUSP5-
overexpressing mature T cells exhibited decreased IL-2-dependent gene expression and 
proliferation (Kovanen et al., 2008). However, whilst striking these results are probably 
more reflective of the role of ERK in immune system development, IL-2 signalling, and 
immune tolerance as the overexpression of DUSP5 will act as a potent ERK inhibitor 
rather than recapitulating its true physiological role. Consequently, either knockdown or 
the genetic ablation of DUSP5 would be much more informative in revealing the bona fide 
role(s) of DUSP5. DUSP5 overexpression was also used to demonstrate that DUSP5 
expression (or ERK inhibition) can help to attenuate collagen-induced arthritis in mice 
(Moon et al., 2014). 
Genetic ablation or siRNA knockdown of DUSP5 have also linked this MKP to other 
physiological functions including: a negative regulator of corneal epithelial cell 
proliferation (Wang et al., 2010), as a negative regulator of IL-33-dependent eosinophil 
function and survival (Holmes et al., 2015), and as a regulator of cardiac fibroblast 
proliferation and cardiac hypertrophy (Fan et al., 2014; Ferguson et al., 2013; Tao et al., 
2015; Wickramasekera et al., 2013). 
1.3.4 DUSP6/MKP-3 
DUSP6/MKP-3 (also known as MKP-3) was independently identified by three groups, and 
shown to selectively bind and dephosphorylate ERK, with only very weak catalytic activity 
against either the JNK or p38 MAPKs (Groom et al., 1996; Mourey et al., 1996; Muda et 
al., 1996). DUSP6/MKP-3 displayed cytoplasmic localisation (Groom et al., 1996; Mourey 
et al., 1996), making it the prototypical member of the cytoplasmic ERK-selective 
subgroup of MKPs. The cytoplasmic localisation of DUSP6/MKP-3 is facilitated by the 
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presence of a leucine-rich NES within the N-terminal non-catalytic domain, which 
mediates the nuclear export of DUSP6/MKP-3 via the canonical chromosome region 
maintenance-1 (CRM1)-dependent nuclear export pathway. Nuclear export is an active 
process, and its inhibition with leptomycin B results in nuclear accumulation of 
DUSP6/MKP-3, suggesting that it can shuttle between the nucleus and cytoplasm. 
Furthermore the NES, along with DUSP6/MKP-3s KIM motif, can facilitate the anchorage 
of dephosphorylated ERK within the cytoplasm (Karlsson et al., 2004). As mentioned 
previously, DUSP6/MKP-3 undergoes catalytic activation following its binding to ERK, 
undergoing a conformational change to bring critical residues within the active site of the 
enzyme site into the optimal position for catalysis (Camps et al., 1998; Nichols et al., 
2000; Stewart et al., 1999). 
The mechanisms of transcriptional control of DUSP6/MKP-3 expression were first 
revealed during studies investigating the role of fibroblast growth factor (FGF) signalling 
in embryogenesis. Initial studies identified DUSP6/MKP-3 expression to occur at sites of 
FGF signalling in mouse embryos (Dickinson et al., 2002). This DUSP6/MKP-3 expression 
was subsequently shown to be induced by FGF signalling, although there was initially 
debate over whether this occurred in a PI3K (Kawakami et al., 2003) or MEK-dependent 
manner (Eblaghie et al., 2003) during chick embryogenesis. Further studies revealed the 
transcriptional induction of DUSP6/MKP-3 to be dependent on ERK activity. This was 
demonstrated through the observation that DUSP6/MKP-3 expression co-localised with 
ERK activity, and was sensitive to ERK inhibition through the use of a MEK inhibitor or by 
ectopic expression of DUSP6/MKP-3 itself during chick embryogenesis (Smith et al., 2006). 
In contrast, mice lacking PDK1, an essential mediator of PI3K signalling still display 
DUSP6/MKP-3 expression (Smith et al., 2006). Additionally, DUSP6-/- mouse embryos 
displayed increased ERK activity, ERK-dependent gene expression and reporter gene 
output from the DUSP6/MKP-3 promoter (Li et al., 2007). Furthermore, the utilisation of 
chemical inhibitors of both the ERK and PI3K pathways supported these results, 
demonstrating a reduction in DUSP6/MKP-3 induction in NIH 3T3 cells or during chick 
embryogenesis following MEK, but not PI3K, inhibition (Ekerot et al., 2008). Finally, 
DUSP6/MKP-3 induction by ERK activity has been shown to be dependent on ERK 
mediated ETS transcription factor activity and direct binding to the DUSP6/MKP-3 
promoter (Ekerot et al., 2008; Zhang et al., 2010).  
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DUSP6/MKP-3 protein levels can be modulated by post-translational modifications, which 
alter protein stability. Phosphorylation of Ser159/197 on DUSP6/MKP-3 promotes its 
ubiquitin-mediated degradation, this can be mediated by ERK (Marchetti et al., 2005), or 
by the phosphorylation of Ser159 alone by the PI3K/mammalian target of rapamycin 
(mTOR) pathway (Bermudez et al., 2008). This ability of the PI3K/mTOR pathway to 
promote DUSP6/MKP-3 degradation constitutes a mechanism of crosstalk by which 
PI3K/mTOR signalling could regulate ERK activity. This could be particularly important in 
Ras-driven cancers, which are able to activate both signalling pathways, or in allowing 
mutations in components of the PI3K/mTOR pathway to promote additional ERK-
dependent tumourigenic functions. 
A significant physiological role for DUSP6/MKP-3 was first suggested when morpholino-
mediated DUSP6/MKP-3 knockdown was shown to disrupt axial polarity during zebrafish 
embryogenesis, due to deregulation of FGF signalling (Tsang et al., 2004). However, this 
phenotype was not recapitulated in DUSP6/MKP-3 knockout mice, where an analysis of 
murine embryogenesis revealed that DUSP6/MKP-3 loss elevated levels of p-ERK and 
promoted a severe variably penetrant phenotype comprising partial postnatal lethality, 
skeletal dwarfism and hearing loss. These phenotypic traits are characteristic of activating 
mutations of FGF receptors, again indicating an essential role for DUSP6/MKP-3 in the 
control of FGF signalling during embryogenesis (Li et al., 2007). However, a second line of 
DUSP6/MKP-3 knockout mice showed no such problems, were viable into adulthood, 
fertile, and otherwise overtly normal, apart from demonstrating an increase in basal ERK 
phosphorylation in the heart, spleen, kidney and brain. The increased ERK activation in 
the heart was associated with increased myocyte proliferation, enlarged organ size and 
protection against heart failure following long term pressure overload in adult mice 
(Maillet et al., 2008). At present it is unclear why these results are so divergent but 
variations in the mouse strain genetic background are a possible cause. 
 More recently, DUSP6/MKP-3 has been shown to be involved in glucose homeostasis, 
diabetes and obesity. DUSP6/MKP-3 expression has been shown to be significantly 
induced in mice following diet-induced obesity or in genetically obese mice (Wu et al., 
2010; Xu et al., 2005a). DUSP6/MKP-3 promotes gluconeogenic gene transcription in 
hepatoma cells and in vivo, following its upregulation in a Forkhead box protein O1 
52 
 
(FOXO1)-dependent manner (Feng et al., 2014a; Jiao et al., 2012), and DUSP6/MKP-3 
ablation protects mice from diet-induced obesity and improves insulin sensitivity (Feng et 
al., 2014b). Finally, alterations in DUSP6/MKP-3 expression has been observed in human 
tumours and there is increasing evidence that DUSP6/MKP-3 plays a role in the 
pathogenesis of several types of cancer, as detailed below. 
1.3.5 MKPs and cancer 
Given the roles of MKPs as negative feedback regulators of MAPKs, it is not surprising that 
alterations in the expression levels of MKPs have been detected in cancers, particularly 
those driven by mutations in upstream components of the MAPK pathways themselves. 
Based on such observations MKPs have been implied to have key roles in cancer 
induction, progression and in mediating the response of tumour cells to chemotherapy 
(Keyse, 2008; Kidger and Keyse, 2016b). Kidger and Keyse, (2016a) summarises the 
current evidence for the deregulation of MKPs in cancer. The overall picture is somewhat 
contradictory and confusing with many MKPs being implicated in both the promotion and 
suppression of tumourigenesis, depending on the cancer type and state of progression. 
However, much of this evidence is based on correlations between altered levels of MKP 
expression and prognosis or tumour progression in relatively small numbers of patients, 
and there is limited evidence defining functional roles for altered MKP expression in 
cancer. This provokes the question, are MKPs playing a significant role in the 
development and maintenance of tumours and if so are they tumour suppressors or 
oncogenes? 
Elevated MKP expression has been associated with poor prognosis or chemoresistance in 
many cancer types (Keyse, 2008). With regard to JNK or p38-specific MKPs this could be 
mediated through their ability to antagonise pro-apoptotic signalling. For example, 
DUSP1/MKP-1 overexpression in prostate and breast cancer is inversely correlated with 
JNK activity, implying an oncogenic function for DUSP1/MKP-1 through the inhibition of 
JNK/p38-mediated apoptosis (Magi-Galluzzi et al., 1997; Wang et al., 2003). However, the 
ability of MKPs to antagonise MAPK-induced proliferation makes them logical tumour 
suppressors and many studies have associated loss of MKP expression with cancer 
progression (Bermudez et al., 2010; Keyse, 2008). Independent studies have revealed the 
downregulation of DUSP2, DUSP4/MKP-2 and DUSP6/MKP-3 expression in lung 
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adenocarcinoma and have linked these events to increased ERK activation and tumour 
progression (Chitale et al., 2009; Lin et al., 2011; Okudela et al., 2009). In multiple cases 
both elevated and decreased MKP expression has been observed in the same tumour, but 
at differing stages of tumour progression. Typically in these cases the MKP is initially 
overexpressed in low grade tumours, followed by loss of expression in higher grade 
cancers. This distinctive pattern of MKP expression has been demonstrated for 
DUSP1/MKP-1 in human epithelial tumours, including prostate, colon and bladder, (Loda 
et al., 1996), DUSP4/MKP-2 in ovarian tumours, (Sieben et al., 2005) and  DUSP6/MKP-3 
in pancreatic cancer (Furukawa et al., 2003). For both DUSP4/MKP-2 in ovarian tumours 
and DUSP6/MKP-3 in pancreatic cancer MKP down regulation coincides with tumour 
progression to invasive carcinoma (Furukawa et al., 2003; Sieben et al., 2005). A 
hypothesis to explain this dynamic alteration of MKP expression through tumour 
progression could be that the initial overexpression is a feedback response to increased 
MAPK signalling in the tumour. This MKP-mediated negative feedback could have an 
oncogenic function through the tempering of ERK activation to prevent oncogenic 
mutations inducing excessive ERK signalling which is able to induce cell cycle arrest, cell 
senescence or apoptosis (Caunt and Keyse, 2013; Deschênes-Simard et al., 2014; Meloche 
and Pouysségur, 2007; Shojaee et al., 2015) or alternatively through antagonising 
JNK/p38 activity to constrain pro-apoptotic signalling. Subsequently, if the tumour 
evolves and acquires additional mutations, which can override the blocks to cell cycle 
progression or pro-apoptotic signalling then a loss of MKP activity could confer a selective 
advantage, as reduced MAPK signalling would be now primarily constraining the 
proliferative capacity of the tumour. 
The ability of MKPs to respond to multiple stimuli, including oncogenic activation of the 
MAPK pathway themselves, and regulate MAPK signalling to mediate diverse cellular 
processes, means it is no surprise that MKPs have demonstrated altered expression in 
cancer and have been implicated to have roles in tumourigenesis. What is perhaps more 
surprising it that these alterations in MKP expression levels have been implicated in 
modulating both the oncogenic and tumour suppressive properties of the MAPKs. 
However, when viewed in perspective of the diverse biological outcomes that MAPK 
signalling pathways can induce dependent on the cellular context, as well as the diverse 
and often opposing roles MAPKs have shown in human cancers, a tissue-specific and 
54 
 
cellular context-dependent role for MKP signalling in cancer appears logical. The ability of 
MKPs to display an oncogenic or tumour suppressive function could be influenced by the 
cancer type, mutational background of the tumour and nature of the driving oncogene(s), 
in particular whether it is likely to rewire MAPK pathways (Caunt and Keyse, 2013). 
Therefore, future studies investigating the role of MKPs in human cancers ideally need to 
perform analysis of MKP expression with regard to tumour grade and the mutational 
background of the tumour. Furthermore, mouse knockout models could be utilised to 
determine whether MKPs have significant functional roles in the initiation and 
progression of cancers, or whether alterations in their activity are simply a consequence 
of signalling pathway deregulation and rewiring in cancers. Together these approaches 
could elucidate under what scenarios MKP expression is being altered, and whether such 
alterations in MKP expression are having functional consequences on the outcome of 
MAPK signalling and tumour progression in particular cancers. 
1.3.5.1 DUSP5 and cancer 
Perhaps due to it being one of the least well studied MKPs, relatively little is known about 
the potential roles in cancer for DUSP5. However, given its function as a nuclear ERK-
specific negative feedback regulator, DUSP5 mRNA and protein levels would be expected 
to be increased and to play some role in cancers driven by activating mutations upstream 
of ERK. This is indeed the case with both DUSP5, and the cytoplasmic ERK-specific 
phosphatase DUSP6/MKP-3, being identified amongst a subset of the most consistently, 
upregulated genes in mutant Ras and BRaf-driven colorectal and endometrial cancer cell 
lines (Kreeger et al., 2009; Vartanian et al., 2013; Yun et al., 2009). A functional role for 
DUSP5 in mutant Ras-driven cell lines was postulated due to high DUSP5 expression 
correlating with decreased ERK activity (Kreeger et al., 2009). Furthermore, oncogenic 
activation of KRasG12V and BRafV600E in normal intestinal epithelial crypt cells (IECs) leads 
to elevated cytoplasmic, but not nuclear, p-ERK levels. This spatial restriction correlated 
with the potent upregulation of the nuclear MKPs DUSP4/MKP-2 and DUSP5 (Cagnol and 
Rivard, 2012). The potential importance of elevated DUSP5 expression can be 
demonstrated by the requirement for DUSP5, and DUSP6/MKP-3, expression to enable 
the proliferation of MCF7 breast cancer cells following phorbol-ester treatment. MCF7 
cells display an ERBB2 gene amplification, therefore increasing ERK pathway activation 
downstream of this RTK. DUSP5 and DUSP6/MKP-3 were shown to be upregulated in an 
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ERK-dependent manner via the transcription factors ETS2 and c-JUN respectively 
following phorbol-ester treatment. The siRNA-mediated knockdown of DUSP5 or 
DUSP6/MKP-3 promoted cell-cycle arrest and senescence, indicated by p21 accumulation, 
whereas the stable-overexpression of DUSP5 or DUSP6/MKP-3 promoted increased 
proliferation (Nunes-Xavier et al., 2010). 
Recently the first evidence for altered expression levels, and possible functional roles, of 
DUSP5 in human cancers has emerged. DUSP5 has been shown to be downregulated in 
human CRC cell lines and tissue samples through hypermethylation (Togel et al., 2012). 
Loss of DUSP5 expression due to aberrant hypermethylation has been detected in 
advanced gastric cancers, but not in the normal gastric mucosa, and DUSP5 promoter 
hypermethylation correlated with significantly shortened patient survival. Furthermore, 
restoring DUSP5 expression in DUSP5 hypermethylated gastric cancer cell lines decreased 
their proliferative capacity and colony-forming ability (Shin et al., 2013). Loss of DUSP5 
expression has also been detected in prostate cancer, where it again correlated with poor 
patient outcome (Cai et al., 2015). However, this study solely detected DUSP5 expression 
through immunohistochemistry (IHC) and the DUSP5 antibody employed in this study was 
shown to detect DUSP5 solely in the cytoplasm and on the cell membrane in prostate 
epithelial and prostate cancer cells. This conflicts with the established subcellular 
localisation for DUSP5 (Mandl et al., 2005), bringing the specificity of their antibody and 
thus these results into question. Overall, DUSP5 has shown elevated expression in 
response to oncogenic stimulation of the ERK pathway, and has been demonstrated to be 
lost in some cancers, implying a tumour suppressive role for DUSP5. Although the fact 
that DUSP5 was required for proliferation of some cancer cells (Nunes-Xavier et al., 2010) 
indicates that in certain contexts DUSP5 could play an oncogenic role through the 
prevention of OIS. 
1.3.5.2 DUSP6/MKP-3 and cancer 
DUSP6/MKP-3, like DUSP5, has been shown to be consistently, highly upregulated in 
many mutant Ras or BRaf-driven cancer cell lines, where it is presumed to constrain 
oncogenic ERK signalling (Bloethner et al., 2005; Croonquist et al., 2003; Haigis et al., 
2008; Packer et al., 2009; Pratilas et al., 2009; Vartanian et al., 2013; Yun et al., 2009). 
Indeed, siRNA-mediated DUSP6/MKP-3 knockdown promoted increased ERK activation 
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and proliferation in KrasG13D/+-driven CRC cell lines, suggesting a tumour suppressive role 
for DUSP6/MKP-3 in CRC (Haigis et al., 2008). However as mentioned previously, 
DUSP6/MKP-3 knockdown promoted cell-cycle arrest and senescence in MCF7 breast 
cancer cells, implying that in alternative contexts DUSP6/MKP-3 is required for 
proliferation and therefore plays an oncogenic role (Nunes-Xavier et al., 2010). 
The first evidence of a link between DUSP6/MKP-3 and human cancer was observed in 
pancreatic ductal adenocarcinoma (PDAC), where DUSP6/MKP-3 protein was shown to be 
overexpressed in the precursor lesions of PDAC, pancreatic intraepithelial neoplasia 
(PanINs), but then subsequently down regulated in approximately 80% of poorly 
differentiated, invasive PDAC (Furukawa et al., 2003). PDAC is initiated by activating 
mutations in KRas in approximately 90% of cases, indicating that ERK signalling may play a 
key role in disease pathogenesis (Kleeff et al., 2016). DUSP6/MKP-3 was initially 
investigated due to its location in chromosomal region 12q21-23.1, which is frequently 
hemizygously deleted in primary pancreatic cancer with poor prognosis (Kimura et al., 
1996, 1998; Yatsuoka et al., 2000). Loss of heterozygosity (LOH) of chromosome 12q was 
detected in around 30% of pancreatic tumour samples tested (Kimura et al., 1996; 
Yatsuoka et al., 2000), which would not account for the total loss of DUSP6/MKP-3 
expression in PDAC tissues. However, no mutations have been detected in the 
DUSP6/MKP-3 gene in PDAC cell lines (Furukawa et al., 1998), suggesting an epigenetic 
mechanism promoting the abrogation of DUSP6/MKP-3 in pancreatic cancer. 
Subsequently, aberrant hypermethylation of the DUSP6/MKP-3 promoter has been 
associated with DUSP6/MKP-3 suppression in pancreatic cancer cell lines and tissues. In 
PDAC cell lines hypermethylation was reversible after treatment with the DNA 
methyltransferase inhibitor 5-azacytidine or the histone deacetylase inhibitor trichostatin 
A, resulting in restored DUSP6/MKP-3 expression (Xu et al., 2005b). Furthermore, 
adenovirus-mediated ectopic expression of DUSP6/MKP-3 in such cells reduces p-ERK 
levels in a dose-dependent manner, inhibiting their proliferation and inducing apoptosis 
(Furukawa et al., 2003). However, conclusions drawn from the overexpression of 
DUSP6/MKP-3, driven by constitutively active promoters, should be treated with caution 
due to its ability to result in near complete ablation of ERK activity in a manner which 
endogenous or physiological levels of DUSP6/MKP-3 might not be able to achieve. Finally, 
whilst the expression of many tumour suppressors involved in pancreatic cancer 
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development, such as p53, CDKN2A or SMAD4, is lost during, and thought to contribute 
to, PanIN progression, the loss of DUSP6/MKP-3 is only observed in invasive carcinoma 
(Furukawa et al., 2005). This evidence has led to the proposal that DUSP6/MKP-3 
expression is induced as a negative feedback regulator of ERK activity in PanINs, which is 
able to restrain the progression of PanINs to invasive carcinoma in a manner that is 
independent of other major tumour suppressors. Consequently, DUSP6/MKP-3 
suppression could be an important factor in the development of malignancy of PDAC 
(Furukawa, 2009; Furukawa et al., 2006). 
DUSP6/MKP-3 has also demonstrated a tumour suppressive function in non-small-cell 
lung cancer (NSCLC) (Okudela et al., 2009), another cancer type which exhibits KRas 
mutations in ~30% of cases (Karachaliou et al., 2013; Suda et al., 2010). In a similar 
manner to pancreatic cancer, low-grade and pre-neoplastic lung lesions expressed high 
levels of DUSP6/MKP-3 protein compared to the normal bronchial epithelial tissue, 
DUSP6/MKP-3 levels were then shown to decrease in an inverse correlation with 
increasing histological grade and the proliferative capacity of the tumours (Okudela et al., 
2009). Furthermore, LOH of the DUSP6/MKP-3 locus was identified in 17.7% of 64 tumour 
samples analysed, where it was associated with reduced DUSP6/MKP-3 expression levels. 
In contrast, no mutations in the protein-coding exons of the DUSP6/MKP-3 gene were 
identified. This study also demonstrated that restoration of DUSP6/MKP-3 expression 
suppressed proliferation in lung cancer cells (Okudela et al., 2009), however such 
overexpression experiments retain the caveat described above. Despite this, further in 
vitro studies in NSCLC cell lines support this data with an inverse correlation between 
levels of DUSP6/MKP-3 and ERK activation detected in H441 cells. Again, DUSP6/MKP-3 
overexpression inhibited proliferation and promoted apoptosis, while this was supported 
by siRNA knockdown experiments demonstrating the opposing phenotype by increasing 
ERK activation and proliferation rates (Zhang et al., 2010). More recently multiple 
quantitative real-time polymerase chain reaction (qRT-PCR)-based studies on large 
cohorts of patient samples have identified a downregulation of DUSP6/MKP-3 expression 
in NSCLC (Díaz-García et al., 2014; Skrzypski et al., 2013), and low DUSP6/MKP-3 
expression correlated with shortened patient survival (Díaz-García et al., 2014). Finally, 
studies in oesophageal squamous cell carcinoma (ESCC) and nasopharyngeal carcinoma 
(NPC) also suggest a tumour suppressor role for DUSP6/MKP-3. DUSP6/MKP-3 protein 
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was shown to be significantly downregulated in ESCC and NPC tissue, compared to 
adjacent normal tissue, and decreased DUSP6/MKP-3 expression correlated with 
decreased patient survival. Restoration of DUSP6/MKP-3 expression ESCC and NPC cell 
lines impairs both cell invasion and epithelial to mesenchymal transition (EMT)-associated 
properties of these cell lines, implicating DUSP6/MKP-3 to have a functional role 
restraining malignant progression and metastasis in these cancers (Wong et al., 2012). 
Subsequent studies focusing on ESCC support this data, with reduced DUSP6/MKP-3 
expression observed in ESCC tissue, at both the protein and mRNA level, and associated 
with increased pathological grade. Low DUSP6/MKP-3 expression in ESCC cell lines was 
shown to be due to promoter hypermethylation and the restoration of DUSP6/MKP-3 
expression promoted increased apoptosis in these cell lines (Ma et al., 2013). 
While the studies above present strong evidence suggesting a tumour suppressor role for 
DUSP6/MKP-3 in multiple cancer types, alternative studies in a range of other cancer 
types have indicated it might be oncogenic. In poorly differentiated and papillary thyroid 
carcinomas (PTC)  DUSP6/MKP-3 is overexpressed at both the protein and mRNA level, 
compared to benign neoplasms, and increasing DUSP6/MKP-3 expression is associated 
with high-risk features of PTC, such as increased tumour size (Degl’Innocenti et al., 2013; 
Kim et al., 2014; Lee et al., 2012). Thyroid carcinomas frequently carry gene 
rearrangements that generate oncogenic forms of RTKs, such as RET/PTC (rearranged in 
transformation/papillary thyroid cancer) or BRafV600E and RAS mutations, therefore the 
ERK pathway is thought to play a central role in thyroid carcinogenesis. DUSP6/MKP-3 
siRNA-mediated knockdown in PTC cell lines reduced proliferation and invasion, 
implicating an oncogenic role for DUSP6/MKP-3 in thyroid cancers (Degl’Innocenti et al., 
2013). This is supported by evidence from breast cancer, where DUSP6/MKP-3 has been 
shown to be overexpressed in HER2-positive breast cancers and triple-negative MDA-MB-
231 cells  (Boulding et al., 2016; Lucci et al., 2010), and DUSP6/MKP-3 knockdown 
suppressed proliferation, migration and invasion in MDA-MB-231 cells (Song et al., 2015). 
Furthermore, DUSP6/MKP-3 is overexpressed in glioblastoma tissue samples and many 
cancer cell lines, where it has been shown to promote increased colony formation in soft 
agar and proliferation in mouse xenograft models (Messina et al., 2011). 
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The strongest evidence for an oncogenic role of DUSP6/MKP-3 comes from a recent study 
of pre-B-cell transformation by BCR-ABL1 activation, as a model of acute lymphoblastic 
leukemia (ALL) (Shojaee et al., 2015). Malignant transformation of human pre-B cells by 
BCR-ABL1 or NRasG12D activation induced immediate cell death in virtually all cells, and 
the small fraction which survived acquired permissiveness through robust activation of 
ERK negative feedback systems. Three of the most strongly upregulated genes were 
DUSP6/MKP-3, sprouty-2, and the transcription factor ETV5 (Ets Varient Gene 5), which 
were induced in an ERK-dependent manner, and subsequently shown all to be essential 
for oncogenic transformation of pre-B cells in mouse models for ALL. High DUSP6/MKP-3 
expression strongly correlated with shorter overall survival for adults with Philadelphia 
chromosome positive (Ph+) pre-B ALL, but showed no correlation with survival in myeloid 
leukemias, indicating a lineage-specific role for DUSP6/MKP-3. This lineage-specific role 
for DUSP6/MKP-3 was supported by evidence that B-cell progenitors from DUSP6-/- mice 
were resistant to BCR-Abl1 induced transformation and colony formation, suggesting an 
oncogenic role for DUSP6/MKP-3. In contrast, myeloid progenitors from DUSP6 -/- mice 
showed elevated BCR-Abl1 induced transformation and colony formation, suggesting a 
tumour suppressive function for DUSP6/MKP-3. To validate the hypothesis that 
DUSP6/MKP-3 might be a therapeutic target in human ALL a previously described 
pharmacological DUSP6/MKP-3 inhibitor, BCI (2-benzylidene-3-(cyclohexylamino)-1-
Indanone hydrochloride), was utilised. BCI treatment caused a rapid increase in ERK 
activity in patient-derived Ph+ ALL cells, coupled with the induction of a cell cycle arrest 
and p53-mediated cell death. Furthermore, BCI treatment is able to overcome resistance 
to tyrosine kinases inhibitors (TKIs) in Ph+ ALL cells, by inducing ERK hyperactivation and 
the associated induction of senescence and apoptosis (Shojaee et al., 2015). However, 
although biochemical studies have demonstrated that BCI inhibits DUSP6/MKP-3 through 
the prevention of ERK-dependent allosteric changes which enable its catalytic activity, 
this drug is non-specific in terms of MKP binding and it also displays clear toxicity, 
therefore the development of more specific compounds is required before DUSP6/MKP-3 
inhibition could be considered in the clinic (Korotchenko et al., 2014; Molina et al., 2009). 
Interestingly, evidence from melanoma paints a heterogeneous role for DUSP6/MKP-3 in 
tumourigenesis. Melanoma is another cancer in which BRafV600E is frequently a driving 
oncogene, and has been shown to upregulate DUSP6/MKP-3 possibly as a mechanism to 
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restrain ERK activity (Bloethner et al., 2005; Packer et al., 2009). DUSP6/MKP-3 is 
upregulated in, non-BRaf mutant, tumourigenic mouse melanocytes, where it promotes 
growth and invasion. These cells appear to have many features in common with a distinct 
subtype of thick primary human melanoma, which display high DUSP6/MKP-3 levels and 
poor prognosis. However, in BRafV600E expressing human melanoma cell lines ectopic 
expression of DUSP6/MKP-3 suppresses colony formation and invasion (Li et al., 2012). 
Consequently, as well as displaying opposing roles in cancer development across distinct 
cancer types, it appears likely that DUSP6/MKP-3 can promote alternative outcomes in 
different subtypes of the same cancer. 
In addition to oncogenic or tumour suppressive roles in cancer DUSP6/MKP-3 has been 
implicated to be involved in the resistance to chemotherapy in a number of cancers. The 
elevated expression of DUSP6/MKP-3 has been associated with tamoxifen resistance in 
breast cancer (Cui et al., 2006) and cisplatin resistance in glioblastoma (Messina et al., 
2011). In this second study DUSP6/MKP-3 knockdown increased the sensitivity of 
glioblastoma cell lines and xenografts to cisplatin treatment (Messina et al., 2011). 
Furthermore, in two recent papers DUSP6/MKP-3 has been shown to play a key role in 
the response of tumour cells to targeted therapeutics, which aim to inhibit signalling from 
mutations upstream of ERK. Hrustanovic et al. (2015) demonstrated that EML4-ALK 
positive lung adenocarcinoma is able to acquire resistance to ALK-specific TKIs via either 
decreased expression of DUSP6/MKP-3 or a gain in copy number of the wild-type KRAS 
gene, resulting in ERK pathway reactivation, which the tumour is dependent on for 
survival. Stable re-expression of DUSP6/MKP-3 was able to re-sensitise TKI resistant cells, 
causing decreased ERK activity and increased cell death, whereas DUSP6/MKP-3 
knockdown promoted increased TKI resistance in drug naïve cells. Furthermore, 
decreased DUSP6/MKP-3 protein expression was detected in TKI-resistant patient tumour 
samples relative to drug naïve samples (Hrustanovic et al., 2015). Activating mutations in 
EGFR are also a common driver mutation for lung cancer, occurring in approximately 14% 
of NSCLC, and consequently EGFR TKI development is a therapeutic option for this disease 
(Russo et al., 2015). However, resistance to EGFR TKIs is an emerging problem, which can 
either occur via intrinsic or acquired resistance. Phuchareon et al. (2015) utilised EGFR 
mutant lung cancer cell lines to demonstrate that EGFR TKI treatment caused high levels 
of cell death, yet surviving cells were capable of proliferating and forming colonies in 
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drug, suggesting they exhibit innate resistance. Such resistant cells only displayed a 
temporary blockade of ERK activity following EGFR TKI treatment, although EGFR 
inhibition was continually effective. Drug treatment was shown to cause a significant 
decrease in DUSP6/MKP-3 expression, due to the loss of activity of the transcription 
factor Ets1 caused by TKI-mediated inhibition of PI3K signalling, rather than any alteration 
in ERK activity. Loss of DUSP6/MKP-3 expression correlated with the rebound in ERK 
activity shortly after EGFR TKI treatment, and reconstitution of DUSP6/MKP-3 expression 
was able to prevent this rebound in ERK activity. Elevated ERK activity following EGFR TKI 
treatment promotes NSCLC cell survival via phosphorylation of the pro-apoptotic BH3-
only protein Bim, which promotes its proteasomal degradation and therefore cell survival. 
This study demonstrates the importance of crosstalk in modulating the activity of MKPs, 
and how this can allow them to modulate ERK activity to promote significant cellular 
phenotypes, such as in this case tumour cell survival and resistance to drug treatment 
(Phuchareon et al., 2015). 
Overall, there is some evidence for both oncogenic and tumour suppressive functions for 
DUSP6/MKP-3 depending on the cancer type and cellular context. Furthermore, 
DUSP6/MKP-3 is able to modulate the effects of many chemotherapeutic treatments. 
Together these traits make a strong case to further develop knowledge of the role of 
DUSP6/MKP-3 in the development and progression of many cancers. As much of the 
evidence linking DUSP6/MKP-3 to cancer is based on correlations between expression 
and patient outcome or cell based studies, one obvious area to focus such efforts would 
be through the development of mouse models to investigate the functional effects of 
DUSP6/MKP-3 ablation on the development of individual cancer types and to 
mechanistically investigate any observed phenotypes. 
1.4 Pancreatic cancer 
1.4.1 Pancreatic cancer overview and epidemiology 
Pancreatic cancer is among the most lethal malignancies worldwide, being responsible for 
the 4th highest number of cancer-related deaths in the western world (Ferlay et al., 2015). 
It has a very poor prognosis with a 5 year survival rate of less than 7%, due to a lack of 
therapeutic options and a poor response to chemotherapy (Jemal et al., 2010). 
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Consequently, if outcomes are not improved pancreatic cancer is projected to surpass 
colon and breast cancers to become the second leading cause of cancer-related mortality 
by 2030 (Rahib et al., 2014). Pancreatic ductal adenocarcinoma (PDAC), is the most 
common form of pancreatic cancer occurring in 75-80% of cases, however there are a 
range of other rare malignant neoplasms of the pancreas including: neuroendocrine 
tumours (~15%), colloid carcinomas (~2%), solid pseudopapillary tumours (~2%), acinar 
carcinomas (~1%) and pancreatoblastomas (~0.5%) (Kleeff et al., 2016). 
The poor prognosis of pancreatic cancer is attributed to several factors; perhaps the most 
important being that it is usually diagnosed at an advanced stage. Late diagnosis is due to 
pancreatic cancer often displaying non-specific or very few symptoms at early stages, a 
lack of reliable biomarkers and difficulties detecting early-stage tumours with current 
imaging techniques (Ryan et al., 2014). Pancreatic cancer is very aggressive and therefore 
often displays local perineural or vascular invasion or distant metastasis prior to 
detection. Consequently, pancreatic cancer is frequently diagnosed too late for 
therapeutic intervention to be successful, with only 10–15% of patients diagnosed eligible 
for surgery, the only option with curative potential (Gillen et al., 2010). Pancreatic cancers 
are also characterised by a range of genetic and epigenetic abnormalities, as well as 
dense stromal reaction, making them very heterogeneous. These traits make pancreatic 
cancers very resistant to chemotherapy, radiotherapy and many molecularly targeted 
therapies (Kleeff et al., 2016). 
Although treatment strategies and patient care have gradually improved, increases in 
incidence and mortality are continuing to rise in Europe and North America, which is likely 
to be due to an aging population (Siegel et al., 2015). Age is the major risk factor 
determinant of pancreatic cancer, with the majority of patients diagnosed over 50 years 
old, with incidence increasing with age. Significant preventable risk factors include 
smoking, obesity and diet, particularly high alcohol intake which has been linked to 
chronic pancreatitis, a major risk factor in its own right (Kleeff et al., 2016). Furthermore, 
diabetes mellitus is both significant risk factor for, and a potential consequence of, 
pancreatic cancer (Bosetti et al., 2014). Finally, there is also a hereditary element to 
pancreatic cancer, with around 10% of patients displaying a family history and there are a 
range of genetic syndromes associated with pancreatic cancer including Peutz-Jeghers 
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syndrome, hereditary pancreatitis and Li-Fraumeni syndrome. Together such syndromes 
are associated with mutations in genes such as LKB1, PRSS1, CDKN2A, BRCA1/2, ATM and 
p53 all of which are associated with an increased risk of disease with variable penetrance 
(Rustgi, 2014). 
1.4.2 The mutational spectrum of human pancreatic cancer 
Global genomic analysis has confirmed the major genes involved in the initiation and 
progression of pancreatic cancer, as well as revealing the complex array of infrequently 
mutated genes, chromosomal rearrangements, copy number changes and epigenetic 
alterations found in this disease (Bailey et al., 2016; Biankin et al., 2012; Jones et al., 
2008; Waddell et al., 2015; Witkiewicz et al., 2015). Activating mutations in KRas are the 
predominant driving mutation in pancreatic cancer, occurring in >90% of tumours. The 
other signature mutations of human pancreatic cancers include the frequent inactivation 
the tumour suppressors p53, SMAD4, and CDKN2A, with each occurring in around 50-80% 
of cancers. Furthermore, there is a small subset of genes which are mutated in around 
10% of pancreatic cancers including, TGFBR2, ARID1A and MUC16 amongst others. 
However, above these common gene alterations few others stand out amongst the varied 
mutational spectrum of pancreatic cancer, with the majority of remaining genes having a 
mutational frequency of <2% (Bailey et al., 2016; Biankin et al., 2012; Jones et al., 2008; 
Waddell et al., 2015; Witkiewicz et al., 2015). Despite this, computational analysis has 
shown that many of these diverse mutations do converge on either distinct signalling 
pathways or cellular processes, including KRas, TGF-β, Wnt, Notch or Hedgehog signalling, 
and axon guidance, chromatin remodelling, G1/S transition or DNA repair processes. 
Consequently deregulation of these pathway and processes could be essential for 
pancreatic cancer development and could be key nodes to target with therapeutic 
strategies (Bailey et al., 2016; Ying et al., 2016). 
Using such genomic data, four pancreatic cancer subtypes have been proposed based on 
their genomic structural variation. These subtypes are stable (<50 structural variants), 
scattered (50-200), unstable (>200) or locally rearranged (<50), which has few structural 
events but these a clustered around particular chromosomes indicated amplified 
oncogenes (Waddell et al., 2015). Pancreatic cancers have also been grouped through 
mRNA expression analysis. Micro-dissected pancreatic epithelium from tumours clusters 
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into three subgroups (Collisson et al., 2011), whereas if the surrounding stroma is 
included four subgroups are identified (Bailey et al., 2016): squamous, pancreatic 
progenitor, immunogenic and aberrantly differentiated exocrine (ADEX). These epithelial 
subtypes seem to be histopatholgically distinct and diverge based on their similarity to 
the developing or adult pancreas. Furthermore the subgroup which least resembles the 
normal pancreas, the squamous subtype, is associated with worse prognosis, indicating 
there is some functional difference between these subtypes (Bailey et al., 2016). 
Interestingly, these expression analysis-derived subtypes do not group with the structural 
variation-derived subtypes (Bailey et al., 2016; Waddell et al., 2015). However, defining 
molecular subtypes based on expression analysis results in differential classification 
depending on the input material and the assumptions made during analysis (Kleeff et al., 
2016), as other groups have identified two epithelial and two stromal tumour subtypes 
when transcripts presumed to be from the normal pancreas are first excluded (Moffitt et 
al., 2015). 
1.4.3 The histological progression of pancreatic cancer 
Pancreatic cancer usually arises in the head of the pancreas, enabling invasion into 
surrounding tissues including the spleen, peritoneal cavity, intestine and lymph nodes, 
and with metastasis commonly occurring in the liver and lungs (Hezel et al., 2006). As 
mentioned previously pancreatic cancer has many subtypes including PDAC, 
neuroendocrine tumours and colloid carcinomas, however from herein PDAC will be the 
focus of this thesis. Within PDAC there are a range of subtypes including typical PDAC, 
and the less common types displaying colloid, adenosquamous, or sarcomatoid histology. 
Typical PDAC primarily exhibits a glandular morphology, with many duct-like structures 
forming within a dense stroma, however there can be significant differences in histology, 
tumour grade, cellular atypia or degree of differentiation between tumours, or within 
regions of the same tumour (Hezel et al., 2006; Kleeff et al., 2016). PDAC tumours are 
graded based on their degree of differentiation, ranging from well differentiated (low 
grade) tumours, baring greater morphological resemblance to normal pancreatic tissue, 
to poorly differentiated (high grade) tumours. Generally, the more poorly differentiated 
the tumour, the more aggressive and malignant it is, with high grade tumours correlating 
with worse prognosis (Wasif et al., 2010).  
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Histopathologic studies have identified three morphologically distinct PDAC precursor 
lesions: PanINs, intraductal papillary mucinous neoplasia (IPMNs) and mucinous cystic 
neoplasia (MCNs). PanINs are the most common precursor lesions in humans. They are 
the smallest of the three precursor lesions found forming small ducts, which display a 
progressive divergence in morphological appearance relative to normal pancreatic ducts. 
PanINs are graded from stages 1, 2 & 3 to represent the stepwise progression in 
morphological dysplasia, due to accumulating genetic alterations (Fig. 1.6) (Hezel et al., 
2006; Ryan et al., 2014). PanIN1a are characterized by the formation of a columnar, 
mucinous epithelium with basally located nuclei within small regular shaped ducts. 
PanIN1b begin to acquire a papillary or basally pseudostratified architecture. Whereas 
PanIN2 and 3 gain increasing levels of architectural disorganization, nuclear atypia and 
loss of polarity, with PanIN3s also displaying the characteristic budding off of small groups 
of epithelial cells into the lumen (Hruban et al., 2001, 2006a). High grade PanINs 
eventually transform into PDAC following invasion beyond the basement membrane of 
the ductal structure.  
Activating mutations in KRas and the aberrant expression of sonic hedgehog (SHH) are 
thought to be key processes in the development of PanINs (Morris et al., 2010a). 
However, the cell of origin for PanIN initiation and subsequent PDAC formation are still 
unclear. Current theories focus on the dedifferentiation of acinar tissue and the 
formation of PanINs through acinar to ductal metaplasia (ADM) or a possible adult stem 
cell role for centroacinar cells, making them susceptible to oncogenic transformation (Roy 
and Hebrok, 2015) – these theories will be discussed in further detail below. As 
mentioned previously activating mutations in KRas occur in ~90% of PDAC cases, however 
KRas mutations are also present at >90% frequency in all grades of human PanIN, 
including the lowest grade PanIN1a lesions (Kanda et al., 2012). This evidence places 
activating KRas mutations as the key molecular driver for PDAC formation. Interestingly, 
>99% of PanIN1As contain mutations in KRAS, CDKN2A, the small g-protein GNAS, or 
BRAF, prompting the hypothesis that as well as KRas these other genes can occasionally 
initiate PDAC development (Kanda et al., 2012).  
KRas mutations are thought to initiate the senescence program to constrain the 
proliferation and expansion of PanIN1As until the subsequent loss of the tumour 
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suppressors CDKN2A, p53 and SMAD4 are able to bypass such inhibition to allow 
continued PanIN proliferation and malignant progression (Caldwell et al., 2012). CDKN2A 
is frequently the initial tumour suppressor lost, with low grade PanINs often displaying a 
lack of expression (Furukawa et al., 2005). Loss of function of CDKN2A usually occurs by 
mutation, deletion or promoter hypermethylation, and by the time lesions have 
progressed to invasive PDAC almost all (~95%) have lost CDKN2A expression (Hezel et al., 
2006). CDKN2A encodes two overlapping tumour suppressors, INK4A and ARF. INK4A is 
an inhibitor of cyclin-dependent kinase 4 (CDK4), which prevents the interaction of cyclin 
D with CDK4, therefore promoting a G1 cell-cycle arrest (Serrano et al., 1993). Whereas, 
ARF stabilizes the transcription factor p53 by inhibiting its MDM2-dependent proteasomal 
degradation, allowing p53 to activate a plethora of genes to induce a cell cycle arrest 
(Nakamura, 2004). The p53 gene is frequently mutated (50-70%) in PDAC, usually by 
mutation of the DNA binding domain, which prevents its ability to induce target gene 
expression and cell-cycle arrest (Furukawa, 2009). Mutant p53 is resistant to degradation 
and accumulates in the nucleus, where it can be identified by IHC. This nuclear 
overexpression of mutant p53 is not found in low grade PanINs, only later-stage PanIN2 
or PanIN3s (Furukawa et al., 2005; Maitra et al., 2003). This is consistent with a role for 
p53 in initially preventing the progression of PanINs. However, the accumulation of DNA 
damage and other cellular stress in higher grade PanINs, would generate selective 
pressure to eliminate p53 function to enable the renewed proliferation and survival of 
such highly aberrant cells (Hezel et al., 2006). Finally, SMAD4, the other major tumour 
suppressor lost during PDAC development, is also lost in high grade PanINs (Furukawa et 
al., 2005; Maitra et al., 2003). SMAD4 is a key component of the TGFβ signalling pathway, 
which can promote wide ranging cellular outcomes including differentiation, apoptosis, 
EMT and migration depending on the signalling context. In primary premalignant tumours 
TGFβ signalling has been frequently shown to have a tumour suppressive role through the 
induction of differentiation, cytostasis or apoptosis (Massagué, 2008, 2012), indicating 
why the loss of SMAD4 could promote PanIN progression. However, the exact functional 
consequences of SMAD4 loss in PDAC progression are not fully understood (Furukawa, 
2009). 
IPMNs are larger lesions than PanINs, usually forming grossly visible lesions (>1cm) which 
arise in the main pancreatic duct or on its branches. At the cellular level IPMNs resemble 
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PanINs, and are also associated with abundant mucin production. IPMN can develop into 
two major types of invasive cancer, typical PDAC and a colloid type characterized by 
excessive mucin production (Shi and Hruban, 2012). MCNs are large, grossly visible, 
mucin-producing epithelial cystic lesions. They are characterised by a distinctive ovarian-
type stroma and an absence of a connection to the duct system. Both IPMNs and MCNs 
develop increasing dysplasia and morphological disorganization as they progress through 
increasing grades towards PDAC (Hezel et al., 2006). Furthermore, they display many 
molecular events in common with PanINs including high prevalence of KRas, CDKN2A, p53 
and SMAD4 aberrations.  However, there are subtle differences with lower frequencies of 
KRas mutations and CDKN2A or SMAD4 inactivation discovered in IPMN than PDAC. 
Furthermore, a range of distinct molecular events have been described in IPMN and MCN, 
together this indicates that the development of each type of precursor lesion might 
represent variations in a common theme promoting pancreatic tumourigenesis (Bailey et 
al., 2016; Hezel et al., 2006). 
PDAC is characterised by a strong desmoplastic reaction, forming an abundant, dense 
collagenous stroma around the tumour or precursor lesions. The stroma is formed of 
extra-cellular matrix (ECM) proteins, including collagens, fibronectin and laminin, as well 
as glycoproteins and a cellular element of pancreatic stellate cells, immune cells and 
endothelial cells (Kleeff et al., 2016). Pancreatic stellate cells (also referred to as cancer 
associated fibroblasts), a subpopulation of cells in the normal pancreas, produce 
collagenous stroma following pancreatic injury, inflammation and cancer development 
(Jaster, 2004). Reciprocal interactions between PDAC tumour cells and adjacent stromal 
cells have been reported to regulate oncogenic signalling and promote proliferation, 
migration and survival functions of each other, indicating pancreatic stellate cells to play 
an important role in pancreatic cancer development, maintenance and resistance to 
therapy (Apte et al., 2013; Tape et al., 2016). 
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Figure 1.6 Histological progression and key molecular aberrations observed during the 
development of pancreatic cancer. Images demonstrating the histological progression of 
pancreatic cancer from normal pancreatic tissue, through pancreatic intraepithelial neoplasia 
(PanIN) precursor lesions, to invasive pancreatic ductal adenocarcinoma (PDAC). PanIN1a are 
characterised as epithelial lesions composed of tall columnar cells, with basally located nuclei 
which exhibit abundant mucin production. PanIN1b display the additional development of a 
papillary or pseudostratified architecture. PanIN2 are characterised by the further development of 
nuclear abnormalities, including some loss of polarity, nuclear crowding, enlarged nuclei and 
hyperchromatism. PanIN3 additionally display: true cribriforming (the budding off of small clusters 
of epithelial cells into the lumen of the lesion), a loss of nuclear polarity, abnormal mitoses, 
prominent macro-nuclei and dystrophic goblet cells (inverted goblet cells with mucinous cytoplasm 
oriented toward the basement membrane and nuclei oriented towards the ductal lumen). The 
schematic below displays the prominent genes which acquire molecular aberrations during 
pancreatic cancer progression. (Hezel et al., 2006; Hruban et al., 2001, 2006a, 2006b; Morris et al., 
2010a) (Images from: http://pathology.jhu.edu/pc/professionals/DuctLesions.php, a web resource 
generated following the National Cancer Institute, Pancreas Cancer Think Tank - Hruban et al., 
2006a). 
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1.4.4 Mouse models of pancreatic cancer 
Genomic analysis has revealed the major genes which are mutated during PDAC 
development, however causative roles for these mutant genes cannot be confirmed 
without the use of model systems to demonstrate functional consequences of such 
mutations. Disease models utilised for pancreatic cancer include traditional cell line and 
xenograft models, as well as more physiologically relevant models such as genetically 
engineered mutant mice (GEMMs) and organoid cultures (Baker et al., 2016; Kleeff et al., 
2016). A range of GEMMs have been generated to validate human PDAC genes, 
investigate the mechanisms by which these act to promote tumour progression and 
develop new therapeutic or diagnostic approaches (reviewed in Gopinathan et al., 2015; 
Guerra and Barbacid, 2013; Herreros-Villanueva, 2012; Pérez–Mancera et al., 2012; 
Westphalen and Olive, 2012). Together with genomic studies from human patients, such 
studies have allowed the generic molecular mechanism of pancreatic carcinogenesis to be 
inferred (Fig. 1.6) (Furukawa, 2009; Hruban et al., 2000). 
PanIN initiation typically requires the acquisition of KRAS activating mutations, which 
occur in >90% of cases. The subsequent progression to invasive PDAC is promoted by the 
loss of tumours suppressors including p53 (50-70%), CDKN2A (>95%), SMAD4 (55%) and 
DUSP6/MKP-3 (40%) (Caldas et al., 1994; Furukawa, 2009; Hezel et al., 2006). The first 
GEMM used to validate such a model was the development of an endogenous, oncogenic 
Kras (KrasLSL-G12D) allele, which could be specifically expressed in the pancreas using tissue-
specific Cre recombinase expression driven by either the pancreatic and duodenal 
homeobox 1 (PDX1) or pancreas-specific transcription factor 1α (Ptf1α) promoters. This 
mutant KRas-driven model generated a full spectrum of PanINs which slowly progressed 
to invasive PDAC, demonstrating that Kras ability to be a major driver of PDAC initiation 
(Hingorani et al., 2003). Further GEMMs were rapidly developed that demonstrated the 
importance of the loss of tumour suppressors in the progression from PanINs to PDAC. 
Genetic ablation of CDKN2A or p53, or endogenous expression of Trp53R172H, an ortholog 
of one of the most common human p53 mutations, cooperate with KrasG12D expression to 
drive the accelerated malignant progression of PanINs to invasive PDAC and in many 
cases increased metastatic potential (Aguirre et al., 2003; Bardeesy et al., 2006a; 
Hingorani et al., 2005). Interestingly, the loss of SMAD4 in a KrasG12D background induces 
PDAC development through progression via either IPMNs (Bardeesy et al., 2006b; Kojima 
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et al., 2007) or MCNs (Izeradjene et al., 2007) rather than PanINs. Progression via IPMN or 
MCN following SMAD4 ablation was slower than the accelerated PanIN progression 
following CDKN2A or p53 loss, supporting the evidence from human tumours that 
IPMN/MCN derived tumours are associated with improved prognosis and survival 
(Bardeesy et al., 2006b; Izeradjene et al., 2007). However, the final MCN-derived PDAC 
tumours often have acquired additional mutations in CDKN2A or p53, therefore 
generating a similar mutational spectra to PanIN-derived PDAC suggesting that the 
sequence and context in which these mutations are acquired has an impact on tumour 
development and histology (Izeradjene et al., 2007).  
Combining genetic alterations in putative oncogenes or tumour suppressor genes with 
oncogenic KRas activation has become the standard strategy to determine their function 
in pancreatic cancer development (Kleeff et al., 2016). The use of such strategies has 
revealed the importance of many signalling pathways in tumour initiation and 
progression, including EGFR (Ardito et al., 2012; Navas et al., 2012), phosphatase and 
tensin homolog (PTEN) (Ying et al., 2011), JNK (Davies et al., 2014), STAT3 (Corcoran et al., 
2011), NRF2 (DeNicola et al., 2011) and LKB1 (Morton et al., 2010). Such approaches have 
also been used to probe the relative importance of the signalling pathways downstream 
of KRas for pancreatic development (Collisson et al., 2012; Eser et al., 2013). The findings 
of such studies will be discussed in detail below. Recently, the development of 
transposon-mediated insertional mutagenesis approaches in KRas mutant, PDAC-
sensitised mice has enabled screening strategies to reveal novel functional genes involved 
in PDAC development (Mann et al., 2012; Pérez-Mancera et al., 2012). Furthermore, 
GEMMs have helped to reveal the important oncogenic function of pancreatic 
inflammation (Guerra et al., 2007, 2011) and immune cells (Bayne et al., 2012; Pylayeva-
Gupta et al., 2012) in PDAC development. The use of Cre-drivers localised to specific 
pancreatic cell types has been used to investigate the cell of origin for pancreatic cancer. 
Interestingly this has revealed that ductal cells are not the most susceptible to oncogenic 
transformation, despite the ductal appearance of PanINs, instead a range of cell types 
appear able to generate PDAC (Morris et al., 2010a; Roy and Hebrok, 2015). Current 
insights into the cellular origin of PDAC will be discussed below. Finally, pancreatic cancer 
GEMMs have been used as pre-clinical models to test therapeutic strategies for PDAC, for 
example the dual-targeting of the ERK and PI3K pathways or additional combinations, 
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although to date such approaches have had limit efficacy (Alagesan et al., 2014; Hayes et 
al., 2016; Ischenko et al., 2015). 
Recently, the development of more complicated GEMMs enabling the inducible, 
pancreas-specific, and reversible expression of genes of interest has enabled studies to 
investigate the role of key PDAC genes in the maintenance of established tumours and to 
investigate the functional consequences of targeting such pathways. Two independent, 
inducible KRasG12D-driven PDAC models have demonstrated that PDAC remains 
dependent on KRasG12D expression for tumour maintenance and that ablation of the 
KRasG12D expression causes rapid tumour regression (Collins et al., 2012; Ying et al., 2012). 
KRasG12D was shown to reprogram metabolic pathways to increase glucose uptake and 
drive anabolic glucose metabolism to give tumour cells a selective advantage in low 
glucose conditions, therefore highlighting the potential to target metabolic pathways in 
PDAC therapeutics (Son et al., 2013; Ying et al., 2012). However, although such studies 
point to a strong tumour regression upon targeting mutant KRas signalling subsequent 
studies revealed that PDAC tumours would evolve to acquire resistance to KRas targeting, 
enabling KRasG12D–independent PDAC recurrence. One primary resistance mechanism was 
revealed to be the amplification and overexpression of the transcriptional coactivator 
Yap1, promoting renewed cell proliferation and tumour regrowth (Kapoor et al., 2014). 
The importance of Yap1 overexpression as a tumour resistance mechanism to mutant 
KRas loss can be illustrated by the fact it was independently revealed to be the top hit in a 
genome-wide screen to identify genes which rescue the survival of KRas-dependent 
cancer cells upon KRas suppression (Shao et al., 2014).  
1.4.5 Key unresolved questions in pancreatic cancer 
1.4.5.1 The cell of origin of pancreatic cancer 
Although many of the mutational events involved in PDAC tumour progression are now 
well characterised the cellular origin/s of PDAC are still unclear. PDAC and PanINs possess 
ductal morphology and markers, therefore this led to the initial assumption that they 
developed from pancreatic ductal cells (Morris and Hebrok, 2009). However, GEMMs 
have allowed evaluation of the ability of specific pancreatic cell types to form PDAC. 
Intriguingly, expression of oncogenic KRas under the control of the ductal promoter 
72 
 
cytokeratin-19 (CK19) failed to generate PanINs or PDAC and did not form a clearly 
malignant phenotype (Brembeck et al., 2003). However, pancreatic acinar tissue was 
known to be susceptible to transdifferentiation into a ductal-like state following insults 
including injury, inflammation or oncogenic transformation. This process, known as acinar 
to ductal metaplasia (ADM) occurs in two stages, an initial dedifferentiation of the acinar 
tissue, where it loses its function and identity, followed by a second stage were 
transdifferentiation leads to the original acinar cell adopting true duct-like characteristics 
(Roy and Hebrok, 2015). 
Consequently, a range of studies were performed which demonstrated the ability of 
acinar tissue to undergo ADM and PanIN initiation following embryonic acinar-specific 
KRasG12D-expression (Grippo et al., 2003; Tuveson et al., 2006). This was supported by 
evidence from a KRasG12V-mutant elastase-cre driven model, whereby embryonic 
KRasG12V-expression induced PanIN and PDAC formation. Surprisingly, adult mice were 
resistant to KRasG12V-induced PanINs and PDAC, even in combination with the loss of 
tumour suppressors CDKN2A or p53, unless this was coupled with a caerulein challenge to 
induce pancreatitis (Guerra et al., 2007, 2011). However, studies using the KRasG12D-
mutant driven by inducible Ptf1α, Elastase, Mist1 and proCPA1 promoters have revealed 
adult acinar tissue to be susceptible to oncogenic transformation without associated 
pancreatitis, although such transformation was typically at low levels and could be 
exacerbated with the induction of pancreatitis (De La O et al., 2008; Friedlander et al., 
2009; Habbe et al., 2008; Kopp et al., 2012). Furthermore, Friedlander et al. (2009) 
revealed that KrasG12D expressing Pdx1-positive cells in the adult pancreas can form 
PanINs in the absence of inflammatory pancreatitis, whereas KrasG12D insulin-positive cells 
can only form PanINs in the presence of pancreatitis. PanIN formation has also been 
induced within the ductal cell lineage, however this required combined expression of 
KRasG12D and homozygous expression of mutant p53 (Tp53R172H), making it much less 
likely to occur than PanIN formation from an acinar origin, which in contrast only required 
KRasG12D expression (Bailey et al., 2015).  
Overall, it appears that any pancreatic cell type is able to give rise to PanINs and PDAC, 
although out of the major cell types of acinar, ductal and insulin-positive (endocrine) cells, 
acinar cells seem to be more readily transformed. This comprises the acinar-centric 
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theory of PanIN formation, whereby ADM is the primary source of PanINs. Another 
possibility is that there is a subset of cells which display “stem cell-like” properties which 
are more readily transformed (Roy and Hebrok, 2015). Centroacinar cells could be such a 
cell type, as they display a stem cell-like location in the transition zone and have been 
shown to have the ability to differentiate into any pancreatic cell type when cultured in 
vitro (Rovira et al., 2010). This is supported by evidence including the predisposition of 
PDX1-positive cells to form PanINs following KRasG12D expression without the necessity for 
associated inflammatory pancreatitis, indicating that such cells are more able to form 
PanINs than mature acinar tissue (Friedlander et al., 2009). This developmental plasticity 
of pancreatic cell types is believed to be due to the frequent reactivation of SHH, Wnt/β-
Catenin and Notch embryonic signalling pathways following mutant KRas expression or 
inflammation, causing the dedifferentiation of mature cell populations, enabling 
oncogenic transformation (De La O et al., 2008; Morris et al., 2010a, 2010b; Thayer et al., 
2003).  
1.4.5.2 The relative contribution of Ras effector pathways in pancreatic 
cancer development 
Activating mutations in KRas drive >90% of PDAC, however KRas mutations can induce the 
activation of a range of effector signalling pathways, including the Raf-ERK, PI3K-AKT and 
Ral pathways, to exert their cellular consequences (Pylayeva-Gupta et al., 2011). Since 
KRas itself is considered a very difficult therapeutic target, many therapeutic strategies 
for pancreatic cancer have been conceived to target the pathways downstream of KRas 
(Bournet et al., 2016; Junttila et al., 2014). Therefore, understanding the relative 
contributions of such signalling pathways to PDAC progression and maintenance would 
help to optimise such therapeutic targeting strategies. 
The precise role of the Raf-ERK pathway in pancreatic carcinogenesis is still not fully 
understood. High p-ERK activation is associated with poor survival amongst patients 
following surgical resection of pancreatic tumours (Chadha et al., 2006). Strikingly, 
activating BRaf mutations are one of the few mutations apart from KRas to have been 
identified in PanIN1As, indicating that they have the ability to drive PanIN formation and 
PDAC development (Kanda et al., 2012). Furthermore, up to 5% of PDAC tumours contain 
activating BRaf mutations, resulting in continuous ERK activity. Interestingly, such 
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tumours express wild type KRas, indicating that BRaf and KRas mutations have some 
degree of redundancy; otherwise you would expect a selective pressure to acquire KRas 
mutations (Calhoun et al., 2003). In support of such evidence BRafV600E-driven GEMMs of 
PDAC have been shown induce PanIN formation and PDAC development, in a manner 
which phenocopies KRasG12D expression (Collisson et al., 2012). Furthermore, MEK 
inhibition impaired the proliferation of PDAC cell lines in vitro and in vivo orthotopic 
xenograft models, and could act synergistically with PI3K pathway inhibition to inhibit 
tumour growth (Collisson et al., 2012). Together this evidence demonstrates that 
hyperactivation of the Raf-ERK pathway alone is sufficient to drive PDAC formation, 
indicating this pathway could play a key role as an effector of mutant KRas. 
In addition to its activation by KRasG12D in pancreatic cancer, the PI3K pathway has been 
shown to be activated by other mechanisms including aberrant activation of RTKs, 
downregulation of PTEN, by mutations in the catalytic subunit of PI3K (p110/PIK3CA) and 
the amplification of AKT2  (Pérez–Mancera et al., 2012). In a manner similar to p-ERK, 
high levels of p-AKT (representing AKT that is activated via phosphorylation at Thr308 and 
Ser473) are associated with poor survival (Chadha et al., 2006). The pancreas-specific 
knockout of PTEN, a negative regulator of PI3K signalling, induced AKT activity, ductal 
metaplasia and the formation of PDAC at a low frequency (Stanger et al., 2005). In 
KRasG12D-driven PDAC GEMMs PTEN ablation can cooperate with KRasG12D expression and 
the loss of other tumour suppressors to accelerate PDAC formation (Hill et al., 2010; 
Kennedy et al., 2011; Ying et al., 2011). More recently, PI3K-p110a, 3-phosphoinositide-
dependent protein kinase 1 (PDK1) and Rac1, but not CRaf, have been shown to be 
essential for KRasG12D-driven PanIN and PDAC formation (Baer et al., 2014; Eser et al., 
2013; Wu et al., 2014). Furthermore, the expression of the mutant PI3K subunit 
p110aH1047R in the pancreas is able to phenocopy KRasG12D-induced PanIN formation and 
the progression to metastatic PDAC (Eser et al., 2013). Together such studies 
demonstrate that in the context of KRasG12D-driven PDAC the PI3K-pathway might play 
more of an essential role than that of the Raf-ERK pathway. However, before this 
conclusion can be confirmed future studies should investigate the effects of total ablation 
of Raf-ERK signalling in KRasG12D-driven PDAC, as was performed for KRasG12D-driven 
NSCLC by Blasco and colleagues (2011).  
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Although some elements of the PI3K pathway have been shown to be essential for PDAC 
development and have shown efficacy in vitro and in GEMMs (Eser et al., 2013; Payne et 
al., 2015), their targeted inhibition has been largely unsuccessful in the clinic (Javle et al., 
2010; Richards et al., 2011). Combinations of PI3K and MEK inhibitors have shown 
synergy and improved efficacy in PDAC GEMMs (Alagesan et al., 2014; Ischenko et al., 
2015), demonstrating that both of these pathways act together to help promote PDAC 
growth and survival. Overall, this draws the conclusion that both of Raf-ERK and PI3K-AKT 
pathways have important independent roles in pancreatic tumourigenesis, and that 
improving our understanding of the function of both pathways and there interactions in 
PDAC will help to enable the generation of new therapeutic strategies. 
1.4.5.3 Potential roles for MKPs in pancreatic cancer 
Pancreatic cancer is predominantly driven by mutant KRas (Kleeff et al., 2016), and many 
MKPs have been shown to be strongly upregulated by such Ras-ERK pathway mutations in 
a variety of cancer types, where they often play a role in modulating tumour 
development (Díaz-García et al., 2014; Kim et al., 2014; Lee et al., 2012; Okudela et al., 
2009; Shojaee et al., 2015). Taken together these traits indicate that MKPs might play 
functional roles in pancreatic cancer development, therefore investigating this hypothesis 
is a key focus of our group. Furthermore, investigating MKPs in pancreatic cancer could 
help demonstrate the relative important of the ERK pathway in this cancer and give 
significant insights into therapeutically modulating the ERK pathway in pancreatic cancer. 
As described previously, there is strong evidence demonstrating changes in DUSP6/MKP-3 
expression throughout the progression of human PDAC (Furukawa et al., 2003, 2005). 
Loss of DUSP6/MKP-3 expression correlates with the progression from high grade PanINs 
to invasive PDAC, leading to the hypothesis that DUSP6/MKP-3 could constrain 
progression from high grade PanIN to PDAC and that DUSP6/MKP-3 loss could be a key 
event during pancreatic carcinogenesis (Furukawa et al., 2006). However, there is 
currently very limited evidence showing that these changes in DUSP6/MKP-3 expression 
which have been observed are playing a functional role in PDAC progression. Therefore, 
future studies could modulate DUSP6/MKP-3 expression in mouse models of PDAC to 
determine whether DUSP6/MKP-3 loss can promote PDAC progression. 
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There is only very limited evidence for changes in expression or possible functional roles 
for other MKPs in pancreatic cancer. DUSP1/MKP-1 has been shown to be overexpressed 
at both the mRNA and protein level in pancreatic cancer or chronic pancreatitis relative to 
normal pancreatic tissue. DUSP1/MKP-1 knockdown decreased the proliferation rate, 
colony formation ability and tumourigenic capacity following xenograft into nude mice of 
pancreatic cancer cell lines, suggesting DUSP1/MKP-1 has an oncogenic function in 
pancreatic cancer (Liao et al., 2003). DUSP4/MKP-2 is strongly upregulated in pancreatic 
cancer cell lines following the expression of mutant KRas or constitutively active MEK, and 
is able to prevent ERK hyperactivation (Yip-Schneider et al., 2001). More recently, 
DUSP4/MKP-2 has been shown to be downregulated during progression from high-grade 
IPMN to invasive pancreatic carcinoma by frequent genomic copy number aberrations 
occurring at 8p11.22-ter causing genomic loss of DUSP4/MKP-2 (Hijiya et al., 2016). 
Restoration of DUSP4/MKP-2 expression in pancreatic cancer cells with such genomic 
events suppressed invasiveness and increased anoikis via ERK inactivation. Utilising an 
orthotopic xenograft model of pancreatic cancer DUSP4/MKP-2 restoration was shown to 
promote increased survival, with mice displaying decreased tumour size and fewer 
metastases. Conversely, knockdown of DUSP4/MKP-2 promoted anoikis resistance, 
invasiveness and cell motility in pancreatic cancer cells expressing DUSP4/MKP-2. 
Together these results imply that DUSP4/MKP-2 downregulation may promote tumour 
growth and invasiveness in pancreatic cancer (Hijiya et al., 2016). Finally, DUSP10/MKP-5 
has been shown to be a direct target of the microRNA miR-92a, which is overexpressed in 
pancreatic cancer cell lines. miR-92a-mediated downregulation of DUSP10/MKP-5 
promotes elevated JNK signalling and cell proliferation (He et al., 2014). 
1.5 Aims 
The primary aim of this thesis was to determine whether the MKPs DUSP5 and 
DUSP6/MKP-3 are able to modulate the oncogenic potential of Ras-ERK pathway 
mutations, and thus play a functional role in the initiation and progression of cancer. Our 
approach involved the utilisation of murine cancer models to determine whether the loss 
of DUSP5 or DUSP6/MKP-3 could alter tumour development in these models, coupled 
with the use of in vitro cell culture based models and immunohistochemical analysis of 
tissue samples to investigate the mechanism by which DUSP loss could be modulating 
cancer development. 
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Our initial project aimed to determine whether DUSP5 loss influences the development of 
skin papillomas in the DMBA/TPA-induced model of skin carcinogenesis. In conjunction 
we investigated the biochemical consequences of DUSP5 loss in MEFs in response to TPA 
or oncogenic stimuli, to determine the mechanism by which DUSP5 loss modulated skin 
carcinogenesis. Our second project aimed to investigate the regulation of DUSP 
expression by mutant KRas in MEFs, and whether the loss of DUSP5 or DUSP6/MKP-3 has 
any functional biochemical consequences on ERK activity and its target substrate or the 
cellular phenotype of KRasG12D expressing MEFs. The final project aimed to use mouse 
models to determine any potential roles for DUSP5 and DUSP6/MKP-3 in the initiation 
and progression of KRasG12D-driven pancreatic ductal adenocarcinoma. 
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Chapter 2 Materials & Methods 
2.1 Mouse strains and in vivo procedures 
2.1.1 Mouse strains and tumour models 
DUSP5fl and DUSP6fl strains were generated by Taconics Artemis, and the DUSP5fl strain 
has been described previously (Rushworth et al., 2014). DUSP6 conditional mice were 
generated by homologous recombination. Briefly, a targeting construct was generated 
which introduced a neomycin selectable marker flanked by LoxP sites into intron 1, along 
with an additional LoxP site following exon 3 of the murine DUSP6 gene. Mouse C57BL/6N 
embryonic stem (ES) cells were electroporated with the linearized targeting construct and 
neomycin-resistant clones were identified by Southern blot. Chimeric mice were 
generated through the microinjection of positive clones into C57BL/6N blastocysts. 
Chimeras were crossed to generate mice expressing the conditional DUSP6 allele and 
germline transmission of the allele was confirmed by Southern blot. Targeted mice were 
crossed with EIIaCre transgenic mice, to enable the mosaic excision of the neomycin 
resistance cassette due to the pre-disposition of Cre to more efficiently recombine LoxP 
sites located closer together (Holzenberger et al., 2000). The resulting chimeric mice were 
crossed and their offspring screened for the neomycin cassette-free conditional DUSP6 
allele by PCR. 
KrasLSL-G12D/+ and Pdx1-cre (Hingorani et al., 2003) strains were obtained for Owen Sansom 
(Beatson Institute, Glasgow). Ptf1α-cre (P48+/Cre) mice (Kawaguchi et al., 2002) were 
obtained from Miguel Constância (University of Cambridge). SerpinB2-/- mice (Dougherty 
et al., 1999) were obtained from Jackson labs (strain B6.129S1-Serpinb2tm1Dgi/J). 
KrasLSL-G12D/+; DUSP5fl and Pdx1-cre; DUSP5fl strains were intercrossed to generate KrasLSL-
G12D; Pdx1-cre; DUSP5fl experimental mice as well as control cohorts for the initial 
pancreatic cancer study. For the second study pancreatic cancer study KrasLSL-G12D, Ptf1α-
cre, DUSP5f,, DUSP6fl and SerpinB2-/- strains were intercrossed to generate mice with the 
required genotype.  
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Figure 2.1 Targeting strategies utilised for the generation of the DUSP5
fl 
and DUSP6
fl 
strains. 
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For the pancreatic cancer studies both survival and age-matched cohorts were generated. 
These cohorts contained an equal balance of both male and female mice. All study mice 
were monitored closely through weighing and health assessment three times per week. 
Mice were removed from the study once they lost over 20% of their maximal body-
weight, generated visible ascites or were moribund and visibly unwell. 
All lines were maintained on a C57/B6 background. All animal procedures were 
performed under license (UK project license number 7008570) in accordance with the UK 
Home Office Animals (Scientific Procedures) Act (1986) and after local ethical review 
following institutional guidelines. 
2.1.2 Skin carcinogenesis model 
DMBA/TPA chemical carcinogenesis was performed as described by Abel and colleagues 
(2009). Briefly, the dorsal fur of 7.5 week-old mice was shaved and, at 8 weeks, animals 
were treated with DMBA (50μg in 100μL acetone). The following week, bi-weekly 
treatment with TPA (12.5ug in 100μL acetone) was commenced to promote papilloma 
formation. Treatment was continued for 25 weeks to enable the assessment of papilloma 
formation. During this time the initiation, number and size of papillomas was recorded 
weekly.  
2.1.3 Genotyping 
Genomic DNA for genotyping was obtained from ear notches. Ear notches were lysed 
overnight in 500µl lysis buffer (75mM NaCl, 25mM EDTA, 1% w/v SDS) containing 
0.4mg/ml proteinase K (Life Technologies). 730µl chloroform (Sigma) and 157µl 5M NaCl 
(Sigma) was added to each sample and this incubated on a rotator for 45 min. Samples 
were then centrifuged at 13,000rpm for 10 min, the upper aqueous phase removed and 
added to an eppendorf containing 500µl isopropanol (VWR). The resulting samples were 
mixed by inversion, centrifuged at 13,000rpm for 10 min and the supernatant removed. 
The resulting DNA was washed in 500µl 70% ethanol, and resuspended in 80µl TE (Tris-
EDTA – Life Technologies) buffer. All genotyping was performed by multiplex PCRs carried 
out using puReTaq Ready-to-go-PCR beads (GE Biosciences). The primers used and 
expected diagnostic products are outlined below. 
81 
 
PCR Primers PCR products 
Cre oMIR 15 (5'-CAAATGTTGCTT GTCTGGTG -3') 206bp (control) & 
370bp (Cre) oMIR 16 (5'-GTCAGTCGAGTGCACAGTTT -3') 
Cre 685 (5'-ACCTGAAGATGTTCGCGA TTATCT -3') 
Cre 1054 (5'-ACCGTCAGTACGTGAGATATCTT -3') 
DUSP5 WT 5’-GCCTTCGATCTTCTCTTG TG-3' 667bp (WT), 
418bp (KO) & 
701bp (floxed) 
KO 5'-AGGGAGCTGCTGTTTTCAGC-3' 
Common 5'-ACCATGAATGCACAGGAACC-3' 
DUSP6 WT 5’-TTCAGACCTCATCTGAAAGACATGAGTAGT-3' 250bp (WT), 
400bp (KO) & 
284bp (floxed) 
KO 5'-CGGCGCCTGCGCCGGGGTAACCTGCCGGTGCG-3' 
Common 5'-TGCGAGTATGAGCGCCCATTTGGTGGATGC-3' 
KRasLSL-
G12D  
WT 5'-CCCCAGCACAGTGCAGTTTTGACACCAGCTTCGGC-3' 450bp (WT) & 
327bp  
(LSL-G12D) 
LSL 5'-AGCTAGCCACCATGGCTTGAGTAAGTCTGCA-3' 
Common 5'-CCGAATTCAGTGACTACAGATGATCAGAG-3' 
SerpinB2 WT 5’-TTTGATAGGCGGGTTGTTTC TCTGT-3’ 500bp (WT) & 
650bp (KO) KO 5’-CAGCCGAACTGTTCGCCAGG-3’ 
Common 5’-GTTTGTCCACCATGCTCCCTCTA-3’ 
Table 2.1 Genotyping PCR Primers 
 
2.2 Tissue processing, histochemistry and 
immunohistochemistry 
2.2.1 Tissue processing 
Tissue samples were fixed in 4% formaldehyde saline solution (VWR) overnight, and then 
transferred to 70% ethanol, before processing using a Citadel Shandon 2000 
(ThermoScientific) to allow paraffin wax infiltration. Processed tissue was placed at the 
required orientation and embedded in paraffin wax blocks. Paraffin blocks were sectioned 
at 5μm and sections adhered to glass microscopy slides (VWR). Slides were baked 
overnight at 60°C before use in histochemical or immunohistochemical staining. 
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2.2.2 Histochemistry 
2.2.2.1 Haematoxylin & Eosin (H&E) staining 
Slides were cleared by incubation in xylenes (2 x 10 min), followed by rehydration through 
decreasing concentrations of ethanol (100% x 2, 95%, 90% & 70% - 2 min each). This was 
followed by a brief rinse in distilled water. Slides were then incubated in Mayer’s 
Haematoxylin (Sigma) for 15 min, before rinsing and “blueing” of the Haematoxylin in 
running tap water for 5 min. The process was repeated for the Eosin stain (Sigma) using 
an incubation time of 40s followed by rinsing in running tap water for 5 min. All slides 
were then dehydrated through increasing concentrations of ethanol (70%, 90%, 95% & 
100% x 2 - 2 min each), cleared in xylenes (2 x 10 min) before mounting under coverslips 
using Omnimount mounting medium (National Diagnostics). 
2.2.2.2 Alcian Blue staining 
Slides were cleared by incubation in xylenes (2 x 10 min), followed by rehydration through 
decreasing concentrations of ethanol (100% x 2, 95%, 90% & 70% - 2 min each). This was 
followed by a brief rinse in distilled water before incubation in Alcian Blue solution 
(Sigma) for 30 min. Slides were then rinsed in running tap water for 5 min to remove any 
excess Alcian Blue. The slides were then counterstained with Nuclear Fast Red (Sigma) for 
5 min, followed by rinsing in running tap water for 5 min. All slides were then dehydrated 
through increasing concentrations of ethanol (70%, 90%, 95% & 100% x 2 - 2 min each), 
cleared in xylenes (2 x 10 min) before mounting under coverslips using Omnimount. 
2.2.3 Immunohistochemistry 
Immunohistochemistry was performed using VectorStain ABC Kits (Vector Laboratories). 
Slides were cleared by incubation in xylenes (2 x 10 min), followed by rehydration through 
decreasing concentrations of ethanol (100% x 2, 95%, 90% & 70% - 2 min each). This was 
followed by a brief rinse in distilled water, before incubation with 3% hydrogen peroxide 
(VWR) for 5 min to quench endogenous peroxidase enzymes within the tissue. Slides 
were then washed in distilled water (3 x 2min), followed by antigen retrieval in sodium 
citrate (10mM, pH 6.0 – Sigma) for 20 min in a water bath at 99oC. The sodium citrate 
solution containing the slides was then removed from the water bath and allowed to cool 
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for a further 20 min, before slides were rinsed in distilled water, then washed in Tris-
buffered saline (TBS)-Tween (3 x 5 min). IHC pen was then used to create a hydrophobic 
barrier around the tissue to be stained.  Slides were blocked for 45 min with goat serum 
solution (from the VectorStain ABC Kit). Primary antibody was diluted in the goat serum 
solution and incubated on the slides overnight at 4°C or at room temperature for 1-2 h. 
Slides were then washed in TBS-Tween (3 x 5 min), before incubation with biotinylated 
secondary antibody for 45 min and ABC-HRP (Horseradish peroxidase) complex for 30 
min, with TBS-Tween washes (3 x 5 min) after each stage. Staining was visualised through 
the application of DAB reagent for the required time. DAB application time was initially 
optimised to produce clear staining whilst minimising background signal. Slides were then 
counterstained with Mayer’s Haematoxylin for 5 min, before rinsing and “blueing” of the 
Haematoxylin in running tap water for 5 min. All slides were then dehydrated through 
increasing concentrations of ethanol (70%, 90%, 95% & 100% x 2 - 2 min each), cleared in 
xylenes (2 x 10 min) before mounting under coverslips using Omnimount mounting 
medium (National Diagnostics). 
The primary antibodies used for immunohistochemistry and their relevant concentrations 
and DAB incubation times are outlined below. 
Primary Antibody Supplier Cat # Dilution Incubation DAB 
aSMA Abcam Ab124964 1 : 2,500 O/N @ 4oC 1 min 
c-Cas3 Cell Signalling 9664 1 : 1,000 O/N @ 4oC 5 min 
CK19 DSHB TROMA-III 1 : 10 O/N @ 4oC 3-5 min 
DUSP5 Abcam Ab200708 Not optimised, also stained relevant 
KO tissue at all conditions attempted. DUSP6/MKP-3 Abcam Ab76310 
Ki67 Cell Signalling 12202 1 : 400 O/N @ 4oC 5 min 
p21 Abcam Ab109199 1 : 500 O/N @ 4oC 3-5 min 
p53 Vector VP-P956 1 : 200 1-2h @ RT 1-3 min 
pAKT (s473) Cell Signalling 4060 1 : 50 O/N @ 4oC 5-10 min 
PDX1 Abcam Ab47267 1 : 10,000 O/N @ 4oC 1 min 
pERK Cell Signalling 4370 1 : 400 O/N @ 4oC 5 min 
Sox9 Millipore Ab5535 1 : 40,000 O/N @ 4oC 1  min 
Table 2.2 Immunohistochemistry (IHC) antibodies and optimised conditions. 
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2.2.4 Imaging and analysis of staining 
All slides required for imaging or analyses were scanned on a Leica Biosystems Aperio XT 
slide scanner and images taken and quantitative analysis performed on Aperio 
ImageScope software (Leica Biosystems). 
2.3 RNA isolation from mouse tissue 
For RNA (ribonucleic acid) isolation small tissue samples (~3mm3) were removed from the 
organ of interest and placed in RNA Later RNase inhibitor solution (Life Technologies), on 
ice for no longer than 30 min. Tissue was then transferred to 300µl RLT lysis buffer 
(Qiagen) and scissor-minced in a 2ml eppendorf, before being lysed with a Tissue Ruptor 
homogeniser (Qiagen) until no visible tissue remained. Total RNA was isolated from the 
sample using an RNeasy fibrous tissue kit (Qiagen) according to the manufacturer's 
instructions. Reverse transcription and quantitative real-time PCR were then carried out 
as explained in section 2.7. 
2.4 Generation of primary cell lines & cell culture 
2.4.1 Generation of primary mouse embryonic fibroblast cell lines 
Primary MEFs were isolated from E13.5 day old embryos generated by crossing parents 
heterozygous for the transgenes of interest to allow embryos of all genotypes to be 
derived from a single litter. To generate KRasLSL-G12D/G12D  MEFs cells had to be isolated 
from E11.5 day embryos to overcome KRas knockout induced embryonic lethality, which 
occurs between E12-14 in mice (Johnson et al., 1997).  
The uterus was dissected from a pregnant female and the embryos removed. From each 
embryo the yolk sac was removed to be used for genotyping. The embryo’s head and 
internal organs were removed on a 10cm plate in phosphate-buffered saline (PBS) and 
the trunk was minced into fine pieces with scissors. 3ml/plate of 0.05% trypsin-EDTA (Life 
Technologies) was added, the solution was then pipetted to disaggregate the tissue. 
3ml/plate Dulbecco’s modified Eagles medium (DMEM), supplemented with 10% Foetal 
Bovine Serum (FBS) (Life Technologies) was added to terminate trypsinisation. Cells were 
then centrifuged at 1,200rpm for 5 min, resuspended in 2ml 0.05% trypsin-EDTA to 
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complete the disaggregation, then plated in DMEM, supplemented with 10% FBS, 100mM 
sodium pyruvate, 2.5 mM L-Glutamine and 100units/ml each of Penicillin and 
Streptomycin (Life Technologies). 
Primary MEFs were subsequently cultured in DMEM, supplemented with 10% FBS, 
100mM sodium pyruvate, 2.5 mM L-Glutamine and 100units/ml each of Penicillin and 
Streptomycin (Life Technologies). 
2.4.2 Generation of primary murine pancreatic ductal 
adenocarcinoma cancer cell lines 
Immediately following dissection and identification of pancreatic ductal adenocarcinoma 
(PDAC) a small piece of tumour (~0.3 x 0.3 x 0.3 cm) was removed and placed into ice-cold 
PBS for no longer than 30 min. The tumour sample was then placed in 0.5ml PBS in a 6cm 
plate and diced into small pieces. 5ml of 1mg/ml collagenase V (Sigma) diluted in DMEM 
(Life Technologies) was then added and the solution incubated at 37°C for 45min. The 
collagenase was subsequently quenched with 5ml PDAC media (DMEM supplemented 
with 20% FBS, 4.5 g l-1 glucose, 1mM L-glutamine, 0.11 g l-1 pyruvate, 50 mgml-1 
gentamycin, 100Uml-1 penicillin and 100mgml-1 streptomycin – Life Technologies) and 
centrifuged at 350g for 5 min. The partly digested tumour was then resuspended in 2ml 
0.05% trypsin/EDTA for 5min at 37°C. The trypsin was quenched with 2ml PDAC media, 
the solution centrifuged at 350g for 5 min and the cell pellet washed in PBS before being 
resuspended in 6ml PDAC media and seeded in a 25cm2 cell culture flask 
(ThermoScientific). Cells were maintained in PDAC media and bulked up for a week 
following isolation, subsequently they were transferred into standard cell culture media 
(DMEM, supplemented with 10% FBS, 100mM sodium pyruvate, 2.5 mM L-Glutamine and 
100units/ml each of Penicillin and Streptomycin - Life Technologies) for use in future 
experiments. 
2.5 Immortalisation of mouse embryonic fibroblast cell 
lines 
Primary MEF cell lines were immortalised for use in transfection experiments through the 
transfection and stable integration of ARF (p14arf) shRNA using a retroviral pSUPER-retro-
shARF vector. Phoenix helper cells were plated 24h before transfection with the pSUPER-
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retro-shARF vector using lipofectamine LTX (Life Technologies), allowing the production 
and packaging of the retrovirus. Virus-containing media was harvested 48h post-
transfection, filter sterilised, and used to transfect primary MEFs in the presence of 8µg 
ml-1 polybrene. Transfected cells were subsequently selected in 2µg ml-1 puromycin 
(Sigma) for 7 days before use in further experiments. 
shARF immortalised MEFs were subsequently cultured in DMEM, supplemented with 10% 
FBS and 100units/ml each of Penicillin and Streptomycin (Life Technologies). 
The pSUPER-retro-shARF vector and phoenix helper cells were kindly provided by Prof 
Martin Eilers (Theodor-Boveri-Institute, Wurzburg, Germany). 
2.6 Transfections of mouse embryonic fibroblasts 
2.6.1 Adenoviral transfections 
Primary or shARF immortalised MEF cell lines were plated 18h before transfection. For 
DUSP5 rescue experiments, Ad5-Empty, Ad5-egr1-DUSP5 and Ad5-egr1-DUSP5-KIM 
adenoviral vectors (C. Caunt, University of Bath) were transfected at titres in the range 
0.1-3 pfu/nl, in DMEM, supplemented with 10% FBS (Life Technologies). Pfu/nl, rather 
than multiplicity of infection (MOI), was used as it more accurately reflected the amount 
of transgene delivery between experiments. For Cre-recombinase transfections Ad5-
CMVempty and Ad5-CMVCre vectors (Gene Transfer Vector Core) were transfected at 
250 MOI in DMEM, supplemented with 10% FBS (Life Technologies). In both protocols 
transfection media was replaced with culture media after 6 h and the cells were 
incubated at 37°C for 18 h before being treated as the experiment demanded. 
2.6.2 siRNA transfections 
shARF immortalised MEFs were transfected with a final concentration of 20nM of siRNA 
oligonucleotides (Life Technologies /Dharmacon). Solutions of siRNA oligonucleotides 
(balanced with negative control siRNA to ensure equal final concentrations if required) 
and Lipofectamine RNAimax (Life Technologies) were prepared separately in OptiMEM 
media. After 5 min, the solutions were mixed and incubated at room temperature for 20 
min. The combined solution was added directly to the cells in culture media and 
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incubated at 37°C for 16 h. Subsequently, the media was changed and the cells treated as 
the experiment required. Throughout this project a combination of reverse and forward 
transfections were used depending on the requirements of the experiment in question. 
The siRNA oligonucleotides used in this project are listed in below. 
siRNA Target Gene Supplier Catalogue Number 
Non-targeting control Life Technologies 4390843 
Egr1 Life Technologies S65378 
 Life Technologies S65380 
 Dharmacon J-040286-05-0005 
 Dharmacon J-040286-06-0005 
Egr3 Life Technologies S65385 
Egr4 Life Technologies S65387 
Table 2.3 siRNA 
 
2.6.3 Plasmid DNA transfections 
Immortalised MEFs were transfected with plasmid DNA as follows. A mixture of plasmid 
DNA and Lipofectamine LTX plus reagent at 1 μl Plus Reagent per μg plasmid DNA (Life 
Technologies) was prepared in OptiMEM media (Life Technologies). After 5 min 
Lipofectamine LTX was added at 1:50, and the mixture incubated at room temperature 
for 20 min. This mixture was added directly to the culture media and the cells incubated 
at 37°C for 16 h. After this time, the cells were treated as the experiment demanded. 
2.7 Quantitative real-time PCR 
Total RNA was isolated from cells using Qiashredder and RNeasy kits (Qiagen) according 
to the manufacturer's instructions. 200ng of RNA was reverse-transcribed in a final 
volume of 50μl using Taqman reverse transcription reagents (Applied Biosystems). The 
thermal cycle used was: 25oC for 5 min, 48oC for 30 min, 95oC for 5 min. The cDNA sample 
was diluted 1:3 in RNase-free water. A 4ng sample of cDNA was analysed by quantitative 
real-time PCR using Taqman pre- validated assay probes and Taqman 2x Universal 
Mastermix (Applied Biosystems). An Applied Biosystems 7500 machine was used with the 
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following cycling conditions: 50oC for 2 min, 95oC for 10 min, 95oC for 15s and 60oC for 1 
min, with the final 2 steps repeated 40 times. Fluorescence output was considered to be 
directly proportional to the input cDNA concentration and was normalised against β-actin 
expression. Taqman qPCR probes used in this project are detailed in the table below. 
Gene (murine) Taqman qPCR Probe ID 
ALDH1A3 Mm00474049_m1 
Beta-actin Mm00607939_s1 
Car2 Mm00501576_m1 
DUSP1/MKP-1 Mm00457274_g1 
DUSP2 Mm00839675_g1 
DUSP4/MKP-2 Mm00723761_m1 
DUSP5 Mm01266104_m1 
DUSP6/MKP-3 Mm00518185_m1 
DUSP7 Mm01232570_m1 
DUSP9/MKP-4 Mm00512648_g1 
EGR1 Mm00656724_m1 
EGR3 Mm00516979_m1 
EGR4 Mm00842279_g1 
Fos Mm00487425_m1 
SerpinB2 Mm00440905_m1 
Sox9 Mm00448840_m1 
Gene (Human) Taqman qPCR Probe ID 
Beta-actin Hs99999903_m1 
EGR1 Hs00152928_m1 
Table 2.4 Taqman qRT-PCR Primers. 
 
2.8 Subcellular fractionation 
For subcellular fractionation experiments MEFs were seeded in 10cm tissue culture 
treated plates. Following the required stimulations cells were harvested by adding 
5ml/plate of trypsin/EDTA mix and incubated at 37oC for 5 min. 10ml of DMEM containing 
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10% FBS was added to quench the trypsin, and the suspension centrifuged at 500g for 5 
min. The cell pellet was washed in 1ml PBS, transferred to a 1.5ml micro-centrifuge tube 
and re-pelleted by centrifugation at 500g for 3 min. Cells were lysed in 100µl ice-cold CER 
I buffer (containing Halt protease and phosphatase inhibitors) from the NE-PER nuclear 
and cytoplasmic extraction reagent kit (Life Technologies). The NE-PER nuclear and 
cytoplasmic extraction reagent kit was then used according to the manufacturer’s 
instructions to isolate the cytoplasmic and nuclear fractions. Briefly, cell lysates in CER I 
buffer were vortexed for 15 s, and incubated on ice for 10 min before the addition of 
5.5µl CER II buffer. The lysate was then vortexed again and incubated for a further minute 
before centrifugation at maximum speed in a microcentrifuge for 5 min. The supernatant 
(cytoplasmic extract) was removed and retained. 50µl NER buffer was added to the 
remaining pellet to be incubated on ice for 40 min and vortexed every 10 min. Finally, the 
lysate was centrifuged at maximum speed in a microcentrifuge for 10 min, and the 
supernatant (nuclear extract) removed. Lysate concentration was then determined via 
Bradford assay and immunoblots performed as outlined below. 
2.9 Immunoblot analysis 
Cells were washed twice in cold PBS and lysed with MKK lysis buffer (20mM Tris Acetate, 
270mM Sucrose, 1mM EDTA, 1mM EGTA, 1% v/v Triton X-100, 1% v/v B-
mercaptoethanol) containing phosphatase and protease inhibitor tablets (Roche). The 
lysates were centrifuged for 10 min at 13000rpm to eliminate debris, the cleared lysate 
removed, and a Bradford assay performed to determine the protein concentration within 
each lysate. Lysate concentrations were normalised with further MKK buffer, followed by 
the addition of reducing agent (4x NuPAGE LDS sample buffer - ThermoScientific) before 
being boiled for 5 min at 95oC. Equivalent quantities of protein were resolved in 4-12% 
gradient Bis-Tris Protein Gels (ThermoScientific), transferred onto Immobilon-FL PVDF 
membranes (Millipore), blocked in 5% milk or 5% BSA, then incubated with the required 
primary antibody at 4oC overnight. Membranes were washed 3 times for 5 min with PBS-
Tween before incubation with corresponding fluorescent-tagged secondary antibodies 
(Cell Signalling/ Life Technologies), diluted in 5% milk, for 1 hour at room temperature, 
avoiding exposure to light. Finally, membranes were washed a further 3 times for 5 min 
with PBS-Tween before reactive bands were visualised and quantified on a Li-Cor Odyssey 
imaging system (LI-COR Biosciences).  
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All immunoblots included in this thesis were performed a minimum of three times for 
quantification. Infrared fluorescent signals are directly proportional to the amount of 
antigen present on Li-Cor Odyssey scanned immunoblots, this linear relationship enables 
accurate and reproducible quantification of changes in protein levels and the detection of 
small consistent effects which might not be immediately obvious by eye. Figure 2.2 shows 
an immunoblot greyscale image from a Li-Cor scan and the multicolour image with the 
raw quantification values below. 
 
 
Figure 2.2 Fluorescent immunoblotting and quantification using a Li-Cor Odyssey. A 
representative image of the multicolour display and quantification values obtained for the same blot 
shown in greyscale above. The multicolour image and quantification demonstrate the ability of this 
technique to reliably detect consistent small changes in protein levels. 
 
Quantification of the protein of interest was normalised to an appropriate loading 
control. Furthermore, to account for differences in raw Li-Cor fluorescence values 
between repeats quantification values were expressed relative to the control sample for 
each individual experiment. Figures are displayed containing the mean quantification 
from all of the experiments performed with a representative image of the immunoblots 
from one experiment alongside. 
Primary and secondary antibodies used and their relevant concentrations and dilution 
buffers are outlined below. 
  
91 
 
Primary Antibody Supplier Cat # Dilution Buffer 
AKT (11E7) Cell Signalling 4685 1 : 1,000 5% BSA 
Beta Tubulin (Clone AA2) Sigma T8328 1 : 10,000 5% Milk/BSA 
DUSP1/MKP-1 Santa Cruz sc-1102 1 : 100 5% Milk 
DUSP4/MKP-2 (S18) Santa Cruz sc-1200 1 : 100 5% Milk 
DUSP5 In house N/A 1 : 2,000 5% BSA 
DUSP6/MKP-3 Abcam AB76310 1 : 1,000 5% Milk 
DUSP9/MKP-4 In house N/A 1 : 2,000 5% Milk 
EGR1 (15F7) Cell Signalling 4153 1 : 500 5% BSA 
ERK Cell Signalling 4695 1 : 1,000 5% BSA 
GAPDH Cell Signalling 2118 1 : 1,000 5% Milk/BSA 
HA-tag - C29F4 Cell Signalling 3724 1 : 1,000 5% BSA 
MEK Cell Signalling 9122 1 : 1,000 5% BSA 
p-AKT (ser473) D9E Cell Signalling 4060 1 : 2,000 5% BSA 
p-ERK (Thr202/Tyr204) Cell Signalling 4370 1 : 1,000 5% BSA 
p-MEK (ser217/221) Cell Signalling 9154 1 : 1,000 5% BSA 
Ras (27H5) - Pan Cell Signalling 3339 1 : 1,000 5% BSA 
Ras G12D New East Bio 26036 1 : 200 5% BSA 
SerpinB2 (M70) Santa Cruz Sc-25746 1 : 100 5% BSA 
UBF Brian McStay N/A 1 : 1,000 5% BSA 
Table 2.5 Primary antibodies – immunoblotting.  
 
Secondary Antibody Supplier Cat # Dilution Buffer 
Alexa Fluor® 680 conjugate, 
Donkey anti-Sheep IgG 
ThermoScientific A-21102 1 : 10,000 5% Milk 
DyLight™ 680 Conjugate, Goat 
anti-rabbit IgG 
Cell Signalling 5366 1 : 10,000 5% Milk 
DyLight™ 800 Conjugate, Goat 
anti-rabbit IgG 
Cell Signalling 5151 1 : 10,000 5% Milk 
DyLight™ 800 Conjugate, Goat 
anti-mouse IgG 
Cell Signalling 5257 1 : 10,000 5% Milk 
Table 2.6 Secondary antibodies – immunoblotting. 
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2.10 Ras-GTP pulldown with Raf1-RBD-GST beads 
For Ras-GTP pulldown experiments 1.5x106 MEFs were seeded onto 15cm tissue culture 
treated plates. Following the required stimulations cells were washed twice in PBS and 
lysed in Mg2+ lysis buffer (MLB) (containing Halt protease and phosphatase inhibitors – 
Life Technologies) from a Ras Activation Assay Kit (Millipore). A Bradford assay was 
performed to allow 600µg of protein to be loaded per pulldown, and then the Ras 
Activation Assay (Ras-GTP pulldown with Raf1-RBD-GST) was performed according to the 
manufacturer’s instructions. Briefly, 600µg of lysate was incubated with 10µg of Raf1-
RBD-GST beads for 45 min at 4oC with gentle agitation. Beads were then pelleted by 
centrifugation (10 s, 14,000xg, 4oC) and washed three times in MLB. Ras was then 
disassociated from the Raf1-RBD-GST beads with the addition of 2X Laemmli reducing 
sample buffer and boiling at 95oC for 5 min. Immunoblots were then performed as 
described previously. 
2.11 Luciferase reporter assays 
Murine Serpin B2 promoter-reporter constructs were kindly provided by Prof Toni Antalis 
(University of Maryland School of Medicine, Baltimore, Maryland) (Udofa et al., 2013). 
These luciferase reporter constructs consisted of wild type, truncated or mutant 
fragments of the murine Serpin B2 proximal promoter cloned into the pGL3 vector. Empty 
pGL3 vector was used as a negative control, and pRL-TK (Renilla luciferase driven by the 
herpes simplex virus thymidine kinase promoter) was co-transfected with the reporter 
constructs to normalize for transfection efficiency. 
MEFs were seeded in 24-well tissue culture treated plates and transfected as described 
previously (2.6.3). MEFs were incubated for 16h post-transfection before treatment with 
100ng/ml final concentration of TPA (12-O-Tetradecanoylphorbol-13-acetate) or a DMSO 
(Dimethyl sulfoxide) control for 8h. For detection of reporter expression the dual 
luciferase reporter assay (Promega) was used according to the manufacturer’s 
instructions, and luminescence measured by an Orion II microplate luminometer 
(Berthold Systems). 
93 
 
2.12 Proliferation assays 
Proliferation assays in MEFs were performed using an adaptation of the protocol 
described in Tuveson et al., (2004). Briefly, 6x104 cells were plated in 6 well tissue culture 
treated plates before infection with 250 MOI of adenoviral Cre or empty adenoviral 
vector as described previously (2.6.1). Cell counts were then taken every 2-3 days until 
the cells reached confluence. Cells of each genotype of interest were taken from a 
minimum of three independent litters of MEFs to ensure other genetic differences 
between MEF lines could not influence the result. Data was presented as the fold increase 
in cell number or the relative difference between the empty and Cre-treated cells to 
demonstrate the effect of the knock-in or knockout of the gene of interest by adenoviral 
Cre. 
2.13 Colony formation assays 
Colony formation assays in MEFs were performed using an adaptation of the protocol 
described in Sage et al., (2000). Cells of each genotype of interest were taken from a 
minimum of three independent litters of MEFs and transfected with 250 MOI of 
adenoviral Cre or empty adenoviral vector as described previously (2.6.1). These cells 
were bulked up before being re-plated onto 10cm plates, in technical triplates, for colony 
formation assays. 
To assess whether the cells have lost contact inhibition so form multi-layered colonies 
(foci), cells were seeded at high density (106 cells per 10cm plate). To determine whether 
cells have been transformed and are able to proliferate from single cells to form colonies 
(clonogenic growth) cells were seeded at low density (103 cells per 10cm plate). Cells 
were then grown for 2-3 weeks, with the media replaced every 2-3 days. After 2-3 weeks 
the media was removed and the cells washed with PBS, before fixation in ice-cold 
methanol. Cells were stained with 0.5% crystal violet (0.5% w/v in 25% methanol, 75% 
H20 – Sigma) and the number of visible colonies approximately ≥2mm counted. 
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Chapter 3 DUSP5 loss promotes HRasQ61L-driven 
skin tumourigenesis through the upregulation of 
SerpinB2 
3.1 Introduction 
DUSP5 is a nuclear-inducible, ERK-specific MKP, with the ability to selectively 
dephosphorylate and subsequently anchor ERK within the nucleus (Mandl et al., 2005). 
DUSP5 expression is specifically induced by ERK activity, making it a classical negative 
feedback regulator of the ERK pathway (Kucharska et al., 2009). Taken together this 
evidence indicates that DUSP5 has the ability to modulate the magnitude, duration and 
spatial localisation of ERK activity (Caunt and Keyse, 2013). Deregulation of the ERK 
pathway, leading to constitutively active ERK signalling, is often observed in human 
cancers due to the high frequency of activating mutations in upstream pathway 
components including RTKs, Ras isoforms and BRaf (Dhillon et al., 2007; Prior et al., 2012). 
The mechanism of action and functional consequences of such mutations in cancer has 
been the subject of intensive study and are relatively well understood. However, the 
importance of also understanding the roles of negative regulators of such pathways and 
their potential influence on tumourigenesis is only just coming to the fore (Lemmon et al., 
2016).  
Thus far, relatively little is known about the specific role(s) of MKPs in cancer 
development, and this is particularly the case for DUSP5 (Keyse, 2008). Many studies have 
revealed increased DUSP5 expression in mutant Ras and BRaf-driven cancer cell lines 
(Kreeger et al., 2009; Pratilas et al., 2009; Vartanian et al., 2013; Yun et al., 2009), where 
it is presumed that this phosphatase plays some role in modulating the increased ERK 
activity which results from oncogene activation. As one of the primary functions of the 
ERK pathway is to promote proliferation, DUSP5-mediated suppression of ERK activity, 
might be assumed to have a tumour suppressive effect. This is consistent with the 
observation that ectopic expression of DUSP5 decreased both ERK activity and 
proliferation in lung and colon cancer cells (Ueda et al., 2003). Furthermore, in both 
gastric and prostate cancer low levels of DUSP5 expression correlate with shortened 
patient survival (Cai et al., 2015; Shin et al., 2013), and the restoration of DUSP5 
expression in gastric cancer cells decreased their proliferative capacity and colony-
95 
 
forming ability (Shin et al., 2013). Together such evidence links DUSP5 with a tumour 
suppressive role. However, hyperactive ERK signalling can also promote cellular 
senescence (Deschênes-Simard et al., 2013; Meloche and Pouysségur, 2007), giving rise to 
the hypothesis that in certain contexts DUSP5 could have an oncogenic role by preventing 
the induction of oncogene induced senescence (OIS) by unrestrained ERK activity. This is 
supported by the observation that the expression of DUSP5 can promote the proliferation 
of certain cancer cells (Nunes-Xavier et al., 2010) and that another ERK-specific MKP, 
DUSP6/MKP-3 has been shown to be essential for the oncogenic transformation of pre-B-
cells in murine models of ALL (Shojaee et al., 2015). 
The majority of studies investigating the role of MKPs in human cancer development are 
limited by the fact they typically rely on correlations between MKP expression and clinical 
outcome (Keyse, 2008; Kidger and Keyse, 2016). Furthermore, the majority of 
experimental studies have used cancer cell lines, coupled with ectopic MKP 
overexpression to investigate their role in vitro. Therefore, there is a requirement for 
genetic loss of function experiments in animal models to reveal any potential roles for 
MKPs in tumourigenesis in vivo. Consequently, in work leading up to the studies described 
here we generated DUSP5-/- mice, which were then subjected to the two-stage 
DMBA/TPA-initiation/promotion skin carcinogenesis model (Abel et al., 2009) to 
investigate the functional consequences of DUSP5 loss on skin cancer development. In 
addition, we isolated DUSP5 wild type and knockout MEFs in order to investigate the 
biochemical and cellular consequences of DUSP5 ablation in an attempt to dissect out the 
mechanism(s) by which any effects on tumourigenesis could be occurring.  
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3.2 Work preceding this thesis 
3.2.1  Loss of DUSP5 sensitises mice to DMBA/TPA-induced skin 
carcinogenesis 
To investigate whether DUSP5 ablation had any effect on the formation of mutant Ras-
induced skin papillomas we utilised the DMBA/TPA-induced, two-stage skin 
carcinogenesis model (Abel et al., 2009). Cohorts of DUSP5+/+, DUSP5+/- and DUSP5-/- mice 
were initially treated with DMBA (50μg) at 8 weeks of age, to induce characteristic 
HRasQ61L mutations, followed by twice weekly promotion with TPA (12.5μg) for 25 wk. 
Mice from all three cohorts began to develop skin papillomas after 5-6 weeks and 
DUSP5+/- and DUSP5-/- mice reached 100% tumour incidence somewhat faster than 
DUSP5+/+ mice (Fig. 3.1A). However, the major difference between the cohorts was that 
DUSP5-/- mice developed a significantly higher papilloma burden than DUSP5+/+ mice, 
reaching an average of 20 papillomas per mouse by 25 weeks, compared to only 10 for 
DUSP5+/+ mice, while DUSP5+/- animals showed an intermediate phenotype (Fig. 3.1B). 
None of the animals of any genotype went on to display invasive, squamous cell 
carcinomas or other malignant skin lesions, probably due to the very low rate of 
malignant conversion in DMBA/TPA-treated C57BL/6 mice  (Abel et al., 2009). The 
papillomas from all three genotypes appeared very similar morphologically, being defined 
as squamous cell papillomas, and the size distribution of papillomas across the genotypes 
appeared unchanged (Fig. 3.1C & D). Finally, DNA sequencing revealed the presence of 
HRasQ61L mutations in ∼90% of the papillomas of each genotype (Fig. 3.1E). This is the 
signature driving mutation in DMBA/TPA-induced skin cancers (Chakravarti et al., 1995), 
indicating that the mechanism of DMBA-induced mutagenesis promoting tumour 
initiation is unaltered following DUSP5 loss. Together this data indicates that DUSP5 acts 
as a tumour suppressor in the DMBA/TPA model of HRas-induced skin cancer. 
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Figure 3.1 Loss of DUSP5 sensitises mice to DMBA/TPA-induced skin carcinogenesis. 
DUSP5
+/+
 (WT), DUSP5
+/−
 (HET), and DUSP5
−/−
 (KO) animals (n = 19 per cohort) were exposed to 
DMBA followed by TPA treatment for 25 weeks. A) Tumour incidence. DUSP5 loss decreased 
latency (P values: WT/HET = 0.0304; WT/KO = 0.0029, repeated measures multivariate ANOVA 
with Tukey’s post hoc analysis). B) Average number of tumours per mouse (P values:  WT/HET = 
0.000761; WT/KO = 0.000002, repeated measures multivariate ANOVA with Tukey’s post hoc 
analysis). C) H&E stained sections of representative skin papillomas at 25 weeks. (Scale bar, 
1mm). D) Tumour size distribution after 25 weeks. E) Percentage of papillomas from each 
genotype with HRas
Q61L
 mutations. Data courtesy of Dr Linda Rushworth. 
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3.2.3  Loss of DUSP5 does not alter whole cell p-ERK levels or the 
proliferation rate of MEFs 
To investigate the molecular mechanism by which DUSP5 loss promotes sensitisation to 
DMBA/TPA-induced skin carcinogenesis, DUSP5+/+, DUSP5+/- and DUSP5-/- MEFs were 
isolated from littermate embryos. DUSP5 is known to specifically target ERK (Mandl et al., 
2005), therefore initially DUSP5 wild-type and knockout MEFs were subjected to TPA 
stimulation and p-ERK levels were determined by immunoblotting. Surprisingly, no clear 
changes in the magnitude or duration of ERK phosphorylation could be detected in 
DUSP5-/- MEFs compared to wild-type (Fig. 3.2A). Furthermore, expression levels of other 
MKPs capable of targeting ERK including DUSP1/MKP-1, DUSP4/MKP-2, DUSP6/MKP-3 
and DUSP9/MKP-4 were also unchanged, indicating that compensatory upregulation of 
other MKPs does not occur in the absence of DUSP5 (Fig. 3.2A). Next we went on to 
investigate basic cellular phenotypes of DUSP5 MEFs. However, we found that DUSP5 loss 
had no effect on the proliferation rate of MEFs or their colony forming potential when 
transfected with Ras mutants (Fig. 3.2B & C). 
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Figure 3.2 DUSP5 loss has no effect on the kinetics of ERK activation, and no clear cellular 
phenotype in MEFs. A) DUSP5
+/+
 (WT), DUSP5
+/−
 (HET), and DUSP5
−/−
 (KO) primary MEFs were 
treated with 100ng/mL TPA for the indicated times. Cells were lysed and proteins analysed by 
immunoblotting using the indicated antibodies. B) Primary MEFs of each genotype were grown in 
the indicated serum conditions cell proliferation was monitored over 80 hours using an IncuCyte 
Zoom live cell imaging system. C) Transforming potential of immortalized WT and KO MEFs 
following expression of wild-type HRas (WT), HRas
Q61L
 (Q61L), or HRas
G12V
 (G12V). 
Representative images (Left) and quantification are shown (Mean ± SEM, n = 3). Data courtesy of 
Dr Linda Rushworth. 
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3.3 Results 
3.3.1 DUSP5 loss specifically increases nuclear p-ERK activation 
following TPA stimulation 
As DUSP5 is a solely nuclear phosphatase, and the nucleus contains only a fraction of the 
total protein of a cell, we hypothesised that spatial alterations in ERK activity might be 
occurring upon DUSP5 loss which would not be detected in whole cell lysates. To address 
this theory we performed subcellular fractionation of lysates from DUSP5+/+ and DUSP5-/- 
MEFs following TPA stimulation. DUSP5 loss was shown to promote a significant increase 
in the levels of nuclear, but not cytoplasmic, p-ERK one hour after TPA stimulation (Fig. 
3.3A).  
To investigate this phenotype in a more detailed and quantitative manner we used 
confocal microscopy and high-content imaging to visualise and quantify the levels of p-
ERK and total ERK at the single cell level in TPA-treated MEFs (Fig. 3.3B & C). This analysis 
revealed that DUSP5 ablation has two key effects on the spatiotemporal regulation of ERK 
signalling at short time points following TPA stimulation. In agreement with our 
biochemical analysis using subcellular fractionation, DUSP5 loss promoted a significant 
increase in the levels of nuclear p-ERK. This occurred rapidly following stimulation, 
peaking between 30-60 minutes after exposure to TPA, then as nuclear p-ERK levels 
decreased towards 360 minutes the difference in p-ERK levels between DUSP5+/+ and 
DUSP5-/- MEFs was lost. This indicates that basal DUSP5 levels as well as its rapid 
induction by ERK activity (Kucharska et al., 2009) have a key role in restraining nuclear 
ERK activity following stimulation. The reduction in the difference in nuclear p-ERK levels 
over time could imply that other negative feedback mechanisms are now compensating 
for the lack of DUSP5, or that by later time points DUSP5 degradation will have 
commenced (Kucharska et al., 2009), meaning its ablation could have less influence on 
nuclear p-ERK levels. Secondly, DUSP5 loss reduces the levels of total ERK retained in the 
nucleus post-stimulation, reflecting DUSP5’s role as a nuclear anchor for 
dephosphorylated ERK (Mandl et al., 2005). Finally, in contrast DUSP5 loss has no effect 
on cytoplasmic levels of either p-ERK or total ERK (Fig. 3.3B & C). 
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Wild type levels of DUSP5 can be restored in DUSP5-/- MEFs through their infection with 
adenovirus expressing Myc-tagged, wild-type DUSP5 under the control of an ERK-
responsive early growth response 1 (Egr1) promoter. Utilising a viral titre, which gives rise 
to protein levels that closely mirror endogenous DUSP5 expression, both confocal and 
high content microscopy (Fig. 3.3B & C) and biochemical fractionation experiments (Fig. 
3.3D) demonstrate that wild-type levels of nuclear p-ERK and total ERK can be rescued in 
DUSP5-/- MEFs (Fig. 3.3B, C & D). Crucially, an adenovirus expressing the DUSP5 KIM 
mutant, which is catalytically active, but unable to bind and inactivate ERK (Mandl et al., 
2005), is unable to reverse the phenotypes observed in DUSP5−/− MEFs (Fig. 3.3B & C). 
This demonstrates that the increased nuclear p-ERK observed in DUSP5-/- MEFs is truly 
dependent on DUSP5 loss, and more precisely dependent on the ability of DUSP5 to bind 
and dephosphorylate ERK. Therefore, this non-redundant function of DUSP5 in the 
regulation of nuclear p-ERK levels implies that DUSP5 loss and the associated increase in 
nuclear ERK activity could contribute to the increased sensitivity of DUSP5-/- mice to Ras-
driven carcinogenesis.  
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Figure 3.3 DUSP5 ablation increases nuclear p-ERK levels following TPA stimulation. A) 
DUSP5
+/+
 (WT) and DUSP5
−/−
 (KO) primary MEFs were stimulated with TPA for 0 or 1 hour, before 
lysis, subcellular fractionation and immunoblotting using the indicated antibodies. Upstream binding 
factor (UBF) and MEK were used to validate separation of nuclear (N) and cytoplasmic (C) 
proteins, respectively. A representative Western blot is shown (Left), alongside p-ERK 
quantification, relative to the WT unstimulated sample, utilising a Li-Cor Odyssey infrared scanner 
(Right). B) Representative confocal images of WT and KO MEFs, after 1 hour TPA stimulation, 
following infection with empty adenovirus (empty Ad), Ad-Egr1 promoter-driven DUSP5-Myc (Ad 
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DUSP5), or Ad-Egr1 promoter-driven KIM mutant of DUSP5-Myc (Ad DUSP5
R53/54A
). (Scale = 60 
μm). C) MEFs were infected with virus prior to the indicated TPA stimulation, and then stained for 
p-ERK, total ERK, Myc or DAPI, before image analysis using high content fluorescence 
microscopy. Graphs represent population average values for nuclear (Nuc) and cytoplasmic (Cyt) 
p-ERK, ERK, or Myc intensity, derived from four separate experiments, with 5,000–10,000 
individual cells per condition. D) WT and KO MEFs were infected with either Ad5-Empty or Ad5-
DUSP5 prior to TPA stimulation for 0 or 1 hour, followed by lysis, subcellular fractionation and 
immunoblotting using the indicated antibodies. A representative Western blot is shown (Left), 
alongside p-ERK quantification (Right). Mean values ± SEM are shown, n = 5 (A), n = 4 (B-C), n = 
3 (D). ns = not significant, *P < 0.05, **P < 0.01, ***P<0.001 using two-way ANOVA and Bonferroni 
post hoc test. Panels B-C courtesy of Dr Christopher Caunt. 
 
 
 
 
 
Figure 3.4 Loss of DUSP5 increases the expression of a subset of TPA-inducible genes. A) 
Heatmap showing significant gene expression changes detected by microarray following the 
indicated TPA treatment of DUSP5
+/+
 (WT) and DUSP5
−/−
 (KO) primary MEFs. Values are log2 
ratios of KO/WT. B) Taqman RT-qPCR assay showing the fold change in mRNA levels (relative to 
WT unstimulated) of the indicated genes in WT and KO MEFs following TPA stimulation. Mean 
values ± SEM are shown (and displayed above the bar on the graph), n = 3. Panel A courtesy of Dr 
Philip East (CR-UK Bioinformatics & Biostatistics group). 
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3.3.2 DUSP5 loss increases the expression of a subset of TPA-
inducible genes 
As nuclear p-ERK is known to regulate the activity of many transcription factors (Cargnello 
and Roux, 2011; Yoon and Seger, 2006), a logical consequence of increased nuclear ERK 
activity following DUSP5 loss would be the alteration of ERK-dependent gene expression. 
Therefore, to investigate the effects of DUSP5 loss on gene expression we performed a 
microarray experiment to compare the gene expression profiles of DUSP5+/+ and DUSP5-/- 
primary MEFs following 0, 1 or 3 hours of TPA stimulation (Fig. 3.4A). Surprisingly this 
revealed that although hundreds of genes are induced in response to TPA stimulation, 
only 20 genes showed significant differences in expression upon DUSP5 ablation 
(Rushworth et al., 2014 - www.ncbi.nim.nih.gov/geo accession No. GSE62433). Of these 
20 genes, 18 were upregulated and 2 were downregulated on DUSP5 loss. RT-qPCR 
analysis could validate the upregulation of many of these genes following TPA stimulation 
of DUSP5-/- MEFs, relative to wild-type (Fig. 3.4B & data not shown). The most strongly 
upregulated gene following DUSP5 ablation was SerpinB2 (also known as plasminogen 
activator inhibitor 2, PAI-2). Interestingly, three members of the early growth-response 
(Egr) family of transcription factors were also significantly upregulated in cells lacking 
DUSP5.  
We chose to focus on SerpinB2 because as well as being our top hit, it had previously 
been demonstrated to play a pro-oncogenic role in DMBA/TPA-mediated skin 
carcinogenesis, and it was suggested that this was due to the promotion of cell survival 
via the inhibition of apoptosis (Tonnetti et al., 2008; Zhou et al., 2001). SerpinB2 
upregulation following DUSP5 loss and TPA stimulation could be validated at both the 
mRNA and protein level in three-independent pairs of DUSP5+/+ and DUSP5-/- primary 
MEFs (Fig. 3.5A & B). SerpinB2 induction can clearly be shown to be ERK-dependent, as it 
is abrogated by pre-treatment of cells with PD184352, a specific MEK inhibitor (Fig. 3.5A 
& B). Furthermore, SerpinB2 upregulation in DUSP5-/- MEFs can be shown to be 
dependent on the loss of DUSP5-mediated inhibition of nuclear p-ERK activity, as 
SerpinB2 mRNA levels are very strongly suppressed by the re-expression of wild-type 
DUSP5, but not the DUSP5 KIM mutant, in DUSP5-/- MEFs (Fig. 3.6). Normalised expression 
levels of adenoviral DUSP5 wild-type and KIM mutant proteins were optimised via 
immunoblotting.  
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Figure 3.5 DUSP5 loss upregulates SerpinB2 in a MEK-dependent manner. SerpinB2 
induction in DUSP5
+/+
 (WT) and DUSP5
−/−
 (KO) primary MEFs at either the mRNA (A) or protein 
(B) level following TPA stimulation for the indicated time, in the presence of the MEK inhibitor 
PD184352 or DMSO control. MEFs were pre-treated with MEK inhibitor 30 min prior to TPA 
stimulation, and maintained in MEK inhibitor for the duration of the experiment. A) Taqman RT-
qPCR assay showing the fold change in SerpinB2 mRNA levels, relative to WT unstimulated. B) 
Immunoblot analysis using the indicated antibodies, following no treatment (NT) or 24 hour TPA 
stimulation (TPA). A representative Western blot is shown (Upper), alongside SerpinB2 
quantification (Lower). DUSP5 is a 42kDa protein and the anti-DUSP5 sheep polyclonal antibody 
used detects a DUSP5 band at this molecular weight, which is inducible following TPA stimulation 
in DUSP5
+/+
, but not DUSP5
−/−
 MEFs. However, this antibody also detects a non-specific band also 
at approximately 42kDa, explaining why the DUSP5
−/− 
MEFs still appear to show DUSP5 
expression. Mean values ± SEM are shown, n = 4 (A), n = 3 (B). ***P < 0.001, ****P<0.0001 using 
two-way ANOVA and Bonferroni post hoc test.  
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Figure 3.6 DUSP5 reintroduction rescues wild-type SerpinB2 expression. Taqman RT-qPCR 
assay showing the fold change in SerpinB2 mRNA levels (relative to WT unstimulated) in DUSP5
+/+
 
(WT) and DUSP5
−/−
 (KO) primary MEFs following infection with empty adenovirus (control), Egr1 
promoter-driven Ad-DUSP5-Myc (Ad-DUSP5), or Ad KIM mutant of DUSP5-Myc (Ad-DUSP5
R53/54A
) 
as indicated and subsequent TPA stimulation. Mean ± SEM, n = 4. ns = not significant, 
****P<0.0001 using two-way ANOVA and Bonferroni post hoc test. 
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3.3.3 SerpinB2 upregulation following DUSP5 loss is dependent 
on Egr1 expression and AP-1 transcription factors 
The induction of SerpinB2 expression is somewhat delayed following TPA stimulation, 
with peak mRNA expression occurring after 3 hours (Fig. 3.5A). In contrast, Egr family 
transcription factors are canonical immediate early genes, with transcription occurring 
rapidly following TPA stimulation and mRNA expression levels peaking after only 1 hour 
(Fig. 3.4A & B). Therefore, we hypothesised that Egr family transcription factors could 
play some role in mediating the induction of SerpinB2 following TPA stimulation. To 
address this question we used siRNA to knockdown either Egr1 alone or a combination of 
Egr1, Egr3 and Egr4 in DUSP5-/- MEFs, and assayed SerpinB2 mRNA induction following 
TPA stimulation. This revealed that Egr1 knockdown significantly reduced TPA-inducible 
SerpinB2 mRNA levels, while combining knockdown of Egr1 with loss of Egr3 and Egr4 
caused no further inhibition of SerpinB2 expression (Fig. 3.7A). Treatment with either 
Egr1, Egr3 or Egr4 siRNA induced a 60-80% decrease in the expression of their respective 
mRNAs following TPA stimulation (Fig. 3.7A). This indicates that the lack of an additional 
response following combined Egr1, 3 and 4 knockdown, in comparison to Egr1 
knockdown alone, is not due to a lack of efficacy of the Egr3 and Egr4 siRNA. However, it 
could be due to the very low expression levels of Egr3 and Egr4 in MEFs relative to Egr1 
expression (Fig. 3.7A). To ensure that the ability of the Egr1 siRNA used to inhibit TPA-
induced SerpinB2 expression was not due to off-target effects of this particular siRNA we 
repeated the Egr1 siRNA knockdown experiment with a panel of three distinct Egr1 
siRNAs. Each Egr1 siRNA inhibited SerpinB2 induction in a manner proportional to its 
ability to knockdown Egr1 mRNA (Fig. 3.7B), providing strong evidence that the inhibition 
of SerpinB2 induction is an on-target effect of Egr1 siRNA-mediated knockdown. 
We went on to further validate this Egr1-dependent mechanism for SerpinB2 induction by 
performing siRNA rescue experiments. siRNA-mediated knockdown of murine Egr1 
reduced TPA-inducible SerpinB2 expression at both the mRNA and protein level in MEFs, 
whereas ectopic overexpression of human EGR1 increased SerpinB2 expression (Fig. 3.7C 
& D). The mRNA produced by the human EGR1 gene is predicted to be resistant to 
knockdown by the murine Egr1 siRNA utilised, based on a lack of homology between the 
siRNA binding sequence in murine Egr1 mRNA and the human EGR1 mRNA. This 
resistance can be confirmed by the expression of human EGR1 mRNA and protein 
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following transfection of DUSP5-/- MEFs with both a human EGR1 containing plasmid and 
murine Egr1 siRNA (Fig. 3.7C & D). Combining siRNA-mediated knockdown of murine 
Egr1, with the expression of the siRNA resistant human EGR1 construct completely 
rescued any effects of Egr1 knockdown on SerpinB2 mRNA expression after 3 hours of 
TPA treatment or SerpinB2 protein levels after 24h of TPA treatment, indicating that the 
modulation of SerpinB2 expression is occurring in an Egr1 –dependent manner (Fig. 3.7C 
& D).  
Finally, we obtained immortalised wild-type and Egr1 knockout MEFs (Krones-Herzig et 
al., 2005; Lee et al., 1995) and demonstrated that cells lacking Egr1 had reduced SerpinB2 
mRNA levels following TPA stimulation and that this could be rescued by ectopic 
expression of human EGR1 in Egr1-/- MEFs (Fig. 3.7E).  Taken together, our results strongly 
suggest that the increased induction of the transcription factor Egr1 plays a positive role 
in the subsequent up-regulation of SerpinB2 expression seen on loss of DUSP5.  
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Figure 3.7 SerpinB2 upregulation following DUSP5 loss is dependent on Egr1 expression. A) 
Taqman RT-qPCR assay showing the fold change in SerpinB2 mRNA levels (relative to WT 
unstimulated) in DUSP5
+/+
 (WT) and DUSP5
−/−
 (KO) shARF immortalised MEFs following 
transfection with scrambled control siRNA, Egr1 siRNA or a combination of Egr1, 3 & 4 siRNA as 
indicated and subsequent TPA stimulation (Upper Panel). mRNA levels of Egr1, Egr3 & Egr4, 
relative to β-actin, from the same experiment demonstrate the efficacy of siRNA knockdown (Lower 
Panel) Representative figures of an experiment performed in duplicate. B) Taqman RT-qPCR 
assay showing the fold change in SerpinB2 mRNA levels (relative to WT unstimulated) in DUSP5
+/+
 
(WT) and DUSP5
−/−
 (KO) shARF immortalised MEFs following transfection with scrambled control 
siRNA or multiple distinct Egr1 siRNAs and subsequent TPA stimulation (Left Panel). mRNA levels 
of Egr1, relative to β-actin, from the same experiment (Right Panel) Representative figures of an 
experiment performed in duplicate. C-D) SerpinB2 expression in DUSP5 WT and KO MEFs at 
either the mRNA (C) or protein (D) level following Egr1 knockdown (Egr1 siRNA + pSG5-Empty 
transfection), human EGR1 overexpression (scrambled siRNA + pSG5-EGR1), Egr1 siRNA rescue 
(Egr1 siRNA + pSG5-EGR1), or control (scrambled siRNA + pSG5-Empty) treatment. C) The fold 
change in SerpinB2 mRNA levels (mean value shown above bar), relative to WT control, following 
3 hour TPA stimulation (Upper Panel). mRNA levels of murine (Egr1) or human EGR1, relative to 
β-actin, from the same experiment (Lower Panel). D) Immunoblot analysis using the indicated 
antibodies, following 24 hour TPA stimulation of only DUSP5 KO MEFs. A representative Western 
blot is shown (Upper Panel), alongside SerpinB2 quantification (Lower Panel). E) The fold change 
in SerpinB2 mRNA levels in Egr1
+/+
 (WT) and Egr1
-/-
 (KO) 3T3 immortalised MEFs following 3 hour 
TPA stimulation. Cells were transfected with a pCMV expression vector encoding wild-type human 
EGR1 (pCMV-EGR1) or an empty vector as indicated (Left Panel). mRNA levels of human EGR1, 
relative to β-actin, from the same experiment (Right Panel). Mean values ± SEM are shown, n = 3. 
ns = not significant, *P < 0.05, **P < 0.01, ***P<0.001 using two-way ANOVA and Bonferroni post 
hoc test (C) or one-way ANOVA and Bonferroni post hoc test (D-E). 
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Figure 3.8 SerpinB2 upregulation required AP-1 transcription factor complexes. A) Relative 
activity in DUSP5
+/+
 (WT) and DUSP5
−/−
 (KO) shARF-immortalised MEFs of a series of truncated 
SerpinB2 promoter–reporter constructs following 8 h of TPA treatment (Lower). The truncated 
SerpinB2 promoter–reporter constructs used and the relative position of known transcription factor 
binding sites are outlined in the schematic above. B) Relative activity in WT and KO MEFs of 
SerpinB2 promoter–reporter constructs containing wild-type or mutant transcription factor binding 
sites as indicated. Assays were performed in the presence of scrambled control siRNA or Egr1 
targeting siRNA as indicated, following 8 h of TPA treatment (Lower). The SerpinB2 promoter-
reporter constructs used, and locations of the transcription factor binding sites which were mutated 
are outlined in the schematic above. All the mutant reporter constructs were made in the -539 
truncated construct. Mean values ± SEM are shown, n = 5 (A), n = 4 (B).  
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To further investigate the mechanism of SerpinB2 induction we obtained SerpinB2 
promoter–reporter constructs (Udofa et al., 2013) to analyse the mechanism of TPA-
induced transcription in DUSP5+/+ and DUSP5-/- MEFs. Utilising a range of differentially 
truncated SerpinB2 promoter–reporter constructs we can show that the region within 
539 base pairs of the start of SerpinB2 exon one is crucial for inducible reporter activity 
following TPA stimulation of MEFs (Fig. 3.8A). Consistent with our previous experiments, 
SerpinB2 reporter activity was significantly increased following DUSP5 ablation. 
Furthermore, by utilising a panel of mutant 539 base pair reporter constructs in which 
individual canonical transcription factor binding sites had been ablated, TPA-inducible 
SerpinB2 reporter activity was shown to be dependent on two Activator protein 1 (AP-1) 
binding sites within the proximal promoter (Fig. 3.8B). Loss of c-AMP response element 
(CRE) and CCAAT-enhancer-binding protein (C/EBP) binding sites also reduced reporter 
activity, although not to the same degree as loss of the AP-1 sites. The decrease in 
reporter activity following the mutation of each particular binding site occurred to a 
similar degree in both DUSP5+/+ and DUSP5-/- MEFs, indicating that DUSP5 loss does not 
alter the repertoire of transcription factors required to initiate SerpinB2 transcription.  
Interestingly, and consistent with our previous experiments, siRNA-mediated knockdown 
of Egr1 significantly decreases the TPA-induced activity of all of the SerpinB2 reporters 
used here irrespective of whether they are wild type or lack individual transcription factor 
binding sites (Fig. 3.8B). This indicates that Egr1 might act in an indirect manner, possibly 
through the regulation of, or interaction with, either AP-1 complexes or transcription 
factors binding at the CRE or C/EBP sites to induce SerpinB2 expression. Alternatively, 
Egr1 could be acting via a binding site, which has not been mutated here. However, the 
latter appears very unlikely as there is no canonical Egr1 consensus sequence (5'-GCG 
TGG GCG-3') (Cao et al., 1990, 1990; Christy and Nathans, 1989) within the 539 base pair 
SerpinB2 reporter used here and interrogation of Encode Chip-seq data 
(http://genome.ucsc.edu/ENCODE/ - Landt et al., 2012) shows no evidence for Egr1 
binding within the SerpinB2 promoter. 
Whilst investigating the role of Egr1 in the regulation of TPA-induced SerpinB2 expression 
we noticed that DUSP5 levels were also decreased following Egr1, but not Egr3 or Egr4, 
knockdown (Fig. 3.9A). The effect of Egr1 knockdown on DUSP5 mRNA expression was 
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proportionally the greatest in unstimulated cells (Fig. 3.9A). This potentially reflects the 
increased ability of other transcription factors to induce DUSP5 expression and 
compensate for the loss of Egr1 following TPA stimulation, therefore subsequent 
investigations into the regulation of DUSP5 expression by Egr1 were performed in 
unstimulated cells. Analysis of DUSP5 mRNA and protein expression in the Egr1 siRNA 
rescue experiment (described in Fig. 3.7C-D) revealed that Egr1 expression is able to 
promote DUSP5 induction in MEFs (Fig. 3.9B & C). This was supported by evidence that 
DUSP5 expression is decreased in Egr1-/- mEFs and can be partially restored through 
ectopic EGR1 expression (Fig. 3.9D). DUSP5 has also been identified as a Egr1 target 
through genome-wide chromatin immunoprecipitation with promoter microarray (ChIP-
Chip) (Kubosaki et al., 2009) and the DUSP5 gene also contains a Egr1 consensus binding 
site within its proximal promoter. Taken together, this evidence places Egr1 as a positive 
regulator of DUSP5 expression, suggesting that DUSP5 also acts to limit its own 
expression at the transcriptional level by down regulating ERK activation and thus Egr1 
expression.  
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Figure 3.9 Egr1 regulates DUSP5 expression to complete a negative feedback loop 
controlling p-ERK levels. A) Taqman RT-qPCR assay showing the fold change in DUSP5 mRNA 
levels (relative to control unstimulated) in  DUSP5
+/+
 (WT) shARF immortalised MEFs following 
transfection with scrambled control siRNA, Egr1 siRNA or a combination of Egr1, 3 & 4 siRNA as 
indicated and subsequent TPA stimulation. mRNA levels of Egr1, Egr3 & Egr4, relative to β-actin, 
from the same experiment demonstrate are shown in Fig. 3.7A. Representative figure of an 
experiment performed in duplicate. B-C) DUSP5 expression in WT MEFs at either the mRNA (B) or 
protein (C) level following Egr1 knockdown (Egr1 siRNA + pSG5-Empty transfection), human 
EGR1 overexpression (scrambled siRNA + pSG5-EGR1), Egr1 siRNA rescue (Egr1 siRNA + 
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pSG5-EGR1), or control (scrambled siRNA + pSG5-Empty) treatment. B) The fold change in 
DUSP5 mRNA levels, relative to control following Egr1 manipulation (Upper Panel). mRNA levels 
of murine (Egr1) or human EGR1, relative to β-actin, from the same experiment (Lower Panel).C) 
Immunoblot analysis using the indicated antibodies, following Egr1 manipulation. The rescue 
condition was not performed for the immunoblot. A representative Western blot is shown (Upper), 
alongside DUSP5 quantification (Lower). D) The fold change in DUSP5 mRNA levels in Egr1
+/+
 
(WT) and Egr1
-/-
 (KO) 3T3 immortalised MEFs following transfection with a pCMV expression 
vector encoding wild-type human EGR1 (pCMV-EGR1) or an empty vector as indicated (Left 
Panel). mRNA levels of human EGR1, relative to β-actin, from the same experiment (Right Panel). 
Mean values ± SEM are shown, n = 3. ns = not significant, *P < 0.05, ****P<0.0001 using one-way 
ANOVA and Bonferroni post hoc test. 
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3.3.4  HRasQ61L synergises with DUSP5 loss and TPA stimulation 
to further increase nuclear p-ERK and SerpinB2 expression 
DMBA/TPA-mediated tumorigenesis is primarily driven by DMBA-induced HRasQ61L 
mutations, which when combined with periodic exposure to the tumour promoter TPA  
give rise to skin papillomas (Abel et al., 2009). Consequently, we investigated the effects 
of HRasQ61L expression either alone or in combination with TPA stimulation on both 
nuclear p-ERK levels and SerpinB2 mRNA and protein induction in DUSP5+/+ and DUSP5-/- 
MEFs. The expression of mutant HRasQ61L in combination with TPA stimulation of DUSP5-/- 
MEFs caused a significant increase in levels of nuclear, but not cytoplasmic, p-ERK in 
comparison to wild-type MEFs (Fig. 3.10A & B). This synergistic increase in levels of 
nuclear p-ERK also correlates with increased SerpinB2 mRNA and protein expression in 
response to the same conditions. HRasQ61L expression, TPA stimulation or DUSP5 ablation 
all individually induce an increase in SerpinB2 expression at both the mRNA and protein 
level in MEFs. However, in combination they can synergise to drive a dramatic increase in 
SerpinB2 expression (Fig. 3.11A & B). HRasQ61L induced SerpinB2 expression is dependent 
on ERK activity as it can be abolished at the protein level by pre-treatment with the MEK 
inhibitor PD184352 (Fig. 3.11B). SerpinB2 promoter–reporter assays demonstrate that 
HRasQ61L, TPA stimulation and DUSP5 loss combine to increase luciferase activity, in a 
manner which can be abrogated by MEK inhibitor treatment or AP-1 binding site 
mutations (Fig. 3.12). Therefore, the synergistic increase in SerpinB2 expression resulting 
from a combination of these conditions is due to elevated ERK-dependent transcription, 
mediated by AP-1 transcription factors. Together, these results demonstrate that as the 
upstream ERK pathway stimulus is increased, through mutant HRas expression, DUSP5 
mediated negative feedback becomes more important in preventing elevated nuclear ERK 
activity and the resulting increase in SerpinB2 expression. 
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Figure 3.10 HRas
Q61L
 expression synergises with DUSP5 loss and TPA stimulation to further 
elevate nuclear p-ERK levels. DUSP5
+/+
 (WT) and DUSP5
−/−
 (KO) primary MEFs were infected 
with Ad5-HA-tagged HRas
Q61L
 (Ad5-HRas
Q61L
) or empty adenovirus (Ad5-Empty), then stimulated 
with TPA for 0 or 1 hour, before lysis, subcellular fractionation and immunoblotting using the 
indicated antibodies. UBF and MEK were used to validate separation of nuclear (N) and 
cytoplasmic (C) proteins, respectively. A representative Western blot is shown (A), alongside p-
ERK quantification (B). Mean ± SEM, n = 3. ns = not significant, *P < 0.05, ****P<0.0001 using two-
way ANOVA and Bonferroni post hoc test. 
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Figure 3.11 HRas
Q61L
 expression synergises with DUSP5 loss and TPA stimulation to further 
elevate SerpinB2 expression. DUSP5
+/+
 (WT) and DUSP5
−/−
 (KO) primary MEFs were infected 
with Ad5-HA-tagged HRas
Q61L
 (Ad5-HRas
Q61L
) or empty adenovirus (Ad5-Empty), then stimulated 
with or without TPA as indicated, prior to analysis of SerpinB2 expression at the mRNA (A) or 
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protein (B) level. A) Taqman RT-qPCR assay showing the fold change in SerpinB2 mRNA levels, 
relative to WT unstimulated. TPA stimulations, where indicated, were for 3 hours. B) Immunoblot 
analysis using the indicated antibodies, following the conditions outlined above, with the additional 
variable of the pre-treatment using the MEK inhibitor PD184352 or a DMSO control. TPA 
stimulations, where indicated, were for 24 hours. A representative Western blot is shown (Upper), 
alongside SerpinB2 quantification (Lower). Mean values ± SEM are shown, n = 3. *P < 0.05, **P < 
0.01, ***P < 0.001, ****P<0.0001 using two-way ANOVA and Bonferroni post hoc test. 
 
 
 
Figure 3.12 HRas
Q61L
-mediated induction of SerpinB2 is also AP1 and MEK-dependent. 
Relative activity in DUSP5
+/+
 (WT) and DUSP5
−/−
 (KO) shARF-immortalised MEFs of SerpinB2 
promoter–reporter constructs containing wild-type or AP1 mutant transcription factor binding sites 
as indicated. Cells were infected with Ad5-HA-tagged HRas
Q61L
 (Ad5-HRas
Q61L
) or empty 
adenovirus (Ad5-Empty), then assays carried out in the presence or absence of TPA and the MEK 
inhibitor PD184352. Mean values ± SEM are shown, n = 3. 
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To determine whether SerpinB2 induction in response to TPA stimulation or HRasQ61L 
expression occurs in vivo and is elevated by DUSP5 loss, we analysed SerpinB2 mRNA (Fig. 
3.13A) and protein (Fig. 3.13B) levels in DMBA/TPA-induced papillomas or in TPA-treated 
skin of DUSP5+/+ and DUSP5-/- mice. SerpinB2 expression was higher in papillomas than in 
TPA-stimulated skin (Fig. 3.13B). This is in agreement with our previous in vitro data, 
showing together HRasQ61L expression (present in papillomas – Fig. 3.1E) and TPA 
stimulation synergise to induce greater SerpinB2 expression that solely TPA stimulation 
alone. Furthermore, at both the mRNA and protein level DUSP5-/- papillomas expressed 
higher SerpinB2 levels than their wild-type counterparts, demonstrating that in vivo 
HRasQ61L expression, TPA stimulation and DUSP5 loss synergise to promote elevated 
SerpinB2 expression. 
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Figure 3.13 SerpinB2 expression is elevated following DUSP5 loss in murine skin and 
DMBA/TPA-induced papillomas. A) RT-qPCR assay showing relative SerpinB2 mRNA levels in 
DUSP5
+/+
 (WT) and DUSP5
−/−
 (KO) papillomas. Mean ± SEM, n = 12. *P < 0.05, using Mann–
Whitney test. B) Immunoblot analysis of SerpinB2 protein expression in DUSP5 WT and KO mouse 
skin and papillomas. A representative Western blot is shown (Left), alongside SerpinB2 
quantification (Right). Mean values ± SEM are shown, n = 4. Panel B courtesy of Dr Linda 
Rushworth. 
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3.3.5 SerpinB2 knockout abrogates the sensitisation of DUSP5-/- 
mice to DMBA/TPA-induced skin carcinogenesis 
DUSP5 ablation promotes a significant increase in SerpinB2 expression in MEFs in 
response to HRasQ61L or TPA stimulation (Fig. 3.11A & B) and the papillomas which arise in 
DUSP5-/- mice display elevated SerpinB2 relative to their DUSP5+/+ littermates (Fig. 3.13A 
& B). Previously published work has shown that transgenic mice overexpressing SerpinB2 
in basal skin keratinocytes are sensitised to DMBA/TPA-induced skin carcinogenesis (Zhou 
et al., 2001), while SerpinB2-/- mice have displayed resistance (Tonnetti et al., 2008). 
Therefore, we hypothesised increased SerpinB2 expression as a consequence of DUSP5 
loss could be promoting the increased tumourigenesis that we observed in DUSP5-/- mice 
(Fig. 3.1A & B). To address this question we obtained SerpinB2-/- mice (Dougherty et al., 
1999) and crossed them with DUSP5-/- mice to generate a double knockout (DKO) cohort. 
The 25 week DMBA/TPA-induced skin carcinogenesis protocol was then repeated on four 
cohorts of mice: DUSP5+/+, DUSP5-/-, SerpinB2-/- and DKO (Fig. 3.14A & B). As observed 
previously DUSP5-/- mice developed approximately double the papilloma burden of wild-
type mice. However, this sensitisation could be completely abrogated by concomitant 
deletion of SerpinB2, with DKO mice displaying a similar tumour burden to wild-type 
animals (Fig. 3.14B). Interestingly, in our hands SerpinB2-/- mice did not display a reduced 
tumour burden relative to wild-type mice, in contrast to a previous study reporting such a 
phenotype (Fig. 3.14B) (Tonnetti et al., 2008). SerpinB2-/- mice did display a slightly 
delayed tumour onset relative to wild-type mice (Fig. 3.14A). Again as observed in our 
initial study, all tumours were squamous cell papillomas, displaying a similar morphology 
and size distribution across all genotypes (Fig. 3.14C). Finally, SerpinB2 expression can be 
detected by IHC in wild-type and DUSP-/- papillomas, with DUSP-/- papillomas displaying a 
greater staining intensity. DKO papillomas do not display SerpinB2 expression confirming 
the genetic knockout and validating our experimental system (Fig. 3.14D). Together these 
results allow us to conclude that the increased sensitivity of DUSP5−/− mice to DMBA/TPA-
induced skin carcinogenesis is dependent on increased SerpinB2 expression, induced by 
the elevated nuclear ERK activity and ERK-dependent gene expression promoted by 
DUSP5 loss. 
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Figure 3.14 SerpinB2 ablation abrogates the sensitisation of DUSP5-/- mice to DMBA/TPA-
induced skin carcinogenesis. DUSP5
+/+
 (WT), DUSP5
−/−
 (DUSP5 KO), SerpinB2
-/-
 (SerpinB2 KO) 
and DUSP5
−/−
; SerpinB2
-/-
 (DKOSB2/5) animals (n = 19 per cohort) were exposed to DMBA 
followed by TPA treatment for 25 weeks. A) Tumour incidence. B) Average number of tumours per 
mouse.  DUSP5 loss significantly increased tumour multiplicity over WT animals, whereas 
SerpinB2
−/−
 or DKOSB2/5 mice were indistinguishable from WT animals (P values for WT/KO = 
0.001, WT/SerpinB2−/− = 0.499 and WT/DKOSB2/5 = 0.851 by repeated measures multivariate 
ANOVA with Tukey’s post hoc analysis). C) H&E stained sections of representative skin papillomas 
at 25 weeks. (Scale bar, 1mm). D) SerpinB2 IHC staining in WT, DUSP5 KO and DKOSB2/5 
papillomas. (Scale bars: upper panels, 200μm and lower panels, 500μm). Data courtesy of Dr 
Linda Rushworth. 
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3.4 Discussion 
DUSP5 is a nuclear, ERK-specific MKP which is induced as a negative feedback regulator 
following ERK activation (Kucharska et al., 2009; Mandl et al., 2005), therefore it has the 
potential to modulate ERK activity in response to oncogenic activation of the Ras-ERK 
pathway in cancer. However, prior to this study there has been no definitive experimental 
evidence that changes in DUSP5 expression can have a causative role in cancer 
development (Kidger and Keyse, 2016). This study demonstrates that DUSP5 acts as a 
tumour suppressor in the DMBA/TPA-induced model of HRas-driven skin carcinogenesis 
(Rushworth et al., 2014). DUSP5 loss promotes increased tumour burden in vivo (Fig. 
3.1B), in a manner, which is dependent on the upregulation of the SerpinB2 (Fig 3.14B). 
At the molecular level DUSP5 exhibits a non-redundant function in suppressing nuclear 
ERK activity, such that DUSP5 loss promotes elevated nuclear p-ERK in response to TPA 
stimulation (Fig. 3.3). This then drives the upregulation of a cohort of ERK-dependent 
genes including SerpinB2 (Fig. 3.4A). Furthermore, HRasQ61L expression synergises with 
DUSP5 loss to promote additional increases in SerpinB2 expression (Fig. 3.11), implying 
that DUSP5-mediated negative feedback becomes even more essential to constrain the 
activity of oncogenic mutations within the Ras-ERK pathway. This supports the proposal 
that ERK-induced negative feedback regulators, such as DUSP5, are an essential response 
to activated upstream oncogenes and can help to constrain the tumourigenic effects of 
such mutations (Pratilas et al., 2009).  
We demonstrate a tumour suppressive function for DUSP5 in HRas-driven skin papilloma 
formation, however this does not rule out an oncogenic role in other tumour contexts 
such as different organs or oncogenic driver mutations. For example, DUSP6/MKP-3 is 
essential for the oncogenic transformation of pre-B-cells in models of ALL (Shojaee et al., 
2015), whereas it acts as a tumour suppressor in mutant KRas-driven pancreatic cancer 
(Chapter 5). This is likely to reflect the ability of hyperactive ERK signalling to promote 
cellular senescence or apoptosis (Deschênes-Simard et al., 2014), therefore alterations in 
the magnitude of ERK activity have the ability to promote or suppress proliferation and 
tumour growth depending on the cellular context. If MKP loss promotes increased ERK 
activity that does not exceed the threshold inducing senescence it will promote increased 
tumourigenesis, making the MKP a tumour suppressor in this context. Whereas, in the 
context of stronger Ras-ERK pathway stimulation MKP activity maybe essential to 
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constrain ERK activity to maintain it below the threshold inducing senescence, to enable 
proliferation, giving the MKP an oncogenic function. 
Here we demonstrate that the nuclear MKP, DUSP5, is able to mediate spatially restricted 
changes in ERK activity specifically in the cellular compartment in which it is localised (Fig. 
3.3). This proves that despite the ability of ERK to shuttle rapidly between the nucleus and 
cytoplasm (Lidke et al., 2010; Zehorai et al., 2010), the precise control of ERK activity in 
specific subcellular compartments can be mediated by MKPs. One interesting puzzle is 
why DUSP5 loss only promotes the upregulation of a small cohort of TPA-inducible genes 
(Fig. 3.4A), as you would expect the increase in nuclear p-ERK resulting from DUSP5 loss 
to increase the expression of most of the hundreds of ERK-responsive genes (Yoon and 
Seger, 2006). One hypothesis would be that as DUSP5 loss is only causing a small 
alteration in nuclear p-ERK levels, only genes which are strongly transcriptionally 
upregulated in response to ERK show a large enough change in their mRNA levels to be 
statistically significant hits in our microarray experiments. The raw microarray data 
supports this, as many well established ERK target genes such as cFos, cJun and 
DUSP6/MKP-3 are all marginally upregulated following DUSP5 loss (Rushworth et al., 
2014 - microarray deposition). Although the changes in expression of such genes do not 
achieve statistical significance, the wide range of ERK target genes affected does imply 
that they are being affected by DUSP5 loss. This theory is also supported by evidence that 
SerpinB2 is known to be a gene which is strongly transcriptionally upregulated in 
response to cellular stresses or TPA stimulation (Stringer et al., 2012), therefore it is more 
likely to be sensitive to DUSP5 loss than other genes which might be transcribed in an 
ERK-dependent manner but are not typically induced in such a dynamic manner to 
particular stimuli. Alternatively, when present DUSP5 could be preferentially binding and 
inactivating ERK bound to specific gene promoters or enhancers within the nucleus, 
therefore it could be selectively minimising the transcription of certain genes. Signalling 
kinases such as the MAPKs do have the ability to localise to sites of active transcription via 
binding to transcription factor complexes within chromatin (Chow and Davis, 2006; Nadal 
et al., 2011). This was first demonstrated in yeast, where the p38 homolog Hog1 was 
shown to associate at stress-responsive promoters through transcription factor binding. 
Once localised to such promoters Hog1 acts to recruit and activate transcription factors, 
chromatin modulators and RNA Pol II (Nadal and Posas, 2010; Pokholok et al., 2006). 
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Subsequent studies in mammalian systems have also revealed that ERK signalling 
pathway complexes are able to bind chromatin and localise at ERK-inducible promoters to 
modulate transcriptional activity in situ (Lawrence et al., 2008; Nelson et al., 2011; Zhang 
et al., 2008). This evidence suggests it would be possible for DUSP5 to co-localise with, 
and regulate the activity of, ERK at such promoters and if any factors were able to 
modulate the binding of DUSP5 to ERK at specific promoters this would constitute a 
mechanism by which DUSP5 loss could differentially regulate specific ERK target genes. 
In addition to SerpinB2, we demonstrated Egr1 to be upregulated upon DUSP5 loss (Fig. 
3.4A). Egr1 is able to promote the expression of both SerpinB2 and DUSP5 (Fig. 3.7 & 3.9). 
This is supported by evidence from recent studies where SerpinB2 has been shown to be 
induced by Egr1 signalling during mammary cell migration (Tarcic et al., 2012), and DUSP5 
was also identified as a TPA-induced Egr1 target gene in THP-1 leukemia cell lines 
(Kubosaki et al., 2009). Therefore, through the regulation of nuclear p-ERK levels, and 
thus Egr1 induction, DUSP5 acts as part of a negative feedback loop to regulate its own 
expression, and the expression of a cohort of ERK-dependent genes including SerpinB2. 
Interestingly, there is no Egr1 transcription factor binding site in the SerpinB2 promoter 
and using transcription factor binding site mutant SerpinB2 promoter-reporter constructs 
we could demonstrate that SerpinB2 induction requires AP1 family transcription factors in 
the presence or absence of DUSP5 (Fig. 3.8B). This is in agreement with previous studies 
which have shown that SerpinB2 induction following phorbol ester stimulation requires 
AP-1 activity in both immune cells and human cancer cell lines (Stringer et al., 2012). 
Together this indicates Egr1 is acting in an indirect manner, most likely through the 
regulation of, or interaction with, AP-1 transcription factors to induce SerpinB2 
expression. This hypothesis is supported by previous studies which have demonstrated 
changes in expression of AP-1 transcription factor components, via microarray analysis, 
following the manipulation of Egr1 activity (Čermák et al., 2010; Zhang et al., 2014). 
Conversely, the DUSP5 promoter contains an Egr1 binding site and Egr1 binding to the 
DUSP5 promoter has been identified via chromatin immunoprecipitation with promoter 
microarray (ChIP-chip) analysis (Kubosaki et al., 2009). ChIP-chip enables the 
identification of the entire spectrum of in vivo DNA binding sites for any given protein. To 
do this the DNA binding regions of a specific protein of interest can be isolated using 
chromatin immunoprecipitation (ChIP), subsequent hybridisation of the isolated DNA 
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fragments with a DNA microarray enable the identification of the specific genomic regions 
isolated (Buck and Lieb, 2004). Therefore, in contrast to SerpinB2, it appears that the 
regulation of DUSP5 expression by Egr1 occurs in a direct manner. 
Papillomas from DUSP5-/- mice displayed elevated SerpinB2 expression relative to 
DUSP5+/+ papillomas (Fig. 3.13A & 3.14D) demonstrating that DUSP5 loss also promotes 
SerpinB2 in vivo. Experiments using DKO mice establish SerpinB2 upregulation as the 
mechanism promoting the increased tumour incidence in DUSP5-/- mice following 
DMBA/TPA treatment (Fig. 3.14B). This result is in line with previous studies which have 
demonstrated an oncogenic role for SerpinB2 in DMBA/TPA-induced skin cancer models. 
Bovine keratin 5 promoter-driven overexpression of SerpinB2 in basal keratinocytes 
sensitized transgenic mice to DMBA/TPA-induced papilloma formation (Zhou et al., 2001), 
whereas SerpinB2-/- mice have been shown to be resistant (Tonnetti et al., 2008). In 
contrast to this second study (Tonnetti et al., 2008), we did not observe resistance to 
DMBA/TPA-induced carcinogenesis in SerpinB2-/- mice. It is unclear why this is the case, as 
both studies used inbred C57BL/6 mice, ruling out genetic background. However, the 
DMBA/TPA treatment protocol of the two studies was slightly different with Tonnetti et 
al. (2008) using a lower initial dose of DMBA to initiate tumourigenesis and then 
monitoring the mice for a shorter (18 week) period. Furthermore, the resistance observed 
by Tonnetti et al. (2008) appears transient as by 17 weeks into their study the SerpinB2-/- 
mice had generated the same papilloma incidence and burden as wild-type mice. 
However, this potential oncogenic role for SerpinB2 in cancer development is still subject 
to debate. In human cancers elevated SerpinB2 expression correlates with improved 
prognosis in multiple cancer types including breast and pancreas, but poor prognosis in 
others such as colorectal and ovarian cancer (Croucher et al., 2008). Furthermore, the 
relative contributions of the extracellular versus intracellular functions for SerpinB2 in 
cancer development are unresolved, and the molecular mechanism by which intracellular 
SerpinB2 could drive carcinogenesis is unclear (Croucher et al., 2008). The previous 
DMBA/TPA-induced carcinogenesis models indicated that intracellular SerpinB2 inhibited 
the induction of apoptosis to promote tumourigenesis (Tonnetti et al., 2008; Zhou et al., 
2001). In contrast, further studies failed to detect any effects of SerpinB2 on apoptosis or 
cell proliferation (Fish and Kruithof, 2006; Major et al., 2011; Schroder et al., 2014), 
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although roles in autophagy (Chuang et al., 2013) and migration (Schroder et al., 2014) 
have been proposed. Therefore the mechanism by which intracellular SerpinB2 could 
regulate tumourigenesis appears unclear. Our initial experiments have not identified any 
changes in apoptosis or autophagy markers in wild-type, DUSP5-/- or SerpinB2-/- MEFs 
following a range of stimuli (Data not shown). Consequently, a more detailed analysis of 
cellular phenotypes following SerpinB2 loss or overexpression is required to determine 
the mechanism by which it is able to promote tumour progression in our model of HRas-
driven skin carcinogenesis. 
The extracellular protease function of SerpinB2, and other Serpin family members, has 
been shown to a mechanism by which brain metastatic cells from lung cancers, overcome 
the metastasis-suppressing effects of plasmin generation in the brain. In this system 
Serpins protect cancer cells from apoptosis and promote vascular co-option (Valiente et 
al., 2014). However, as the papillomas formed during the initiation phase of the 
DMBA/TPA-induced skin cancer model are still benign, non-invasive lesions (Abel et al., 
2009), such action to remodel the stroma to enable migration or metastasis is unlike to 
be the mechanism driving increased sensitivity to tumourigenesis in our system. The mice 
used in our study were inbred C57BL/6 mice, a genetic background which is known to be 
highly resistant to the malignant conversion of papillomas into invasive squamous cell 
carcinomas (SCC) (Abel et al., 2009). Therefore, it would be interesting to generate 
DUSP5-/- on a more susceptible genetic background, such as FVB mice, to investigate 
whether DUSP5 loss and SerpinB2 overexpression have any further effects on the 
malignant progression and metastatic potential of DMBA/TPA-induced skin tumours. 
In conclusion, this chapter demonstrates that DUSP5 acts as a tumour suppressor in HRas-
driven skin carcinogenesis, through its non-redundant function in regulating nuclear ERK 
activity and resulting gene expression. DUSP5 loss promotes elevated nuclear p-ERK 
levels, driving the induction of SerpinB2 which is able to sensitise DUSP5-/- mice to 
DMBA/TPA-induced skin carcinogenesis.  
 
 
129 
 
Chapter 4 DUSP5 and DUSP6 are induced 
following endogenous KRasG12D expression in 
MEFs, where they play distinct roles in 
modulating ERK signalling 
4.1 Introduction 
In the previous chapter we demonstrated that DUSP5 loss in combination with TPA 
stimulation or mutant HRasQ61L expression resulted in increased nuclear p-ERK levels and 
the upregulation of a cohort of ERK-responsive genes, including SerpinB2. This was 
sufficient to drive a sensitisation to DMBA/TPA-induced skin carcinogenesis in DUSP5-/- 
mice, in a manner dependent on SerpinB2. This demonstrates that DUSP5 performs a 
non-redundant function in the control of nuclear ERK activity, ERK localisation and ERK-
dependent gene expression (Rushworth et al., 2014). However, our in vitro experiments 
were performed following either ectopic expression of HRasQ61L or acute stimulation with 
TPA, which do not accurately mimic the true physiological conditions within a cancer cell 
driven by Ras-ERK pathway mutations. 
In previous studies it has been possible to study the effects of mutant Ras expressed at 
physiological levels, either through the knock-in of KRasG12D at the endogenous gene locus 
in MEFs (Guerra et al., 2003; Tuveson et al., 2004) or through the generation of isogenic 
cell lines using homologous recombination, which differ only in the presence or absence 
of the mutant Ras allele (Haigis et al., 2008; Vartanian et al., 2013). Surprisingly, these 
studies have revealed that the presence of a constitutively active KRas mutant allele is not 
sufficient to cause increased  levels of either  p-ERK or p-AKT indicating that the activity of 
the PI3K and MEK-ERK pathways is relatively unaffected (Guerra et al., 2003; Haigis et al., 
2008; Tuveson et al., 2004; Vartanian et al., 2013). In contrast, ectopic overexpression of 
mutant Ras does promote increased ERK activation in both MEFs and Hela cells 
(Rushworth et al., 2014; White et al., 1995). Despite this apparent lack of effector 
pathway activation, endogenous mutant Ras expression is still able to induce significant 
changes in gene expression (Vartanian et al., 2013) and result in the partial 
transformation of host cells (Guerra et al., 2003; Tuveson et al., 2004; Vartanian et al., 
2013). However, full cellular transformation requires the acquisition of additional genetic 
events (Guerra et al., 2003; Tuveson et al., 2004). Furthermore, in vivo expression of 
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endogenous mutant Ras initially has mild phenotypic consequences, with progression to 
invasive tumours occurring rather slowly until facilitated by the gain of further mutations 
or loss of tumour suppressors (Guerra et al., 2003; Hingorani et al., 2003, 2005, Jackson et 
al., 2001, 2005; Johnson et al., 2001; Tuveson et al., 2006). 
The lack of activation of Ras effector pathways following mutant Ras activation at 
endogenous levels suggests that negative feedback systems are induced and are able to 
restrain the activation of such pathways. Indeed Vartanian et al., (2013) revealed that 
strong negative feedback signalling to the EGF receptor plays a role in restraining Ras 
effector pathway activation following mutant KRas expression. Furthermore, they 
identified the upregulation of multiple MKPs, including DUSP5 and DUSP6/MKP-3, by 
mutant KRas, which could be a mechanism for restraining ERK activation. MKPs comprise 
a key negative feedback system of the MAPK pathways (Caunt and Keyse, 2013). 
Upregulation of DUSP5 and DUSP6/MKP-3 in the presence mutant Ras or BRaf signalling 
has also been identified in many other human cancer cell lines (Cagnol and Rivard, 2012; 
Haigis et al., 2008; Kreeger et al., 2009; Montero-Conde et al., 2013; Packer et al., 2009; 
Pratilas et al., 2009; Yun et al., 2009). This is supported by in vivo evidence from many 
human cancers, as the upregulation of MKPs has been demonstrated in many Ras and 
BRaf mutant human tumours (Caunt and Keyse, 2013; Kidger and Keyse, 2016a, 2016b).  
Taken together there is a broad range of evidence pointing to roles for MKPs in 
constraining ERK activity following upstream oncogenic mutations such as those in Ras. 
However, the relative contribution of MKPs to the negative feedback mechanisms 
responsible for restraining p-ERK levels following constitutive pathway activation and the 
consequences of MKP loss have not been investigated. Therefore, this study aimed to 
utilise KRasLSL-G12D/+ MEFs (Tuveson et al., 2004), as a model system to characterise the 
upregulation of MKPs by endogenous mutant Ras activation, and to investigate the 
biochemical and cellular consequences of DUSP5 and DUSP6/MKP-3 loss in the context of 
mutant Ras.  
We focussed on changes in the expression of DUSP5 and DUSP6/MKP-3 in our 
experiments as they are both ERK-specific MKPs and are induced in response to ERK 
activity as classical negative feedback regulators of this pathway (Groom et al., 1996; 
Kucharska et al., 2009; Mandl et al., 2005; Mourey et al., 1996; Smith et al., 2006). 
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Therefore, any potential consequences of their ablation should be mediated through the 
ERK pathway downstream of mutant KRas without invoking changes in the activities of 
either JNK or p38 MAPK’s, which could be the case with other MKPs. Furthermore, DUSP5 
and DUSP6/MKP-3 display differential subcellular localisation, with DUSP5 localised to the 
nucleus (Mandl et al., 2005) while DUSP6/MKP-3 is found predominantly in the cytoplasm 
(Groom et al., 1996; Mourey et al., 1996). Thus, this study will also aim to investigate 
whether the loss of ERK negative feedback components in specific subcellular 
compartments can alter the spatiotemporal control of ERK activity and differentially 
regulate ERK signalling outcomes. 
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4.2 Results 
4.2.1 KRasG12D induces DUSP5 and DUSP6/MKP-3 expression in a 
MEK-dependent manner 
To investigate potential changes in MKP expression following the expression of mutant 
KRas at endogenous levels, we used the well-established KRasLSL-G12D knock in allele. Prior 
to Cre-mediated recombination, this allele is effectively null (Jackson et al., 2001; Tuveson 
et al., 2004) and as homozygous deletion of KRas causes early embryonic lethality 
(Johnson et al., 1997) we first isolated littermate MEF cell lines from either wild-type or 
heterozygous KRasLSL-G12D/+ mice. Before commencing any experiments we isolated MEFs 
from multiple litters of mice to ensure that for each experiment biological replicates 
could be performed in distinct MEF lines isolated from different parents, and that within 
each replicate the individual MEF lines used were derived from littermates. This should 
ensure that any effects observed result from the genetic changes we have introduced and 
not stochastic genetic variation within our cell lines. 
To knock-in the KRasG12D allele we infected MEFs with adenovirus expressing Cre-
recombinase. We initially performed titration experiments to optimise the titre of 
adenoviral-Cre used to infect cells (Fig. 4.1A), followed by time course experiments to 
determine the minimum time period following infection by which the majority of KRasLSL-
G12D/+ MEFs in a given culture had undergone Cre-mediated recombination (Fig. 4.1B). 
Recombination of the KRasLSL-G12D allele was determined by performing PCR analysis of 
genomic DNA isolated from KRasLSL-G12D/+ MEFs following infection with either empty 
adenovirus or adenoviral-Cre using oligonucleotide primers capable of distinguishing the 
WT, LSL-KrasG12D, and recombined KrasG12D alleles. Together these experiments 
demonstrate that infection using a viral titre of 250 MOI is sufficient to induce complete 
recombination of the KRasLSL-G12D allele in a culture of KRasLSL-G12D/+ MEFs when assayed 24 
hours post-infection (Fig. 4.1A-B). This same viral titre was used in all future experiments 
and the biological effects of KRasG12D knock-in were not investigated until at least 24 
hours post-infection. To confirm that our KRasG12D knock-in MEFs were producing 
functional, constitutively active mutant KRasG12D protein, we infected wild-type and 
KRasLSL-G12D/+ MEFs with adenoviral-Cre or empty adenovirus and immunoprecipitated 
GTP-bound Ras using the Ras-binding domain of Raf1. Only Cre-treated KRasLSL-G12D/+ MEFs 
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showed a significant increase in the level of active GTP-bound Ras and the presence of 
RasG12D protein (Fig. 4.1B), validating our experimental system. 
Before assaying the expression of MKPs in response to KRasG12D expression in detail we 
wanted to determine the optimal experimental conditions to observe any potential 
responses. In previous studies investigating the biochemical activation of ERK and AKT 
following KRasG12D expression in MEFs, cells were lysed and samples taken at 48 hours 
post-infection (Tuveson et al., 2004). Consequently, we utilised this time point, but also 
wanted to assess whether additional serum stimulation would improve our ability to 
detect altered MKP regulation following KRasG12D expression. We considered this 
important because under basal, unstimulated conditions MKPs are typically expressed at 
very low levels and can be difficult to detect (Kucharska et al., 2009). However, our 
experiments revealed that DUSP5 and DUSP6/MKP-3 were expressed at higher levels in 
Cre-treated KRasLSL-G12D/+ MEFs when compared to wild type MEFs under normal growth 
conditions (10% serum) and that overnight serum starvation and re-stimulation with 20% 
serum for 2 hours was not necessary to induce increased expression of DUSP5 and 
DUSP6/MKP-3 (Fig. 4.2). Consequently, we decided to use steady state growth conditions 
for all further experiments. 
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Figure 4.1 Validation of adenoviral-Cre mediated KRas
G12D 
knock-in in MEFs. A-B) PCRs of 
genomic DNA from KRas
LSL-G12D/+ 
MEFs demonstrating the excision of the Lox-STOP-Lox (LSL)-
cassette from the KRas
LSL-G12D 
allele upon adenoviral-Cre (Cre) treatment, but not empty 
adenovirus (E). Control lysates from untreated KRas
LSL-G12D/+ 
(Het) and KRas
+/+ 
(WT) MEFs validate 
the size of 450bp WT and 327bp LSL-cassette bands. Cre-mediated recombination of the KRas
LSL-
G12D 
allele results in the loss of the 327bp band and the formation of a 484bp fragment (450bp WT 
fragment, plus an additional 34bp from the single LoxP site remaining). A) Cells were treated with 
500, 250 or 125 MOI of adenovirus and DNA isolated at 8 hours post infection. B) Cells were 
treated with 250 MOI of adenovirus and DNA isolated at 4, 8 or 24 hours post adenoviral infection. 
C) MEFs of the indicated genotype were infected with adenoviral-Cre (Ad5CMV-Cre) or empty 
adenovirus (Ad5CMV-Empty) 24h prior to lysis and pull down of GTP-bound Ras using the RAS-
binding domain (RBD) of CRAF. GTP-bound Ras or Ras
G12D
 and input levels of total Ras in whole 
cell lysates were measured by immunoblotting.  
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Figure 4.2 MKP induction following KRas
G12D
 knock-in under different serum conditions. 
MEFs of the indicated genotype were infected with adenoviral-Cre (C) or empty adenovirus (E) 
prior to modulation of their serum conditions. MEFs were either left to grow in 10% FBS, serum 
starved in 0.5% FBS for 18 hours, or serum starved in 0.5% FBS for 18 hours followed by a 20% 
FBS stimulation for 2 hours. Cells were lysed and proteins analysed by immunoblotting using the 
indicated antibodies. Representative image of experiment performed in duplicate. 
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To investigate the induction of MKPs following KRasG12D expression we infected KRasLSL-
G12D/+ MEFs with adenoviral-Cre or empty adenovirus and assessed protein and mRNA 
levels at 24, 48 and 72 hours post-infection (Fig. 4.3-4). Following KRasG12D knock-in a 
consistent upregulation of p-MEK (representing MEK that is activated via phosphorylation 
at Ser217/221) levels could be observed. In contrast, p-ERK levels only displayed a minor 
upregulation at 24 and 48 hours post KRasG12D expression, before returning to wild-type 
levels by 72 hours post-infection (Fig. 4.3A-B). Taken together this suggests that KRasG12D 
expression is promoting an increase in upstream ERK pathway activity, demonstrated by 
the consistently elevated p-MEK levels, however negative feedback regulation must be 
acting upon ERK itself to return ERK activity to wild-type levels by 72 hours post-KRasG12D 
expression. Several MKPs capable of dephosphorylating and regulating ERK, including 
DUSP2, DUSP4/MKP-2, DUSP5 and DUSP6/MKP-3 are consistently upregulated at both 
the mRNA and protein level following KRasG12D expression (Fig. 4.3-4), indicating that 
these enzymes are likely to play a key role in modulating ERK activity in response to 
KRasG12D expression. Interestingly, despite the observation that ERK activation is 
effectively constrained following KRasG12D expression, the levels of SerpinB2 mRNA and 
protein are increased at all time points (Fig. 4.3-4). We have previously shown that 
SerpinB2 expression is induced in an ERK-dependent manner in MEFs (Fig. 3.5), making it 
a robust readout of ERK-dependent gene expression. This implies that despite the lack of 
any observable changes in steady-state p-ERK levels, flux through the pathway could be 
increased to promote the activation of certain ERK targets. One explanation for the latter 
result is that ERK activity is altered in distinct subcellular compartments or fractions and 
that these changes are not readily detected by Western blotting of whole cell lysates.  
The ERK-specific MKPs DUSP5 and DUSP6/MKP-3 have been shown to be induced in 
response to ERK activity and thus act as negative feedback regulators of pathway activity 
(Kucharska et al., 2009; Smith et al., 2006), however other studies have implied that 
DUSP6/MKP-3 can be regulated by the PI3-kinase pathway which is also activated as a 
downstream effector pathway by expression of mutant Ras (Park et al., 2014; Phuchareon 
et al., 2015). To explore this possibility under conditions where mutant Ras is expressed 
at endogenous levels, we treated KRasLSL-G12D/+ MEFs with specific inhibitors of either MEK 
(PD184352) or PI3K (PI-103) following adenoviral-Cre treatment to determine which of 
these pathways was mediating KRasG12D-induced MKP expression (Fig. 4.5-6). Following 
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treatment with PD184352 levels of p-MEK are increased, although ERK phosphorylation is 
inhibited (Fig. 4.5). This is because PD184352 is an allosteric, non-ATP competitive MEK 
inhibitor(Sebolt-Leopold et al., 1999; Solit et al., 2006), therefore the compound does not 
block MEK phosphorylation but prevents the structural changes in MEK which enable its 
activity. Consequently, p-MEK levels dramatically increase following PD184352 treatment 
due to the relief of negative feedback between ERK and Raf, stimulating enhanced MEK 
phosphorylation. 
Our results clearly show that KRasG12D–driven expression of both DUSP5 and DUSP6/MKP-
3 is dependent on ERK activity, but not PI3K activity, at both the protein (Fig. 4.5) and 
mRNA levels (Fig. 4.6). Interestingly, DUSP6/MKP-3 protein expression was somewhat 
increased following PI3K inhibition in these cells, a result in agreement with previous 
experiments in which immortalised mouse fibroblasts (NIH3T3) exposed to fibroblast 
growth factor (FGF) were treated with these inhibitors (Ekerot et al., 2008). Furthermore, 
increased expression of DUSP2, DUSP4/MKP-2 and DUSP7 mRNA’s was also shown to be 
induced by KRasG12D and abrogated by the inhibition of ERK, but not PI3K, activity (Fig. 
4.6).  Finally, DUSP9/MKP-4 mRNA was induced by KRasG12D but not significantly 
downregulated by either MEK or PI3K inhibition, whereas DUSP1/MKP-1 mRNA was not 
induced by KRasG12D (Fig. 4.6). Overall, this demonstrates that the majority of MKPs 
capable of targeting the Ras-ERK pathway are induced by ERK activity and can probably 
act as negative feedback regulators in response to mutant KRasG12D expression.  
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Figure 4.3 Ras effector pathway activation and MKP induction following KRas
G12D 
knock-in. 
KRas
LSL-G12D/+ 
MEFs were infected with adenoviral-Cre (C) or empty adenovirus (E) for 24, 48 or 72 
hours prior to cell lysis, and immunoblotting using the indicated antibodies. A representative 
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Western blot is shown (A), alongside protein quantification utilising a Li-Cor Odyssey infrared 
scanner (B). Mean values ± SEM are shown, n = 3. ns = not significant, *P < 0.05, **P < 0.01, 
***P<0.001 using two-way ANOVA and Bonferroni post hoc test, comparing Empty v Cre 
treatments. 
 
 
 
Figure 4.4 MKP induction following KRas
G12D
 knock-in. Taqman RT-qPCR assays showing the 
fold change in mRNA levels of the indicated genes following Cre-mediated KRas
G12D
-knock-in, 
relative to empty adenovirus treatment. KRas
LSL-G12D/+ 
MEFs were infected with adenoviral-Cre 
(Ad5-Cre) or empty adenovirus (Ad5-Empty) for 24, 48 or 72 hours prior to cell lysis and RNA 
isolation. Mean values ± SEM are shown, n = 3. ns = not significant, *P < 0.05, **P < 0.01, 
***P<0.001 using two-way ANOVA and Bonferroni post hoc test, comparing Empty v Cre 
treatments. 
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Figure 4.5 MKP induction following KRas
G12D
 knock-in is dependent on ERK, but not PI3K, 
pathway activation. KRas
LSL-G12D/+ 
MEFs were infected with adenoviral-Cre (Cre) or empty 
adenovirus (Empty) for 48 hours prior to cell lysis, and immunoblotting using the indicated 
antibodies. MEFs were also treated with DMSO control, the MEK inhibitor PD184352 (PD) or the 
PI3K inhibitor Pi103 4 hours prior to lysis. Western blot is shown (A), alongside protein 
quantification (B). Mean values ± SEM are shown, n = 3. ns = not significant, *P < 0.05, **P < 0.01, 
****P<0.0001 using one-way ANOVA and Bonferroni post hoc test. 
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Figure 4.6 MKP induction following KRas
G12D
 knock-in is dependent on ERK, but not PI3K, 
pathway activation. Taqman RT-qPCR assays showing the fold change in mRNA levels of the 
indicated genes following Cre-mediated KRas
G12D
-knock-in and inhibitor treatment, relative to 
empty adenovirus treatment. KRas
LSL-G12D/+ 
MEFs were infected with adenoviral-Cre (Ad5-Cre) or 
empty adenovirus (Ad5-Empty) for 48 hours, combined with treatment with DMSO control, the MEK 
inhibitor PD184352 (PD) or the PI3K inhibitor Pi103 4 hours prior to lysis. Mean values ± SEM are 
shown, n = 3. *P < 0.05, **P < 0.01, **P < 0.001, ****P<0.0001 using one-way ANOVA and 
Bonferroni post hoc test.  
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4.2.2 KRasG12D expression induces DUSP5 and DUSP6/MKP-3 in a 
dose-dependent manner to constrain ERK activity 
Thus far we have shown that multiple MKPs, including DUSP5 and DUSP6/MKP-3, are 
upregulated in response to mutant KRasG12D expression (Fig. 4.3-4), and that this 
upregulation is dependent on ERK activity (Fig. 4.5-6). Together this indicates that MKPs 
act as negative feedback regulators to constrain constitutive activation of the ERK 
pathway. To extend these results and to determine whether MKPs are induced in a dose-
dependent manner in response to oncogenic stimuli, we set out to generate MEFs, which 
were homozygous for the KRasLSL-G12D allele. Although KRas homozygous knockout is 
embryonic lethal in mice, death occurs between embryonic days 12-14 (E12-14) (Johnson 
et al., 1997), therefore we attempted to derive MEFs from mouse embryos at E11.5 in the 
hope that cells would still be viable at this early embryonic stage. This strategy, though 
resulting in lower yields of MEFs (in terms of cell numbers), was successful and enabled 
the isolation of homozygous mutant KRas (KRasLSL-G12D/LSL-G12D) MEFs. These cells were 
viable, although E11.5 MEFs of all genotypes proliferated more slowly than cells derived 
from later (E13.5) embryos when grown prior to adenoviral infection. Initially we 
validated the genotype of our KRasLSL-G12D/LSL-G12D MEFs via PCR analysis of genomic DNA in 
the presence or absence of adenoviral-Cre treatment. KRasLSL-G12D/LSL-G12D MEFs amplified 
only the characteristic LSL-cassette PCR product prior to Cre-treatment and this was 
converted into the single KRasG12D knock-in PCR product following Cre-mediated 
recombination (Fig. 4.7A). Furthermore, homozygous KRasG12D knock-in promoted 
increased RasG12D protein levels and Ras activity, determined by the level of GTP-bound 
Ras, relative to the heterozygous KRasG12D knock-in (Fig. 4.7B), demonstrating the 
expected functional consequences of the presence of two copies of the mutant allele. 
  
143 
 
 
Figure 4.7 Validation of KRas
G12D 
homozygous MEFs. A) PCR of genomic DNA from KRas
LSL-
G12D/LSL-G12D 
(G12D/G12D) and KRas
LSL-G12D/+ 
(G12D/+) MEFs demonstrating the excision of the 
LSL-cassette upon adenoviral-Cre (Cre) treatment, but not empty adenovirus (Empty). Cells were 
lysed and DNA isolated 24 hours post adenoviral infection. Control lysates from untreated KRas
LSL-
G12D/LSL-G12D 
(Hom), KRas
LSL-G12D/+ 
(Het) and KRas
+/+ 
(WT) MEFs validate the size of 450bp WT and 
327bp LSL-cassette bands. Cre-mediated recombination of the KRas
LSL-G12D 
allele results in the 
formation of a 484bp fragment. B) MEFs of the indicated genotype were infected with adenoviral-
Cre (Ad5CMV-Cre) 24h prior to lysis and pull down of GTP-bound Ras using the RAS-binding 
domain (RBD) of CRAF. GTP-bound Ras or Ras
G12D
 and input levels of total Ras in whole cell 
lysates were measured by immunoblotting. 
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To investigate the effects of increasing mutant KRas-driven oncogenic stimulus on ERK 
activity and MKP induction, wild-type, KRasLSL-G12D/+ and KRasLSL-G12D/LSL-G12D MEFs were 
infected with adenoviral-Cre and Ras effector pathway activation and MKP induction 
compared between genotypes (Fig. 4.8-9). Expression of one or two alleles of mutant 
KRasG12D induced increased p-MEK levels relative to wild-type MEFs, and KRasG12D/G12D 
MEFs displayed marginally higher levels than heterozygous KRasG12D/+ MEFs (Fig. 4.8). This 
indicates that mutant KRasG12D expression is driving increased activation of the ERK 
pathway in a dose-dependent manner, consistent with the increased Ras activity 
observed in these cells (Fig. 4.7B). However, p-ERK levels are not significantly increased 
following knock-in of either one or two copies of the KRasG12D allele, relative to wild-type 
MEFs (Fig. 4.8). Expression of the ERK-targeting MKPs DUSP2, DUSP4/MKP-2, DUSP5 and 
DUSP6/MKP-3 is reduced in empty adenovirus treated KRasLSL-G12D/LSL-G12D MEFs where 
KRas expression is absent, reflecting the importance of ERK pathway activity in inducing 
the expression of these MKPs (Fig. 4.6 & 4.8-9) (Brondello et al., 1997; Kucharska et al., 
2009; Smith et al., 2006). However, when taking into account this reduced initial 
expression of these MKPs in KRasLSL-G12D/LSL-G12D MEFs, KRasG12D expression can be shown 
to promote a dose-dependent increase in DUSP5 and DUSP6/MKP-3 mRNA and protein 
levels and the mRNA expression of DUSP2 and DUSP4/MKP-2 (Fig. 4.8-9). Furthermore, 
the expression of DUSP7 and DUSP9/MKP-4 mRNA is significantly upregulated upon 
homozygous, but not heterozygous, KRasG12D expression (Fig. 4.9), perhaps reflecting the 
necessity for increased negative feedback activity in the presence of a stronger stimuli. 
Together these results indicate that MKPs are likely to play a role in maintaining the 
constant level of p-ERK observed following the expression of either one or two copies of 
mutant KRasG12D. 
Previous experiments demonstrated the upregulation of SerpinB2 mRNA and protein 
levels in response to the expression of one allele of mutant KRasG12D (Fig. 4.3-4). Again 
utilising SerpinB2 expression as a measure of ERK-dependent gene we can demonstrate 
that mutant KRasG12D expression induces ERK-target genes in a dose-dependent manner 
(Fig. 4.8-9), again indicating that although the apparent p-ERK levels assayed by Western 
blotting of whole cell lysates are not increased, signalling flux through the pathway is 
likely to be increased following KRasG12D expression. Interestingly, levels of p-AKT are not 
elevated following knock-in of one or two copies of the KRasG12D allele, implying that 
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negative feedback systems are also preventing increased PI3K signalling following 
constitutive KRas activation (Fig. 4.8). 
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Figure 4.8 Dose-dependent MKP induction following KRas
G12D 
knock-in maintains constant 
levels of p-ERK. Wild-type (+/+), KRas
LSL-G12D/+ 
(G/+) and KRas
LSL-G12D/LSL-G12D 
(G/G) MEFs were 
infected with adenoviral-Cre (Ad5-Cre) or empty adenovirus (Ad5-Empty) for 48 hours prior to cell 
lysis, and immunoblotting using the indicated antibodies. A representative Western blot is shown 
(A), alongside protein quantification (B). Mean values ± SEM are shown, n = 3 *P < 0.05, **P < 
0.01, ***P<0.001 using two-way ANOVA and Bonferroni post hoc test, comparing KRas genotypes.  
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Figure 4.9 Dose-dependent MKP induction following KRas
G12D 
knock-in. Taqman RT-qPCR 
assays showing the fold change in mRNA levels of the indicated genes following Cre-treatment of 
MEFs of the indicated genotype, relative to wild-type cells infected with empty adenovirus. Wild-
type (+/+), KRas
LSL-G12D/+ 
(G/+) and KRas
LSL-G12D/LSL-G12D 
(G/G) MEFs were infected with adenoviral-
Cre (Ad5-Cre) or empty adenovirus (Ad5-Empty) for 48 hours prior to cell lysis and RNA isolation. 
Mean values ± SEM are shown, n = 3. *P < 0.05, **P < 0.01, ***P<0.001, ***P<0.001 using two-
way ANOVA and Bonferroni post hoc test, comparing KRas genotypes. 
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The knock-in of one allele of mutant KRasG12D has been shown to increase the 
proliferation rate of MEFs and also to enable colony formation through the loss of contact 
inhibition (Tuveson et al., 2004). Consequently, if there is an increase in ERK-dependent 
gene expression following homozygous KRasG12D expression, despite negative feedback 
systems including MKPs constraining total p-ERK levels, it could be hypothesised that 
homozygous KRasG12D expression would have an additional effects on cellular phenotypes 
relative to the activation of one KRasG12D allele. Therefore, we investigated whether 
modulation of cellular phenotypes, such as proliferation rate, occurs in a dose-dependent 
manner following the knock-in of one or two alleles of KRasG12D. 
To address this question we performed proliferation assays on wild-type, KRasLSL-G12D/+ 
and KRasLSL-G12D/LSL-G12D MEFs in the presence or absence of adenoviral-Cre treatment. 
Empty adenoviral infected MEFs of all genotypes proliferated at a similar rate, which did 
not significantly differ from that of wild-type cells infected with adenoviral-Cre. Whereas, 
the knock-in of one or two alleles of KRasG12D significantly increased the proliferation rate 
of MEFs compared to wild-type cells (Fig. 4.10A). This increased proliferation upon 
KRasG12D expression can be clearly demonstrated by calculating the fold change in cell 
number (Fig. 4.10B) or the percentage increase in the gradient of the linear component of 
the growth curves (Fig. 4.10C) comparing the empty to Cre-treated MEFs of each 
genotype. This should normalise for any initial differences in proliferation rate of 
individual MEF cell lines due to genetic differences independent of KRas genotype. These 
graphs show that Cre-treatment of wild-type MEFs has no significant effect on 
proliferation rate, whereas the knock-in of one or two alleles of KRasG12D induces an 
approximate doubling or tripling or the proliferation rate respectively (Fig. 4.10B-C).  
Colony formation assays were also performed on KRasLSL-G12D/+ and KRasLSL-G12D/LSL-G12D 
MEFs. In agreement with previously published data, these assays demonstrated that 
when MEFs are seeded at high density KRasG12D expression can induce colony formation 
through the loss of contact inhibition (Fig. 4.11A) (Tuveson et al., 2004). However, in 
colony formation assays KRasG12D dose does not seem to affect the phenotype observed, 
with the knock-in of either one or two alleles of KRasG12D sufficient to permit colony 
formation. Furthermore, neither one nor two alleles of KRasG12D are sufficient to enable 
clonogenic growth, as neither genotype is able to form colonies when seeded at very low 
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density (Fig. 4.11B). Taken together these results demonstrate that despite negative 
feedback systems, such as MKPs, constraining p-ERK induction, KRasG12D expression is able 
to promote altered cellular phenotypes in MEFs.  
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Figure 4.10 KRas
G12D 
knock-in promotes increased proliferation in MEFs. Wild-type (+/+), 
KRas
LSL-G12D/+ 
(G/+) and KRas
LSL-G12D/LSL-G12D 
(G/G) MEFs were seeded at low density, infected with 
adenoviral-Cre (Cre) or empty adenovirus (Empty) and left to proliferate until confluent. A) Cell 
counts of each cell line and treatment. B) Fold change in cell number for each genotype post-cre 
treatment (Cre/empty cell count for each measurement). C) Percentage increase in gradient for 
each genotype post-cre treatment (Linear regression performed for every MEF line in each 
condition, to calculate the gradient. Then % increase in gradient of the cre-treated lines over the 
empty-treated lines calculated for each genotype). Mean values ± SEM are shown, n = 3. *P < 
0.05, **P < 0.01, using one-way ANOVA and Bonferroni post hoc test. 
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Figure 4.11 KRas
G12D 
knock-in enables loss of contact-inhibition and colony formation. MEFs 
of the indicated genotypes were infected with adenoviral-Cre (Ad5-Cre) or empty adenovirus (Ad5-
Empty) prior to seeding at high (A) or low (B) density. MEFs were grown for 2-3 weeks until foci 
were visible, before fixation and visualisation with crystal violet. Representative images shown of 
experiments performed in triplicate. B) No colonies formed from cells seeded at very low density. 
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4.2.3 DUSP5 loss alters gene expression in KRasG12D expressing 
MEFs 
MKPs are a component of the negative feedback mechanism responsible for constraining 
ERK activity following KRasG12D expression (Fig. 4.8-9). However, it is unknown whether 
individual MKPs perform non-redundant functions in the regulation of ERK activity is 
response to KRasG12D expression. To address this question we first crossed DUSP5 
knockout mice with KRasLSL-G12D/+ mice and utilised this transgenic line to generate 
littermate MEFs which all contained the KRasLSL-G12D/+ allele and were either DUSP5+/+, 
DUSP5+/- or DUSP5-/-. Subsequently, KRasG12D expression was induced in these MEFs 
through adenoviral-Cre treatment and changes in Ras effector signalling and MKP 
induction investigated after 48 hours. Following the loss of one or two alleles of DUSP5 
KRasG12D MEFs demonstrated no changes in either p-MEK or p-AKT levels, however 
surprisingly whole cell p-ERK levels appeared slightly reduced (Fig. 4.12). There also 
appeared to be marginal compensatory upregulation of other MKPs including DUSP2 and 
DUSP6/MKP-3 following the homozygous loss of DUSP5 in KRasG12D expressing MEFs (Fig. 
4.12 & 4.13A). However, the most striking phenotype was the consistent upregulation of 
multiple ERK target genes including both SerpinB2 and Egr1 upon homozygous DUSP5 loss 
in KRasG12D expressing MEFs (Fig. 4.12 & 4.13B). SerpinB2 and Egr1 expression was 
investigated following DUSP5 loss in KRasG12D expressing MEFs because as well as being 
well established ERK transcriptional targets (Shaul and Seger, 2007; Stringer et al., 2012), 
both of these genes were top microarray hits upregulated in DUSP5-/- MEFs upon TPA 
stimulation (Fig. 3.4A) (Rushworth et al., 2014).  
This indicates that DUSP5 loss might be inducing similar mechanistic changes in ERK 
activity following ERK pathway stimulation by mutant KRasG12D expression as we observed 
following TPA stimulation, whereby DUSP5 loss is able to promote increased nuclear ERK 
activation and therefore elevated ERK-dependent gene expression (Fig. 3.3 & 3.4) 
(Rushworth et al., 2014). To address we performed preliminary experiments using 
subcellular fractionation (Fig. 4.14A-B) and high-content microscopy (Fig. 4.14C) to assess 
levels of nuclear and cytoplasmic p-ERK in KRasG12D expressing MEFs in the presence or 
absence of DUSP5. Surprisingly, we were unable to identify any changes in p-ERK 
localisation following DUSP5 loss in the presence of KRasG12D. At the present time it is 
unclear why we are unable to detect these changes in ERK activity or localisation, despite 
153 
 
clear evidence that signalling flux through the ERK pathway is increased as evidenced by 
the changes in ERK-dependent gene expression seen following DUSP5 loss in these cells 
(Fig. 4.12-13). This may reflect the sensitivity of our detection methods under conditions 
where pathway flux is changed, but less dramatically than after TPA-stimulation or 
ectopic oncogene expression or the fact that recombination is relatively slow in achieving 
full expression of mutant KRas compared with the acute effects of TPA or ectopic 
oncogene expression.  
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Figure 4.12 Ras effector pathway activation and MKP induction following KRas
G12D 
knock-in 
and DUSP5 knockout. KRas
LSL-G12D/+ 
MEFs which were either DUSP5
+/+
, DUSP5
+/-
 or DUSP5
-/-
 
were infected with adenoviral-Cre (Ad5-Cre) or empty adenovirus (Ad5-Empty) for 48 hours prior to 
cell lysis, and immunoblotting using the indicated antibodies. A representative Western blot is 
shown (A), alongside protein quantification (B). Mean values ± SEM are shown, n = 3. *P < 0.05, 
**P < 0.01, ***P<0.001, ****P<0.0001 using two-way ANOVA and Bonferroni post hoc test, 
comparing DUSP5 genotypes.  
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Figure 4.13 DUSP5 loss alters ERK-dependent gene expression following KRas
G12D 
knock-in. 
Taqman RT-qPCR assays showing the fold change in mRNA levels of the indicated genes 
following Cre-treatment of KRas
LSL-G12D/+ 
 MEFs of the indicated DUSP5 genotype, relative to wild-
type cells infected with empty adenovirus. MEFs were infected with adenoviral-Cre (Ad5-Cre) or 
empty adenovirus (Ad5-Empty) for 48 hours prior to cell lysis and RNA isolation. A) ERK-targeting 
MKPs. B) ERK-target genes. Mean values ± SEM are shown, n = 3. *P < 0.05, **P < 0.01, 
****P<0.0001 using two-way ANOVA and Bonferroni post hoc test, comparing DUSP5 genotypes. 
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Figure 4.14 DUSP5 loss has no clear effect on ERK localisation or activation following 
KRas
G12D 
knock-in. A-B) KRas
LSL-G12D/+ 
MEFs which were either DUSP5
+/+
, DUSP5
+/-
 or DUSP5
-/-
 
were infected with adenoviral-Cre (Ad5-Cre) or empty adenovirus (Ad5-Empty) for 48 hours prior to 
cell lysis, subcellular fractionation and immunoblotting using the indicated antibodies. Upstream 
binding factor (UBF) and MEK were used to validate separation of nuclear (N) and cytoplasmic (C) 
proteins, respectively. A representative Western blot is shown (A), alongside protein quantification 
(B). Mean values ± SEM are shown, n = 3. ns = not significant. C) KRas
LSL-G12D/+ 
MEFs of the 
indicated DUSP5 genotype were infected with virus for 48 hours then stained for p-ERK or DAPI, 
before image analysis using high content fluorescence microscopy. Mean (± SEM) nuclear p-ERK 
intensity is shown derived from 5,000–10,000 individual cells per condition. Representative figure 
of an experiment performed in duplicate. Panel C courtesy of Dr Christopher Caunt.  
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4.2.4 DUSP6/MKP-3 loss causes no significant effects on 
KRasG12D signalling in MEFs 
To continue our investigation into whether individual MKPs perform non-redundant 
functions in the regulation of ERK activity in response to KRasG12D expression, we 
generated MEFs containing the KRasLSL-G12D/+ allele and a conditional DUSP6/MKP-3 allele. 
These cells enabled us to investigate whether DUSP6/MKP-3 plays any role in the 
regulation of KRasG12D induced ERK activity and to compare and contrast the effects of the 
loss of this cytoplasmic ERK-specific MKP, with that of the nuclear, ERK-specific MKP 
DUSP5. DUSP6/MKP-3 conditional mice were crossed with KRasLSL-G12D/+ mice, and these 
mice were utilised to generate littermate MEFs which all contained the KRasLSL-G12D/+ allele 
and were either DUSP6+/+, DUSP6+/fl or DUSP6fl/fl. KRasG12D expression and DUSP6/MKP-3 
loss was induced in these cell lines through adenoviral-Cre treatment and changes in Ras 
effector signalling and MKP activation investigated. Following homozygous loss of 
DUSP6/MKP-3 KRasG12D expressing MEFs demonstrated no changes in either p-MEK or p-
AKT levels, however whole cell p-ERK levels appeared slightly increased (Fig. 4.15). This 
indicates that DUSP6/MKP-3 might play a significant and non-redundant role in the 
negative feedback response constraining ERK activity induced by KRasG12D expression. The 
observed effect of DUSP6/MKP-3 loss on KRasG12D-driven ERK activity could be enabled 
due to the lack of significant compensatory upregulation of other MKPs (Fig. 4.15 & 
4.16A). However, despite the increase in whole cell p-ERK levels observed, the loss of 
DUSP6/MKP-3 in the presence of KRasG12D expression does not promote the upregulation 
of ERK target genes such as SerpinB2 and Egr1 (Fig. 4.16B).   
Overall, these results demonstrate that although DUSP5 loss does not cause a detectable 
change in ERK activity or localisation in the presence of KRasG12D expression (Fig. 4.12 & 
4.14), the loss of DUSP6/MKP-3 does cause an increase in levels of whole cell p-ERK (Fig. 
4.15). In contrast, DUSP5 loss is sufficient to drive increased ERK-dependent expression of 
multiple target genes (Fig. 4.13B), including SerpinB2 and Egr1, whereas DUSP6/MKP-3 
loss in not (Fig. 4.16B). Therefore, DUSP5 loss must be promoting some changes in 
nuclear ERK activity to be able to induce the observed changes in ERK-dependent gene 
expression. However, such changes in ERK activity are likely to be below the sensitivity 
threshold of our detection methods due to the relatively modest pathway stimulation 
resulting from KRasG12D expression, in contrast to the potent, acute stimulation following 
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TPA stimulation where changes in nuclear p-ERK levels could be detected (Fig. 3.3). The 
effects of DUSP6/MKP-3 loss are potentially restricted to solely cytoplasmic ERK activity, 
which could explain the lack of transcriptional effects. Furthermore, as the majority of 
ERK is localised to the cytoplasm the loss of a cytoplasmic MKP such as DUSP6/MKP-3 has 
the potential to cause greater alterations in whole-cell ERK activity, possibly explaining 
why a phenotype could be detected following the loss of DUSP6/MKP-3, but not DUSP5. 
Another potential cause for the lack of an observable change in p-ERK levels following 
KRasG12D expression and DUSP5 loss could be the induction of compensatory upregulation 
of other MKPs (Fig. 4.13A), whereas DUSP6/MKP-3 loss does not stimulate any such 
response (Fig. 4.16A). The compensatory upregulation of other MKPs did not occur 
following the TPA stimulation of DUSP5-/- MEFs (Fig. 3.2), these differing responses could 
reflect the difference between the prolonged pathway stimulation following KRasG12D 
expression and the acute stimulation in response to TPA. 
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Figure 4.15 Ras effector pathway activation and MKP induction following KRas
G12D 
knock-in 
and DUSP6/MKP-3 knockout. KRas
LSL-G12D/+ 
MEFs which were either DUSP6
+/+
, DUSP6
+/fl
 or 
DUSP6
fl/fl
 were infected with adenoviral-Cre (Ad5-Cre) or empty adenovirus (Ad5-Empty) for 48 
hours prior to cell lysis, and immunoblotting using the indicated antibodies. A representative 
Western blot is shown (A), alongside protein quantification (B). Mean values ± SEM are shown, n = 
3. *P < 0.05, **P < 0.01, ***P<0.001, ****P<0.0001 using two-way ANOVA and Bonferroni post hoc 
test, comparing DUSP6/MKP-3 genotypes. 
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Figure 4.16 DUSP6/MKP-3 loss does not alter ERK-dependent gene expression following 
KRas
G12D 
knock-in. Taqman RT-qPCR assays showing the fold change in mRNA levels of the 
indicated genes following Cre-treatment of KRas
LSL-G12D/+ 
 MEFs of the indicated DUSP6/MKP-3 
genotype, relative to wild-type cells infected with empty adenovirus. MEFs were infected with 
adenoviral-Cre (Ad5-Cre) or empty adenovirus (Ad5-Empty) for 48 hours prior to cell lysis and RNA 
isolation. A) ERK-targeting MKPs. B) ERK-target genes. Mean values ± SEM are shown, n = 3. **P 
< 0.01, ****P<0.0001 using two-way ANOVA and Bonferroni post hoc test, comparing DUSP5 
genotypes. 
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4.2.5 DUSP5 or DUSP6/MKP-3 ablation have no effect on KRasG12D 
mediated proliferation and colony formation in MEFs 
Despite the observation that loss of either DUSP5 or DUSP6/MKP-3 in KRasG12D expressing 
MEFs appear to have limited biochemical consequences, we wanted to explore the 
possibility that the loss of either MKP is able to induce any changes in the cellular 
phenotypes of these MEFs. We hypothesised changes might be observed upon MKP loss 
because the expression of mutant KRas in MEFs or human cancer cells does not stimulate 
increased activation of Ras effector pathways, yet is able to drive increased proliferation, 
gene expression and partial transformation (Fig. 4.9-11) (Tuveson et al., 2004; Vartanian 
et al., 2013). This situation is analogous to the loss of DUSP5 or DUSP6/MKP-3 in the 
presence of KRasG12D expression, as the loss of DUSP5 promotes no changes in ERK 
activity, but increases in ERK-dependent gene expression, whereas DUSP6/MKP-3 loss 
promotes a marginal increase in ERK activity, but no changes in ERK-dependent gene 
expression. 
Initially, we investigated the proliferation rate of KRasG12D expressing MEFs in the 
presence or absence of either DUSP5 or DUSP6/MKP-3. KRasLSL-G12D/+ MEFs, which were 
either DUSP5+/+, DUSP5+/- or DUSP5-/- were infected with adenoviral-Cre or empty 
adenovirus and allowed to proliferate until confluent. Adenoviral-Cre treated KRasLSL-
G12D/+; DUSP5-/- MEFs displayed the greatest increase in cell number throughout the assay, 
indicating that DUSP5 loss could promote an increased proliferation rate in KRasG12D 
expressing MEFs, (Fig. 4.17A). However, on more careful examination this appears to be a 
potential consequence of the parental, non-KRasG12D expressing cells, as the empty 
adenoviral treated KRasLSL-G12D/+; DUSP5-/- MEFs also display increased proliferation over 
their DUSP5+/+ and DUSP5+/- counterparts (Fig. 4.17A). In support of this theory, 
normalising the Cre-treated MEFs of each genotype to their empty-treated controls did 
not reveal a significant increase in proliferation of KRasG12D expressing MEFs following 
DUSP5 loss, although there was a slight trend towards increased proliferation following 
the loss of one or two alleles of DUSP5 (Fig. 4.17B-C). To further validate this conclusion 
DUSP5+/+, DUSP5+/- or DUSP5-/- with or without the KRasLSL-G12D allele were infected with 
empty or Cre-containing adenovirus and pulse-labelled with Edu after 48 hours, to 
determine the percentage of cells which have entered S-phase. Again, no increase in 
proliferation was observed in KRasG12D expressing MEFs following DUSP5 loss (Fig. 4.17D). 
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Furthermore, in this assay DUSP5-/- MEFs in the absence of KRasG12D did not display 
increased proliferation over their wild-type counterparts.   
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Figure 4.17 DUSP5 loss has no significant effect on proliferation in KRas
G12D 
knock-in MEFs. 
KRas
LSL-G12D/+ 
MEFs of each DUSP5 genotype (DUSP5
+/+
, DUSP5
+/-
 or DUSP5
-/-
) were seeded at 
low density, infected with adenoviral-Cre (Cre) or empty adenovirus (Empty) and left to proliferate 
until confluent. A) Cell counts of each cell line and treatment. B) Fold change in cell number for 
each genotype post-cre treatment (Cre/empty cell count for each measurement). C) Percentage 
increase in gradient for each genotype post-cre treatment (Linear regression performed for every 
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MEF line in each condition, to calculate the gradient. Then % increase in gradient of the cre-treated 
lines over the empty-treated lines calculated for each genotype). A-C) Mean values ± SEM are 
shown, n = 3. ns = not significant, using one-way ANOVA and Bonferroni post hoc test. D) KRas 
wild-type and KRas
 LSL-G12D/+
 MEFs of the indicated DUSP5 genotype were infected with adenoviral-
Cre (Cre) or empty adenovirus (Empty) and left to proliferate for 48 hours, prior to a 2 hour 
fluorescent EdU pulse label, immunostaining and high content microscopy. Plots show the mean (± 
SEM) percentage of EdU positive cells (% S-phase) derived from 5,000–10,000 individual cells per 
condition in technical triplicate (Left panel) and the relative increase in proliferation (Right panel). 
Representative figure of an experiment performed in duplicate. Panel D courtesy of Dr Christopher 
Caunt. 
 
 
Figure 4.18 DUSP6/MKP-3 loss has no effect on proliferation in KRas
G12D 
knock-in MEFs. 
KRas
LSL-G12D/+ 
MEFs of each DUSP6/MKP-3 genotype (DUSP6
+/+
, DUSP6
+/fl
 or DUSP6
fl/fl
) were 
seeded at low density, infected with adenoviral-Cre (Cre) or empty adenovirus (Empty) and left to 
proliferate until confluent. A) Cell counts of each cell line and treatment. B) Fold change in cell 
number for each genotype post-cre treatment (Cre/empty cell count for each measurement). C) 
Percentage increase in gradient for each genotype post-cre treatment (Linear regression 
performed for every MEF line in each condition, to calculate the gradient. Then % increase in 
gradient of the cre-treated lines over the empty-treated lines calculated for each genotype). Mean 
values ± SEM are shown, n = 3. ns = not significant, using one-way ANOVA and Bonferroni post 
hoc test.  
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Similarly to DUSP5, DUSP6/MKP-3 loss does not significantly alter the proliferation rate of 
KRasG12D expressing MEFs (Fig. 4.19A-C). KRasG12D expressing MEFs regardless of their 
DUSP6/MKP-3 genotype display almost an identical increase in their proliferation rate 
when compared to their empty adenovirus treated parental cell lines (Fig. 4.19B-C). 
However in contrast to DUSP5 (Fig. 4.17A), the DUSP6/MKP-3 parental cell lines display 
much more consistent proliferation rates (Fig. 4.18A). This could be due to the 
DUSP6/MKP-3 cell lines containing a conditional DUSP6/MKP-3 allele, so prior to Cre-
treatment DUSP6/MKP-3 is present in all cell lines, making them genetically identical for 
our genes of interest. Whereas, the DUSP5 cell lines do not contain conditional alleles so 
even the cells not exposed to Cre-treatment are genetically different with regard to 
DUSP5. Despite this, we would not expect to see altered proliferation rates of the DUSP5 
knockout cells relative to wild-type, as our previous experiments have detected a 
difference in their proliferation rates in short-term assays (Fig. 3.2B) (Rushworth et al., 
2014).  
To confirm this is the case in longer-term proliferation assays, we obtained mice 
expressing a conditional DUSP5 allele and isolated DUSP5fl/fl MEFs. DUSP5fl/fl MEFs 
expressed full length DUSP5 protein, which could be abrogated by Cre-treatment (Fig. 
4.19A). Proliferation assays were subsequently performed comparing the effects of Cre-
mediated DUSP5 ablation with DUSP6/MKP-3 ablation. Neither loss of DUSP5 nor 
DUSP6/MKP-3 promoted increased proliferation in MEFs (Fig. 4.19B-C). In contrast, there 
was a slight initial decrease in cell number in the Cre-treated, DUSP5 or DUSP6/MKP-3 
knockout cells (Fig. 4.19B-C). This is likely to be due to the genotoxic effect of Cre-
treatment (Loonstra et al., 2001), as the cell lines did not continue to proliferate more 
slowly over time as would be expected if the loss of either MKP was having a detrimental 
effect on proliferation. Instead following the initial drop in cell number the proliferation 
rate of the Cre-treated lines approximately mirrored the proliferation rate of their empty 
adenovirus treated counterparts (Fig. 4.19B). Furthermore, the DUSP5 knockout cells 
actually proliferated marginally faster towards the end of the assay and “made-up” the 
initial loss in cell number which was probably caused by Cre-mediated genotoxic stress 
(Fig. 4.19C). Together this indicates that potentially DUSP5 ablation might promote a very 
minor increase in proliferation, though this is within the experimental error of this 
approach.  
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Figure 4.19 Conditional knockout of DUSP5 or DUSP6/MKP-3 has no effect on proliferation 
in MEFs. A) DUSP5
+/+
 or DUSP5
fl/fl 
 MEFs (from two distinct embryos) infected with adenoviral-Cre 
(Ad5-Cre) or empty adenovirus (Ad5-Empty) for 48 hours prior to TPA stimulation, cell lysis, and 
immunoblotting using the indicated antibodies. B-C) DUSP5
fl/fl 
and DUSP6
fl/fl
 MEFs were seeded at 
low density, infected with adenoviral-Cre (Cre) or empty adenovirus (Empty) and left to proliferate 
until confluent. B) Cell counts of each cell line and treatment. C) Fold change in cell number for 
each genotype post-cre treatment (Cre/empty cell count for each measurement). Mean values ± 
SEM are shown, n = 3.  
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KRasG12D expression in MEFs is also sufficient to induce partial transformation, enabling 
colony formation via the loss of contact inhibition, but not the ability for colonies to form 
from single cells (Fig. 4.11) (Tuveson et al., 2004). Therefore, we investigated whether 
DUSP5 or DUSP6/MKP-3 loss was able to modulate these phenotypes in colony formation 
assays. Colony formation through the loss of contact inhibition occurred at a similar 
frequency in all KRasG12D expressing MEFs regardless of the DUSP5 or DUSP6/MKP-3 
genotype (Fig. 4.20A & 4.21A), indicating that the loss of DUSP5 or DUSP6/MKP-3 is not 
enabling an increased initiation of colony formation. Furthermore, KRasG12D expressing 
MEFs are refractory to clonogenic growth when seeded at a low cell density (Tuveson et 
al., 2004), and the additional ablation of neither DUSP5 nor DUSP6/MKP-3 was sufficient 
to enable this process (Fig. 4.20B & 4.21B). Taken together these results demonstrate 
that loss of DUSP5 or DUSP6/MKP-3 does not alter the proliferation rate or colony 
forming ability of KRasG12D expressing MEFs, despite being able to regulate ERK-
dependent transcription and p-ERK levels respectively. 
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Figure 4.20 DUSP5 loss has no effect on colony formation KRas
G12D 
knock-in MEFs. MEFs of 
the indicated genotypes were infected with adenoviral-Cre (Ad5-Cre) or empty adenovirus (Ad5-
Empty) prior to seeding at high (A) or low (B) density. MEFs were grown for 2-3 weeks until foci 
were visible, before fixation and visualisation with crystal violet. A) Representative image shown 
(Upper panel) and quantification of foci ≥2mm, mean ± SEM, n = 3 (Lower). B) No colonies formed 
from cells seeded at very low density. Representative images shown of experiment performed in 
triplicate.  
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Figure 4.21 DUSP6/MKP-3 loss has no effect on colony formation KRas
G12D 
knock-in MEFs. 
MEFs of the indicated genotypes were infected with adenoviral-Cre (Ad5-Cre) or empty adenovirus 
(Ad5-Empty) prior to seeding at high (A) or low (B) density. MEFs were grown for 2-3 weeks until 
foci were visible, before fixation and visualisation with crystal violet. A) Representative image 
shown (Upper panel) and quantification of foci ≥2mm, mean ± SEM, n = 3 (Lower). B) No colonies 
formed from cells seeded at very low density. Representative images shown of experiment 
performed in triplicate.  
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4.3 Discussion 
The MKPs DUSP5 and DUSP6/MKP-3 are negative feedback regulators of ERK-activity 
(Kucharska et al., 2009; Smith et al., 2006). Here we demonstrate that both DUSP5 and 
DUSP6/MKP-3 are upregulated by KRasG12D expression in a dose-dependent manner in 
MEFs (Fig. 4.8-9), and that this upregulation is dependent on ERK activity (Fig. 4.5-6). The 
upregulation of DUSP5 and DUSP6/MKP-3 is likely to play a role in constraining ERK 
activity following KRasG12D expression, as despite the constitutive activation of mutant 
KRas, p-ERK levels are not increased (Fig. 4.8). KRasG12D expression does however induce 
increased ERK-dependent gene expression (Fig. 4.6 & 4.9), proliferation (Fig. 4.10) and the 
partial transformation of MEFs (Fig. 4.11A). 
DUSP5 ablation does not induce any detectable change in ERK activity or localisation in 
response to KRasG12D expression in MEFs (Fig. 4.12 & 4.14), making it initially appear that 
DUSP5 is functionally redundant in the regulation of KRasG12D-induced ERK activity. 
However, DUSP5 loss is able to promote the transcriptional upregulation of multiple ERK-
target genes including SerpinB2 and Egr1 (Fig. 4.13B), indicating that DUSP5 loss is likely 
to be altering nuclear ERK activity to a degree, which is below the sensitivity of our 
detection methods. In contrast, DUSP6/MKP-3 loss promotes a marginal increase in total 
p-ERK levels (Fig. 4.15), but no increase in ERK-dependent gene expression (Fig. 4.16B) in 
response to KRasG12D expression. Furthermore, neither the loss of DUSP5 nor 
DUSP6/MKP-3 is able to modulate KRasG12D-driven proliferation or colony formation in 
MEFs (Fig. 4.17-4.21). 
The inability of endogenous expression of mutant Ras to induce elevated levels of p-ERK 
has been reported in multiple studies (Guerra et al., 2003; Haigis et al., 2008; Tuveson et 
al., 2004; Vartanian et al., 2013), and is replicated by our data (Fig. 4.8). Despite this lack 
of observable increases in the activation of Ras effector pathways, expression of mutant 
KRas is able to drive increased proliferation, gene expression and partial transformation, 
indicating signalling flux through the pathways must be increased (Fig. 4.9-11) (Tuveson 
et al., 2004; Vartanian et al., 2013). Negative feedback signalling to upstream RTKs has 
been proposed as one mechanism by which effector pathway activation is constrained 
following mutant Ras expression (Vartanian et al., 2013). In addition to this, MKP 
overexpression is observed in many mutant Ras or BRaf-driven human cancers (Kidger 
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and Keyse, 2016a, 2016b), although in some cases MKP levels are overexpressed in low 
grade tumours before being lost in high grade, malignant tumours (Furukawa et al., 2003, 
2005; Loda et al., 1996; Okudela et al., 2009; Saigusa et al., 2013). This expression pattern 
supports the hypothesis that MKP expression is induced following oncogenic activation of 
the Ras-ERK pathway, where is it able to constrain ERK activity and thereby possibly 
restrict tumour growth. The subsequent loss of MKP expression in certain high-grade 
tumours could then contribute to their growth and malignancy. In this study we have 
demonstrated robust upregulation of the MKPs DUSP2, DUSP4/MKP-2, DUSP5 and 
DUSP6/MKP-3 in a dose-dependent manner following KRasG12D expression in MEFs (Fig. 
4.9). This presents strong evidence that MKPs do comprise at least part of the negative 
feedback system responsible for constraining ERK activity in response to oncogenic 
activation of the Ras-ERK pathway. This is supported by evidence from multiple 
microarray studies which have detected increased expression of multiple MKPs in mutant 
Ras or BRaf-driven cancer cells (Montero-Conde et al., 2013; Pratilas et al., 2009; 
Vartanian et al., 2013; Yun et al., 2009). Furthermore, DUSP6/MKP-3 has been shown to 
be upregulated in KRasG13D-driven CRC cell lines, compared to isogenic cells in which the 
mutant allele has been deleted by homologous recombination (Haigis et al., 2008). 
Despite the strong upregulation of DUSP5 or DUSP6/MKP-3 following KRasG12D expression 
we found that ablation of either DUSP5 or DUSP6/MKP-3 alone had limited detectable 
biochemical effects on ERK signalling in the presence of KRasG12D expression (Fig. 4.12, 
4.14 & 4.16). We were unable to detect changes in ERK activity or localisation following 
DUSP5 loss in the presence of KRasG12D expression using either western blotting of whole 
cell lysates or high-content microscopy (Fig. 4.12 & 4.14). The latter result was 
unanticipated as we have previously demonstrated that DUSP5 loss promotes increased 
nuclear p-ERK levels, without significantly altering whole cell p-ERK, in response to TPA 
stimulation or the ectopic expression of mutant HRas (Fig. 3.3 & 3.10) (Rushworth et al., 
2014). Therefore, it would be assumed that DUSP5 loss would promote a similar 
phenotype following endogenous KRasG12D-driven ERK activation, yet this did not seem to 
be the case. However, in contrast to the lack of detectable changes in either ERK 
localisation or activity, we did detect transcriptional upregulation of multiple ERK-target 
genes including SerpinB2 and Egr1 following DUSP5 loss in these cells (Fig. 4.13B). This 
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replicates the findings in TPA stimulated DUSP5 knockout MEFs, where SerpinB2 and Egr1 
were amongst a cohort of 20 genes upregulated following DUSP5 loss (Fig. 3.4). 
One possible hypothesis to explain this apparent contradiction is that while acute 
stimulation promotes robust Ras-ERK pathway activation amplifying the effects of DUSP5 
loss on ERK activity and localisation, the constitutive (and lower level) expression of the 
endogenous oncogene promotes a more prolonged but conservative level of pathway 
stimulation. In this scenario DUSP5 loss would have more modest effects on ERK activity 
following endogenous KRasG12D expression, making any changes much harder to detect in 
our assays. Although some degree of altered ERK activity must be present to be driving 
the changes in ERK-dependent gene expression observed (Fig. 4.13B). Furthermore, the 
constitutive pathway activation following KRasG12D expression would give more time to 
enable the compensatory upregulation of other MKPs (Fig. 4.13A), which could also be 
minimising detectable changes in ERK activity. Alternatively, it is possible that when 
present DUSP5 could be preferentially binding and inactivating nuclear p-ERK bound to 
specific transcription factor complexes, therefore it could be selectively regulating the 
transcription of certain genes. In such a scenario DUSP5 loss could induce increased 
expression of particular genes without having a significant effect on the total level of 
nuclear p-ERK. The localisation of MAPKs to the promoters of genes undergoing 
transcriptional activation has been described in multiple studies in both yeast and 
mammalian cells, as discussed in chapter 3 (Nadal et al., 2011). Therefore, it is possible 
that MKPs, such as DUSP5, are also able to localise to such sites to regulate the 
transcription of precise sets of genes. 
Conversely, DUSP6/MKP-3 loss in KRasG12D expressing MEFs promotes a marginal increase 
in whole cell ERK activity, yet is unable to induce any changes in ERK-dependent gene 
expression (Fig. 4.15 & 4.16B). This inability to alter ERK-dependent gene expression 
implies that DUSP6/MKP-3 could be solely elevating cytoplasmic p-ERK levels, which is in 
line with its function as a cytoplasmic MKP (Groom et al., 1996; Mourey et al., 1996). 
Further studies utilising the high content microscopy based approach are required to 
validate whether DUSP6/MKP-3 loss is able to solely induce changes in cytoplasmic p-ERK 
levels, and to quantify the effects of DUSP6/MKP-3 loss. This result is perhaps surprising 
given the propensity of cytoplasmic p-ERK to be shuttled to the nucleus following its 
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phosphorylation in the cytoplasm (Lidke et al., 2010). However, we were unable to detect 
changes in whole cell or cytoplasmic p-ERK levels following the stimulation of DUSP6+/+ 
and DUSP6-/- MEFs with either TPA or serum (Jim Caunt, unpublished data). The 
unexpected divergence of these two models could be due to the use of conditional 
DUSP6/MKP-3 alleles in combination with KRasG12D expression. Consequently, when 
utilising the conditional DUSP6/MKP-3 allele the assay was performed in close proximity 
to the DUSP6/MKP-3 loss, potentially meaning that signalling pathway remodelling 
following DUSP6/MKP-3 loss was not complete and other negative regulators of ERK were 
yet to compensate for DUSP6/MKP-3 loss. This theory is supported by observations of 
lower compensatory upregulation of other MKPs in KRasG12D expressing DUSP6-/- MEFs 
relative to DUSP5-/- counterparts (Fig. 4.13A & 4.16A). Alternatively, it is possible that 
DUSP6/MKP-3 loss is unable to induce compensatory upregulation of other MKPs in the 
presence of KRasG12D expression, which could be the reason why whole cell p-ERK levels 
are increased, yet this would not explain the divergence between the different 
experimental systems. Increased cytoplasmic p-ERK would be expected to alter the 
regulation of a wide-range of ERK targets within the cytoplasm which control many 
cellular processes (Yoon and Seger, 2006). Future work could utilise phospho-proteomic 
approaches to determine which ERK-target proteins show significantly increased 
phosphorylation upon DUSP6/MKP-3 loss. 
Expression of one allele of KRasG12D in MEFs has been shown to induce increased 
proliferation and partial transformation enabling colony formation via the loss of contact 
inhibition, but clonogenic growth (Tuveson et al., 2004). Here we have been able to 
replicate these findings, as well as demonstrate that expression of two KRasG12D alleles 
promotes further increases in proliferation relative to one allele, but no changes in the 
colony forming ability (Fig. 4.10-11). This phenotype is in agreement with the current 
literature as the wild-type Ras allele, when carrying a heterozygous mutation, has been 
proposed to play a tumour suppressive role in cancer development (Singh et al., 2005). 
Indeed, wild-type Ras alleles are frequently lost in Ras-driven cancers (Singh et al., 2005), 
and the ablation of the wild-type Ras allele in combination with mutant Ras promotes 
increased proliferation in vitro (Bentley et al., 2013) and tumourigenesis in certain in vivo 
cancer models (Kong et al., 2016). Consequently, it is not surprising that the replacement 
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of a wild-type KRas allele with an additional KRasG12D allele promotes increased 
proliferation in MEFs. 
This study also demonstrated that neither DUSP5 nor DUSP6/MKP-3 loss had any effect 
on KRasG12D-driven proliferation and colony formation (Fig. 4.17-4.21). DUSP5 loss in the 
presence of KRasG12D did appear to demonstrate a slight trend towards increased 
proliferation rate (Fig. 4.17). However, this was complicated by differing initial 
proliferation rates of DUSP5 MEF lines prior to Cre-mediated KRasG12D knock-in, therefore 
these experiments could be repeated utilising MEFs isolated containing the conditional 
DUSP5 allele which we recently obtained (Fig. 4.19). DUSP6/MKP-3 ablation promoted no 
change in the proliferation rate of KRasG12D expressing MEFs (Fig. 4.18). This is in contrast 
to previous reports which have demonstrated increased proliferation following siRNA 
mediated knockdown of DUSP6/MKP-3 in CRC (Haigis et al., 2008) or NSCLC cell lines 
(Zhang et al., 2010). The differences between these studies and ours could be due to the 
different cell context, or the increased mutational burden in human cancer cell lines, 
compared to our primary MEFs in which solely KRasG12D expression is induced. This could 
results in a more essential role for DUSP6/MKP-3 in restraining ERK-mediated 
proliferation in these cancer cell lines. 
Neither DUSP5 nor DUSP6/MKP-3 loss induced any changes in KRasG12D-driven colony 
formation or enabled clonogenic growth (Fig. 4.20-21). This is not particularly surprising 
given that an additional KRasG12D allele was not sufficient to permit clonogenic growth in 
MEFs (Fig. 4.11). Furthermore, previous studies have shown that either loss of tumour 
suppressors such as p53, or gain of the oncoprotein E1a are required to enable clonogenic 
or anchorage-independent growth in KRasG12D expressing MEFs (Tuveson et al., 2004). 
This indicates that deregulation of additional signalling pathways is likely to be required 
to permit clonogenic growth of KRasG12D expressing MEFs, making it unlikely that solely 
further increases in Ras effector pathways such as the ERK pathway will promote this 
phenotype. Following our work investigating DUSP5 and DUSP6/MKP-3 loss in mouse 
models of KRasG12D-driven pancreatic cancer (Chapter 5), it would be interesting to extend 
our cellular phenotypic assays in these KRasG12D-driven MEFs to investigate potential roles 
of DUSP5 and DUSP6/MKP-3 loss on their capacity to migrate and invade. 
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In conclusion, this part of my project has strongly suggested that the MKPs DUSP5 and 
DUSP6/MKP-3 are components of the negative feedback response to oncogenic KRasG12D 
activation, which is responsible for maintaining homeostatic levels of p-ERK despite 
constitutive pathway activation. However, loss of DUSP5 or DUSP6/MKP-3 does not 
modulate KRasG12D-driven proliferation or colony formation, despite inducing the 
transcriptional upregulation of particular ERK target genes or marginal increases in whole 
cell p-ERK levels respectively. 
176 
 
Chapter 5 DUSP5 and DUSP6/MKP-3 suppress 
the development of KRasG12D-driven pancreatic 
cancer 
5.1 Introduction 
In chapter 3 we demonstrated that DUSP5 acts as a tumour suppressor in mutant HRas-
driven murine skin carcinogenesis by showing that mice lacking DUSP5 were sensitised to 
papilloma development following treatment with DMBA/TPA (Fig. 3.1). Mechanistically, 
this was driven by DUSP5 loss permitting elevated nuclear pERK levels in response to Ras-
ERK pathway activation. This induced the upregulation of a subset of ERK-dependent 
genes including SerpinB2 (Fig. 3.3-4), and the increased expression of SerpinB2 was 
essential for the increased sensitivity of DUSP5-/- mice to skin carcinogenesis (Fig. 3.14). 
However, in human skin cancer HRas is not thought to be a predominant driving 
oncogene (Hodis et al., 2012), therefore we wanted to investigate the role of DUSP5 in a 
more physiologically relevant murine cancer model. 
Consequently, we chose to investigate and compare the effects of either DUSP5 or 
DUSP6/MKP-3 loss in a mouse model of KRasG12D-driven pancreatic cancer. This model 
was chosen for a number of reasons. Firstly, both DUSP5 and DUSP6/MKP-3 mRNA’s are 
highly expressed in the pancreas (NCBI RefSeq data: 
http://www.ncbi.nlm.nih.gov/gene/1847 & http://www.ncbi.nlm.nih.gov/gene/1848). 
Secondly, activating KRas mutations are the key driver events in human pancreatic ductal 
adenocarcinoma (PDAC) having been identified in around 90% of tumours (Kleeff et al., 
2016), making this a highly clinically relevant disease model. Finally, in chapter 4 we 
demonstrated that both DUSP5 and DUSP6/MKP-3 are two of the most strongly 
upregulated MKPs in response to the expression of endogenous KRasG12D, indicating that 
these phosphatases form part of the negative feedback controls which restrain ERK 
activity following constitutive pathway activation (Fig. 4.8-9). This suggests that DUSP5 
and DUSP6/MKP-3 might be overexpressed in KRasG12D-driven tumours, and that the loss 
of either MKP could have functional consequences for either tumour initiation or 
progression. At least in MEFs, neither DUSP5 nor DUSP6/MKP-3 ablation had dramatic 
biochemical or cellular consequences when coupled with KRasG12D expression (Fig. 4.12-
21). DUSP5 loss did not significantly alter ERK activity or localisation, yet did result in 
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increased ERK-dependent gene expression (Fig. 4.12-14). In contrast, DUSP6/MKP-3 loss 
caused a slight increase in levels of p-ERK but without causing any changes in expression 
of the ERK-dependent genes we assayed (Fig. 4.15-16). Furthermore, loss of either DUSP5 
or DUSP6/MKP-3 did not lead to changes in either KRasG12D-driven cell proliferation or cell 
transformation as assayed by focus formation (Fig. 4.17-21). However, it is possible that 
the loss of these phosphatases could alter one of the many other cellular phenotypes not 
investigated here. Alternatively, DUSP5 or DUSP6/MKP-3 loss in the presence of KRasG12D 
might give rise to more overt phenotypic effects in vivo or in different cellular contexts. 
Multiple studies have reported increased DUSP6/MKP-3 expression in a range of mutant 
Ras or BRaf-driven tumours, including pancreatic cancer, NSCLC, thyroid cancer and ALL 
(Degl’Innocenti et al., 2013; Furukawa et al., 2003, 2005; Lee et al., 2012; Okudela et al., 
2009; Shojaee et al., 2015), indicating that DUSP6/MKP-3 expression could be important 
in these cancers. In pancreatic cancer and NSCLC DUSP6/MKP-3 overexpression has been 
identified in low-grade neoplastic lesions, whereas DUSP6/MKP-3 expression is frequently 
lost in high-grade, invasive carcinomas (Furukawa et al., 2003, 2005; Okudela et al., 2009). 
This suggests that in these cancers, although DUSP6/MKP-3 is initially upregulated as a 
negative feedback regulator in response to ERK pathway activation, DUSP6/MKP-3 is 
acting as a tumour suppressor as its loss is selected for during tumour progression. In 
contrast, in thyroid cancer and ALL, DUSP6/MKP-3 overexpression is maintained and 
correlates with a worse patient prognosis, suggesting a pro-oncogenic role 
(Degl’Innocenti et al., 2013; Lee et al., 2012; Shojaee et al., 2015). In ALL an oncogenic 
role for DUSP6/MKP-3 has been demonstrated experimentally, with DUSP6-/- mice being 
resistant to NRasG12D-induced ALL (Shojaee et al., 2015). Furthermore BCI, a small 
molecule inhibitor of DUSP6/MKP-3, selectively induced cell death in human pre-B ALL 
cells expressing hyperactive ERK, demonstrating that DUSP6/MKP-3 could be a putative 
therapeutic target in this cancer (Shojaee et al., 2015). Overall, this evidence suggests 
that MKPs, such as DUSP6/MKP-3, are important components of the negative feedback 
control of ERK activity, which can act as oncogenes or tumour suppressors in a context-
dependent manner. However, there is limited experimental evidence definitively proving 
such roles and investigating the mechanisms by which these occur. 
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Finally as mentioned above, changes in DUSP6/MKP-3 expression have been identified 
during pancreatic cancer progression. DUSP6/MKP-3 protein is overexpressed in the 
PanINs, the pre-neoplastic precursor lesions of PDAC, prior to subsequent 
downregulation in poorly differentiated, invasive PDAC (Furukawa et al., 2003, 2005). 
Decreased DUSP6/MKP-3 expression in invasive PDAC was shown to occur due to 
aberrant hypermethylation of the DUSP6/MKP-3 promoter (Xu et al., 2005), or by LOH of 
the DUSP6/MKP-3 containing region of chromosome 12q in up to 30% of tumours 
(Kimura et al., 1996; Yatsuoka et al., 2000). Unlike other tumour suppressors including 
p53 and CDKN2A which are lost during and contribute to PanIN progression, DUSP6/MKP-
3 loss is seemingly only observed in invasive PDAC (Furukawa et al., 2005). This 
encourages the hypothesis that DUSP6/MKP-3 expression is constraining ERK activity in 
PanINs, which is preventing progression of PanINs to invasive PDAC (Furukawa, 2009; 
Furukawa et al., 2006). However, there is currently no experimental evidence 
demonstrating whether DUSP6/MKP-3 loss can accelerate PDAC development. 
In contrast to DUSP6/MKP-3, there are currently no publications linking DUSP5 with a role 
in pancreatic cancer. However, analysis of transcriptome datasets generated through 
SAGE (serial analysis of gene expression) on RNA from the 24 pancreatic cancers and 
multiple PDAC cell lines by Jones et al., (2008) reveals that DUSP5 expression is 
downregulated in many pancreatic cancer tissues and cell lines relative to the normal 
pancreatic ductal epithelium. This could suggest that the decrease in DUSP5 expression is 
selected for during PDAC development. Therefore, this study aimed to utilise KRasG12D-
driven mouse models of PDAC (Hingorani et al., 2003) to investigate whether loss of 
DUSP5 or DUSP6/MKP-3 is able to modulate pancreatic tumour initiation and progression. 
This will determine whether DUSP6/MKP-3 acts as tumour suppressor in this mutant 
KRas-driven PDAC, as is suggested by current evidence. Furthermore, comparison of any 
potential phenotypes could determine whether the differential subcellular localisation of 
MKPs is able to specifically control the spatial activity of ERK, resulting in distinct 
functional consequences for tumour progression. 
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5.2 Results 
5.2.1 Loss of DUSP5 or DUSP6/MKP-3 does not affect normal 
pancreatic development 
Before investigating any potential roles for DUSP5 and DUSP6/MKP-3 loss in mutant KRas-
driven pancreatic carcinogenesis we wanted to determine whether loss of either 
phosphatase might have consequences for normal pancreatic development. Both DUSP5 
(Rushworth et al., 2014) and DUSP6/MKP-3 (Maillet et al., 2008) knockout mice have 
previously been shown to be viable, fertile, and otherwise overtly normal. However, to 
investigate any potential consequences of either DUSP5 or DUSP6/MKP-3 loss on 
pancreatic development in more detail we examined pancreata from wild-type, DUSP5-/- 
and DUSP6-/- mice isolated at 2, 4 and 6 months of age. All MKP knockout mice and their 
respective wild-type controls were littermates generated from het x het crosses. Upon 
histological examination, pancreata of all genotypes displayed normal proportions and 
disposition of the expected tissue types and structures, including islets of Langerhans 
(endocrine tissue), acinar cells (exocrine tissue) and pancreatic ducts, when compared to 
wild type organs (Fig. 5.1). Pancreata from both DUSP5 and DUSP6/MKP-3 knockouts 
were also examined for the presence of abnormal ducts and neoplastic precursor lesions 
(PanINs) and none were detected (Fig. 5.1). Finally, the loss of either phosphatase did not 
cause any significant change in pancreas to body-weight ratios (Data not shown). 
Therefore, we can conclude that loss of either DUSP5 or DUSP6/MKP-3 alone does not 
affect normal pancreatic development, at least in terms of tissue morphology, nor does it 
seem to promote any neoplastic changes in pancreatic tissues. 
  
180 
 
 
Figure 5.1 Loss of DUSP5 or DUSP6/MKP-3 has no effect on pancreatic development. 
Representative H&E images of wild-type (DUSP5
+/+
 & DUSP6
+/+
), DUSP5
-/-
 and DUSP6
-/-
 
pancreata. Asterisks indicate Islets of Langerhans and arrows indicate pancreatic ducts. Scale, 
200μm. 
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5.2.2 PDX1-Cre driven model of KRasG12D-induced pancreatic 
cancer 
To investigate whether DUSP5 ablation had any effect on the development of KRasG12D-
driven PDAC KRasLSL-G12D/+; PDX1-Cre mice (Hingorani et al., 2003) were crossed with 
DUSP5fl/fl mice. This enabled the generation of mice in which endogenous KRasG12D can be 
knocked-in through the Cre-mediated excision of the Lox-Stop-Lox (LSL) cassette and 
DUSP5 can be knocked out. The PDX1-Cre allele was initially utilised to drive pancreatic 
Cre expression as this is the most frequently used Cre-driver allele in GEMMs of 
pancreatic cancer (Guerra and Barbacid, 2013; Pérez–Mancera et al., 2012). During 
mouse development, PDX1 (pancreatic and duodenal homeobox 1, also known as insulin 
promoter factor 1) a homeodomain containing transcription factor, is expressed in the 
pre-pancreatic endoderm from E8.5 and is expressed in the progenitors of all major 
pancreatic cell lineages (acini, islet and ductal cells). In postnatal mice PDX1 expression is 
retained in acini and islet cells, with the highest expression in β-cells of the islets 
(Magnuson and Osipovich, 2013). 
However, PDX1 expression is not completely restricted to the developing pancreas, with 
expression also observed in foregut endothelium progenitor cells during early 
development (Offield et al., 1996), and in cells of the intestine, stomach and skin 
(Hingorani et al., 2003). When combined with the KRasLSL-G12D allele the leakiness of PDX1-
Cre expression and the resulting recombination in other tissues induces intestinal 
hyperplasia, occasionally resulting in the formation of intussusceptions (intestinal 
invaginations resulting in blockage) (Fig. 5.2A), the development of hyperplastic polyps of 
the duodenum (mucocutaneous papillomas) or intestinal metaplasia of the gastric 
epithelium (Hingorani et al., 2003). Unfortunately, in our particular study study KRasLSL-
G12D/+; PDX1-Cre expressing mice, regardless of their DUSP5 genotype, displayed intestinal 
intussusceptions with very high penetrance (approx. 60%), typically occurring between 
30-150 days of age (Fig. 5.2B-C). This is considerably higher than the ~5% background 
intussusception rate normally observed when using this model (Owen Sansom, Beatson 
Institute Glasgow personal communication). We hypothesise that the increased 
intussusception we see is due to the presence of a persistent pinworm infection within 
our animal facility. Although pinworm infections are generally considered to be mildly or 
even non-pathogenic in animals these gastronintestinal parasitic nematodes can 
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stimulate host humoral immune responses resulting in inflammation. It is therefore likely 
that this exacerbates KRasG12D-induced intestinal hyperplasia, resulting in an increased 
frequency of intussusceptions in our experimental animals.  
The high penetrance of intussusception and resulting lethality prevented us from 
conducting any meaningful survival analysis to investigate the effect of DUSP5 loss on 
KRasG12D-driven pancreatic tumourigenesis, and also made the generation of age-matched 
cohorts difficult. To circumvent this and obtain preliminary data from this model, we 
generated a small age-matched cohort at 42 days, as this was prior to the peak of 
intussusception occurrence and therefore minimised the loss of mice (Fig. 5.2C). KRasG12D-
expressing pancreata displayed a marginal increase in pancreatic size and weight relative 
to control animals (Fig. 5.3A) and the sporadic induction of ADM and low grade PanIN 
formation (Fig. 5.3B), as described previously (Hingorani et al., 2003). Loss of one or two 
alleles of DUSP5 in the presence of KRasG12D generated a slight increase in pancreatic 
weight relative to KRasG12D alone, though this was not statistically significant, perhaps 
reflecting the small cohort size and magnitude of the phenotype. However, DUSP5 loss in 
the presence of KRasG12D promoted an increased burden of ADM, and the associated 
formation of reactive stroma around these lesions (Fig. 5.3B-C). Few clearly defined 
PanINs were observed in all cohorts and no significant alteration in the progression of 
pancreatic cancer precursor lesions was observed (Fig. 5.3D). This is not unexpected given 
the age of this cohort and the relatively slow progression of pancreatic tumourigenesis 
normally observed in this model (Hingorani et al., 2003). 
This limited evidence indicates that DUSP5 loss might promote the initiation of KRasG12D-
driven PDAC. However, due to the high penetrance of intussusceptions we could not 
investigate potential effects of DUSP5 loss on PanIN progression, PDAC development and 
metastasis and how these variables affect survival using the PDX1-Cre driven model. 
Therefore, we needed to utilise an alternative model to further investigate the effects of 
DUSP5 loss on KRasG12D-driven pancreatic tumourigenesis. 
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Figure 5.2 KRas
LSL-G12D/+
; PDX1-cre mice displayed high mortality due to intussusceptions. 
A) A representative image of an intussusception removed from a KRas
LSL-G12D/+
; PDX1-cre 
expressing mouse. B) The proportion of mice of the indicated cohorts, which were removed from 
the study due to intussusceptions. C) Kaplan-Meier curves demonstrating the intussusception-free 
survival of the indicated cohorts. Cohorts consisted of the following genotypes: KRas
+/+
; PDX1-cre; 
DUSP5
+/+
 (PDX1 Cre, n = 10), KRas
LSL-G12D/+
; PDX1-cre; DUSP5
+/+ 
(DUSP5
+/+
, n = 41), KRas
LSL-
G12D/+
; PDX1-cre; DUSP5
+/fl 
(DUSP5
+/-
, n = 44) and KRas
LSL-G12D/+
; PDX1-cre; DUSP5
fl/fl 
(DUSP5
-/-
, n 
= 44). 
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Figure 5.3 DUSP5 loss promotes increased KRas
G12D
-driven pancreatic cancer initiation. A) 
Pancreata from 42 day age-matched mice of the indicated cohorts were harvested and their 
pancreas to body weight ratios calculated. Cohorts consisted of the following genotypes: KRas
+/+
; 
PDX1-cre; DUSP5
+/+
 (PDX1-Cre, n = 6), KRas
LSL-G12D/+
; PDX1-Cre; DUSP5
+/+ 
(DUSP5
+/+
, n = 9), 
KRas
LSL-G12D/+
; PDX1-Cre; DUSP5
+/fl 
(DUSP5
+/-
, n = 4) and KRas
LSL-G12D/+
; PDX1-Cre; DUSP5
fl/fl 
(DUSP5
-/-
, n = 4). B) Representative H&E images of the indicated cohorts. Scale, 200μm. C-D) 
Quantification of the number of pancreatic cancer precursor lesions per mm
2
 in the indicated 
cohorts (C), and these expressed as a percentage of the total number of lesions (D). Quantification 
performed on one representative section per mouse, following serial sectioning of the pancreas. 
Mean values ± SEM are shown, n = 8, 4, 4.  
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5.2.3 Ptf1α-Cre driven model of KRasG12D-induced pancreatic 
cancer 
5.2.3.1 Loss of DUSP5 or DUSP6/MKP-3 promotes increased KRasG12D-
induced pancreatic cancer initiation 
Due to the high penetrance of intestinal intussusceptions in our initial PDX1-Cre driven 
KRasG12D-induced pancreatic cancer model (Fig. 5.2B-C), we switched the promoter used 
to drive Cre-recombinase expression to that of the pancreas-specific transcription factor 
1α (Ptf1α) gene. In contrast to PDX1, lineage tracing experiments have shown Ptf1α to be 
a transcription factor expressed solely in the developing pancreas from E9.5, and in 
postnatal acinar tissue (Hingorani et al., 2003; Kawaguchi et al., 2002). Consequently, Ras-
driven pathology and tumours are much less common in other tissues following mutant 
KRasG12D expression driven by the Ptf1α-Cre allele, and intussusceptions do not occur 
(Hingorani et al., 2003; Westphalen and Olive, 2012). A further difference between the 
two Cre-drivers alleles is that while the PDX1-Cre allele results in stochastic Cre 
expression and recombination across the pancreas, the Ptf1α-Cre allele results in 
completely uniform expression and recombination throughout all developing pancreatic 
tissues (Hingorani et al., 2003). 
When utilising the Ptf1α-Cre driven model of KRasG12D-induced pancreatic cancer we 
decided to perform a direct comparison between the potential effects of DUSP5 and 
DUSP6/MKP-3 loss on pancreatic tumourigenesis. Initially, we validated the Ptf1α-Cre 
mediated pancreas-specific recombination of the KRasLSL-G12D, DUSP5fl/fl and DUSP6fl/fl 
conditional alleles to be used in this study. DNA was isolated from 100 day old mice 
containing each allele in combination with Ptf1α-Cre, and genotyping PCRs were 
performed to identify whether recombination had occurred. Ptf1α-Cre expression was 
sufficient induce excision of the LSL-cassette in the KRasLSL-G12D allele and of the exons 
targeted by the DUSP5fl/fl and DUSP6fl/fl alleles (Fig. 5.4A-C). In MEFs, we have previously 
shown that, Cre-mediated excision of the LSL-cassette in the KRasLSL-G12D allele promotes 
the expression of mutant KRasG12D, and an associated increase in GTP-bound Ras (Fig. 
4.1B). Furthermore, Cre-mediated excision of the targeted exons of the DUSP6fl/fl 
conditional allele prevented DUSP6/MKP-3 mRNA or protein expression (Fig. 4.15-16). To 
validate the DUSP5fl/fl allele MEFs were generated, which when subjected to Cre-
treatment demonstrated excision of the targeted exons (Fig. 5.5A). However, even 
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without being subject to Cre-treatment DUSP5fl/fl MEFs demonstrate very low DUSP5 
mRNA and protein expression relative to DUSP5+/+ MEFs (Fig. 5.5B-C), indicating that this 
conditional allele is hypomorphic. Despite this, the DUSP5fl/fl allele was utilised for the 
following in vivo models as it was the only conditional allele available at the time and 
unlike a knockout allele non-pancreatic tissue would retain an albeit reduced level of 
DUSP5 expression. 
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Figure 5.4 Validation of Ptf1a-cre mediated recombination of conditional alleles in the 
pancreas. A) PCR of genomic DNA from KRas
LSL-G12D/+
; Ptf1α-cre mice demonstrating the excision 
of the Lox-STOP-Lox (LSL)-cassette from the KRas
LSL-G12D 
allele in the presence of Ptf1α-cre in 
pancreatic lysates. Control lysates from untreated KRas
LSL-G12D/LSL-G12D 
(LSL) and KRas
+/+ 
(WT) 
MEFs validate the size of 327bp LSL-cassette and 450bp WT bands. Cre-mediated recombination 
of the KRas
LSL-G12D 
allele results in the formation of a 484bp fragment (LSL+Cre). B) PCR of 
pancreatic, genomic DNA from Ptf1α-cre; DUSP5
fl/fl 
mice demonstrating the excision of exon 2 of 
the DUSP5 allele in the presence of Ptf1α-cre. Control lysates from DUSP5
fl/fl 
(Lox), DUSP5
-/-
 (KO) 
and DUSP5
+/+
 (WT) mice validate the 701bp, 418bp and 667bp bands respectively. C) PCR of 
pancreatic, genomic DNA from Ptf1α-cre; DUSP6
fl/fl 
mice demonstrating the excision of 
DUSP6/MKP-3 exons 2 and 3 in the presence of Ptf1α-cre. Control lysates from DUSP6
fl/fl 
(Lox) 
and DUSP6
-/-
 (KO) mice validate the 284bp and 400bp bands respectively. 
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Figure 5.5 The conditional DUSP5 allele is hypomorphic. A) PCR of genomic DNA from 
DUSP5
fl/fl
, DUSP5
fl/+ 
and
 
DUSP5
+/+ 
MEFs demonstrating the excision of exon 2 of the DUSP5 
floxed allele in the presence of adenoviral-Cre (Cre) but not empty adenovirus (NT). Control lysates 
from DUSP5
-/-
 (KO), DUSP5
fl/fl 
(Lox) and DUSP5
+/+
 (WT) mice validate the 418bp, 701bp and 
667bp bands respectively. B) Taqman RT-qPCR assay showing the fold change in DUSP5 mRNA 
levels of DUSP5
+/+
, DUSP5
fl/fl
 (two cell lines) and DUSP5
-/-
 MEFs following TPA stimulation 
(100ng/ml) relative to the unstimulated DUSP5
+/+ 
MEFs. Representative figure of an experiment 
performed in duplicate. Mean ± SEM of technical replicates, n =3, shown. C) MEFs of the indicated 
genotype were stimulated with TPA for 0, 1, 2 & 4 hours prior to cell lysis, and immunoblotting 
using the indicated antibodies. Representative image of experiment performed in duplicate is 
shown. 
  
189 
 
To investigate whether loss of either DUSP5 or DUSP6/MKP-3 is able to modulate 
KRasG12D-driven pancreatic cancer initiation and progression, age-matched cohorts of 
KRasLSL-G12D/+; Ptf1α-Cre (KC) mice which were wild-type, heterozygous or homozygous for 
either DUSP5fl/fl or DUSP6fl/fl alleles were generated, alongside Ptf1α-Cre controls. 
Therefore, the experimental cohorts consisted of: KRas+/+; Ptf1α-cre; DUSP+/+ (Ptf1α-cre), 
KRasLSL-G12D/+; Ptf1α-cre; DUSP+/+ (KC), KRasLSL-G12D/+; Ptf1α-cre; DUSP5+/fl (KCD5+/-), KRasLSL-
G12D/+; Ptf1α-cre; DUSP5fl/fl (KCD5-/-), KRasLSL-G12D/+; Ptf1α-cre; DUSP6+/fl (KCD6+/-) and 
KRasLSL-G12D/+; Ptf1α-cre; DUSP6fl/fl (KCD6-/-) mice. Initially, a 56 day (2 month) old cohort 
was generated. At this age KCD5-/- and KCD6-/- mice demonstrated a significant increase in 
their pancreas to body weight ratio, compared to KC mice (Fig. 5.6). Furthermore, 
histological analysis revealed an increased burden of ADM, PanINs and associated 
reactive stroma following the loss of either DUSP5 or DUSP6/MKP-3 in the presence of 
KRasG12D when compared to the effects of KRasG12D expression alone (Fig. 5.7). This 
increased PanIN burden in KCD5-/- and KCD6-/- mice can be clearly observed following 
Alcian Blue staining (Fig. 5.8A), which stains the mucin secreted by PanINs (Hingorani et 
al., 2003). Furthermore, the characteristic dense reactive stroma, which forms around 
developing PanINs can be clearly visualised using immunohistochemical (IHC) detection of 
αSmooth Muscle Actin (αSMA) (Fig. 5.8B).  
Quantification of this phenotype reveals there is a significant decrease in acinar tissue 
present in KCD5-/- and KCD6-/- pancreata, relative to KC, with heterozygous KCD5+/- and 
KCD6+/- pancreata displaying an intermediate phenotype (Fig. 5.9A). This acinar atrophy 
should represent a reliable surrogate measure for the amount of tumour initiation 
occurring, as pancreatic cancer precursor lesions are thought to arise primarily through 
acinar dedifferentiation and ADM in KRasG12D-driven mouse models of pancreatic cancer 
when KRasG12D-expression is induced in all pancreatic cell lineages (Guerra and Barbacid, 
2013; Kopp et al., 2012; Morris et al., 2010). This indicates that following DUSP5 or 
DUSP6/MKP-3 loss a greater proportion of the pancreas is undergoing KRasG12D-driven 
metaplasia and tumourigenesis. KCD5-/- and KCD6-/- pancreata also display a significant 
increase in the total number of PanINs per mm2 of pancreatic tissue when compared to 
KC pancreata (Fig. 5.9B), although at this young age the vast majority of lesions are either 
ADM or PanIN1a in all cohorts (Fig. 5.9C). PanINs were scored utilising well established 
histological criteria (Hingorani et al., 2003; Hruban et al., 2001, 2006a), whereas small 
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ductal lesions surrounded by reactive stroma which have not fulfilled the required criteria 
to be confirmed as PanINs were scored as ADM. ADM have been defined as, proliferative 
lesions appearing as tubular structures, consisting of swollen acinar cells, with a ductal, 
PanIN-like appearance, often surrounded by a reactive stroma (Hruban et al., 2006b). 
Therefore, ADM are structures which replace the acinar parenchyma, but contain traits of 
both acinar and ductal differentiation. 
Quantification of the percentage of total lesions which are each histological grade reveals 
a marginal increase in the number of PanIN1a and PanIN1b lesions following the loss of 
DUSP6/MKP-3 in the presence of KRasG12D (Fig. 5.9D). This data indicates that 
DUSP6/MKP-3 loss could be promoting accelerated progression of KRasG12D-expressing 
PanINs, however this could be more conclusively demonstrated in an older age-matched 
cohort where the pancreata display an increased number of higher grade lesions. A higher 
percentage of KCD6-/- mice display with higher grade PanIN2s and PanIN3s than KC mice 
(Fig. 5.9E), which could support the case for accelerated PanIN progression. However, this 
observation could alternatively be due to KCD6-/- pancreata having an increased number 
of lesions initiated (Fig. 5.9B-C), therefore increasing the chance that at least one will 
progress to these higher grades. Taken together these data indicate that loss of either 
DUSP5 or DUSP6/MKP-3 is able to promote increased, or accelerated, pancreatic cancer 
initiation in the presence of KRasG12D. 
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Figure 5.6 Loss of DUSP5 or DUSP6/MKP-3 promotes increased pancreatic weight following 
the initiation of KRas
G12D
-driven pancreatic tumourigenesis. Pancreata from 56 day age-
matched mice of the indicated cohorts were harvested and their pancreas to body weight ratios 
calculated. Cohorts consisted of the following genotypes: KRas
+/+
; Ptf1α-cre; DUSP
+/+
 (Ptf1α-cre), 
KRas
LSL-G12D/+
; Ptf1α-cre; DUSP
+/+ 
(KC), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
+/fl 
(KCD5
+/-
), KRas
LSL-
G12D/+
; Ptf1α-cre; DUSP5
fl/fl 
(KCD5
-/-
), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
+/fl 
(KCD6
+/-
) and KRas
LSL-
G12D/+
; Ptf1α-cre; DUSP6
fl/fl 
(KCD6
-/-
). Mean shown, n = 5, 7, 7, 7, 7, 7. Ns = not significant, *P < 
0.05, **P < 0.01, using one-way ANOVA and Bonferroni post hoc test. 
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Figure 5.7 Loss of DUSP5 or DUSP6/MKP-3 promotes increased KRas
G12D
-driven ADM and 
PanIN initiation. Representative images of H&E stained pancreata from 56 day age-matched mice 
of the indicated cohorts, with a 200μm (A) or 1mm (B) scale. Cohorts consisted of the following 
genotypes: KRas
+/+
; Ptf1α-cre; DUSP
+/+
 (Ptf1α-cre, n = 5), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP
+/+ 
(KC, n 
= 7), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
+/fl 
(KCD5
+/-
, n = 7), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
fl/fl 
(KCD5
-/-
, n = 7), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
+/fl 
(KCD6
+/-
, n = 7) and KRas
LSL-G12D/+
; Ptf1α-cre; 
DUSP6
fl/fl 
(KCD6
-/-
, n = 7). 
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Figure 5.8 DUSP5 or DUSP6/MKP-3 loss promotes increased KRas
G12D
-driven PanIN 
initiation and the formation of reactive stroma. Representative images of Alcian Blue/Nuclear 
Fast Red (A) and αSmooth Muscle Actin (αSMA) IHC (B) stained pancreata from 56 day age-
matched mice of the indicated cohorts. Cohorts consisted of the following genotypes: KRas
+/+
; 
Ptf1α-cre; DUSP
+/+
 (Ptf1α-cre, n = 5), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP
+/+ 
(KC, n = 7), KRas
LSL-G12D/+
; 
Ptf1α-cre; DUSP5
+/fl 
(KCD5
+/-
, n = 7), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
fl/fl 
(KCD5
-/-
, n = 7), KRas
LSL-
G12D/+
; Ptf1α-cre; DUSP6
+/fl 
(KCD6
+/-
, n = 7) and KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
fl/fl 
(KCD6
-/-
, n = 7). 
Scale, 500μm and 2mm respectively. 
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Figure 5.9 Loss of DUSP5 or DUSP6/MKP-3 promotes increased KRas
G12D
-driven ADM and 
PanIN initiation. Quantification of the pancreatic precursor lesion development in 56 day age-
matched pancreata of the indicated cohorts. Cohorts consisted of the following genotypes: 
KRas
LSL-G12D/+
; Ptf1α-cre; DUSP
+/+ 
(KC), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
+/fl 
(KCD5
+/-
), KRas
LSL-
G12D/+
; Ptf1α-cre; DUSP5
fl/fl 
(KCD5
-/-
), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
+/fl 
(KCD6
+/-
) and KRas
LSL-
G12D/+
; Ptf1α-cre; DUSP6
fl/fl 
(KCD6
-/-
). A) Percentage acinar tissue remaining in the pancreata of 
each cohort following KRas
G12D
-driven ADM and PanIN initiation. B) Total number of PanINs of all 
histological grades per mm
2
 in the indicated cohorts. C-D) Quantification of the number of 
pancreatic cancer precursor lesions, divided into each histological grade, per mm
2
 in the indicated 
cohorts (C), and these expressed as a percentage of the total number of lesions (D). E) 
Percentage of mice of the indicated cohorts that displayed at least one of each PanIN grade. 
Quantification performed on one representative section per mouse, following serial sectioning of 
the pancreas. Mean values ± SEM are shown, n = 7, 7, 7, 6, 7. Ns = not significant, *P < 0.05, **P 
< 0.01, ***P < 0.001 using one-way ANOVA and Bonferroni post hoc test.  
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To further investigate the effect of DUSP5 or DUSP6/MKP-3 loss on the progression of 
KRasG12D-driven PanINs through higher histological grades, towards PDAC formation, a 
second age-matched cohort was generated consisting of 100 day old mice. At 100 days 
there were no significant differences in the mean pancreas to body weight ratios of the 
different KRasG12D-expressing cohorts (Fig. 5.10). Interestingly, although the mean 
pancreas to body weight ratios of the KRasG12D-expressing DUSP5 or DUSP6/MKP-3 wild-
type and heterozygous cohorts increased in relation to their respective 56 day cohorts, 
the KCD5-/- and KCD6-/- cohorts displayed decreased ratios after 100 days (Fig. 5.6 & 10). 
Histological analysis demonstrates that both KCD5-/- and KCD6-/- pancreata display 
increased acinar atrophy and a higher burden of ADM, PanINs and reactive stroma 
relative to their KC counterparts (Fig. 5.11-12). Quantification of the percentage acinar 
tissue remaining confirms this observation, as multiple KCD5-/- or KCD6-/- pancreata 
display an almost complete replacement of acinar tissue with PanINs and associated 
reactive stroma (Fig. 5.13A). However, some KC pancreata are also nearing complete loss 
of acinar tissue, indicating that loss of DUSP5 or DUSP6/MKP-3 is potentially accelerating 
the rate of KRasG12D-driven ADM and PanIN initiation, to generate the increased burden of 
pre-neoplastic lesions observed in the 56 day pancreata.  
Interestingly, at this age only KCD6-/- pancreata display a significant increase in the total 
number of PanINs relative to KC (Fig. 5.13B), whereas in the 56 day cohort both DUSP5 
and DUSP6/MKP-3 loss induced a significant increase in PanIN number (Fig. 5.9B). 
Breakdown of the grades of lesions observed revealed a clear increase in PanIN1a and 
PanIN1b in KCD6-/- pancreata relative to KC pancreata (Fig. 5.13C). Whereas, KCD5-/- 
pancreata only display an increase in ADM lesions relative to KC pancreata, with similar 
numbers of each PanIN grade observed (Fig. 5.13C). These phenotypes are readily visible 
in the H&E stained pancreata (Fig. 5.11A). KRasG12D expression alone induces scattered 
ADM and PanIN formation amongst acinar tissue, whereas KCD6-/- pancreata typically 
display an increased number of tightly packed PanINs covering a larger area of the 
pancreas. In contrast, although they display a similar loss of acinar tissue to KCD6-/-, KCD5-
/- pancreata display more diffuse PanIN development with a larger proportion of the 
tissue covered by ADM lesions and reactive stroma (Fig. 5.11A). 
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DUSP6/MKP-3 loss also appears to accelerate the progression of pancreatic cancer 
precursor lesions towards higher, more dysplastic grades. A higher proportion of PanIN1b 
and PanIN2 are present in KCD6-/-, relative to KC, pancreata (Fig. 5.13D) and more KCD6-/- 
mice present with PanIN2 or PanIN3 than KC mice (Fig. 5.13E). In contrast, DUSP5 loss 
does not seem to accelerate KRasG12D-driven PanIN progression (Fig. 5.13D), and the 
observation that more KCD5-/- pancreata present with PanIN2 than KC pancreata could be 
explained by the increased or accelerated initiation of tumourigenesis occurring following 
DUSP5 loss (Fig. 5.9A-C). 
Overall, the histological analysis of age-matched pancreata demonstrates that loss of 
either DUSP5 or DUSP6/MKP-3 accelerates or increases the KRasG12D-induced initiation of 
ADM and PanINs (Fig. 5.9A-C & 5.13A-C). However, only the loss of DUSP6/MKP-3 is also 
able to promote accelerated progression of pancreatic cancer precursor lesions to higher 
more dysplastic grades (Fig. 5.13D-E). 
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Figure 5.10 Loss of DUSP5 or DUSP6/MKP-3 causes no significant alteration in pancreatic 
weight in 100d mice, following the initiation of KRas
G12D
-driven pancreatic tumourigenesis. 
Pancreata from 100 day age-matched mice of the indicated cohorts were harvested and their 
pancreas to body weight ratios calculated. Cohorts consisted of the following genotypes: KRas
+/+
; 
Ptf1α-cre; DUSP
+/+
 (Ptf1α-cre), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP
+/+ 
(KC), KRas
LSL-G12D/+
; Ptf1α-cre; 
DUSP5
+/fl 
(KCD5
+/-
), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
fl/fl 
(KCD5
-/-
), KRas
LSL-G12D/+
; Ptf1α-cre; 
DUSP6
+/fl 
(KCD6
+/-
) and KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
fl/fl 
(KCD6
-/-
). Mean shown, n = 4, 9, 7, 7, 
4, 6. Ns = not significant, using one-way ANOVA and Bonferroni post hoc test. 
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Figure 5.11 Loss of DUSP5 or DUSP6/MKP-3 promotes increased KRas
G12D
-driven ADM and 
PanIN initiation, in 100d mice. Representative images of H&E stained pancreata from 100 day 
age-matched mice of the indicated cohorts, with a 200μm (A) or 1mm (B) scale. Cohorts consisted 
of the following genotypes: KRas
+/+
; Ptf1α-cre; DUSP
+/+
 (Ptf1α-cre, n = 4), KRas
LSL-G12D/+
; Ptf1α-cre; 
DUSP
+/+ 
(KC, n = 9), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
+/fl 
(KCD5
+/-
, n = 7), KRas
LSL-G12D/+
; Ptf1α-cre; 
DUSP5
fl/fl 
(KCD5
-/-
, n = 7), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
+/fl 
(KCD6
+/-
, n = 4) and KRas
LSL-G12D/+
; 
Ptf1α-cre; DUSP6
fl/fl 
(KCD6
-/-
, n = 6). 
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Figure 5.12 DUSP5 or DUSP6/MKP-3 loss promotes increased KRas
G12D
-driven PanIN 
initiation and the formation of reactive stroma, in 100d mice. Representative images of αSMA 
IHC stained pancreata from 100 day age-matched mice of the indicated cohorts. Cohorts consisted 
of the following genotypes: KRas
+/+
; Ptf1α-cre; DUSP
+/+
 (Ptf1α-cre, n = 4), KRas
LSL-G12D/+
; Ptf1α-cre; 
DUSP
+/+ 
(KC, n = 9), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
+/fl 
(KCD5
+/-
, n = 7), KRas
LSL-G12D/+
; Ptf1α-cre; 
DUSP5
fl/fl 
(KCD5
-/-
, n = 7), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
+/fl 
(KCD6
+/-
, n = 4) and KRas
LSL-G12D/+
; 
Ptf1α-cre; DUSP6
fl/fl 
(KCD6
-/-
, n = 6).Scale, 2mm. 
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Figure 5.13 Loss of DUSP5 or DUSP6/MKP-3 promotes increased KRas
G12D
-driven ADM and 
PanIN initiation, in 100d mice. Quantification of the pancreatic precursor lesion development in 
100 day age-matched pancreata of the indicated cohorts. Cohorts consisted of the following 
genotypes: KRas
LSL-G12D/+
; Ptf1α-cre; DUSP
+/+ 
(KC), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
+/fl 
(KCD5
+/-
), 
KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
fl/fl 
(KCD5
-/-
), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
+/fl 
(KCD6
+/-
) and 
KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
fl/fl 
(KCD6
-/-
). A) Percentage acinar tissue remaining in the 
pancreata of each cohort following KRas
G12D
-driven ADM and PanIN initiation. B) Total number of 
PanINs of all histological grades per mm
2
 in the indicated cohorts. C-D) Quantification of the 
number of pancreatic cancer precursor lesions, divided into each histological grade, per mm
2
 in the 
indicated cohorts (C), and these expressed as a percentage of the total number of lesions (D). E) 
Percentage of mice of the indicated cohorts that displayed at least one of each PanIN grade. 
Quantification performed on one representative section per mouse, following serial sectioning of 
the pancreas. Mean values ± SEM are shown, n = 9, 7, 7, 4, 6. Ns = not significant, *P < 0.05 using 
one-way ANOVA and Bonferroni post hoc test.  
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5.2.3.2  SerpinB2 does not mediate the increased initiation of ADM and 
PanINs following DUSP5 loss in KRasG12D-expressing pancreata 
We have previously shown that DUSP5 ablation promotes increased DMBA/TPA-induced 
skin carcinogenesis in a SerpinB2 dependent manner (Fig. 3.14) (Rushworth et al., 2014). 
Furthermore, endogenous KRasG12D expression (Fig. 4.12-13), as well as TPA or exogenous 
expression of HRasQ61L (Fig. 3.11), is able to induce the increased expression of SerpinB2 in 
DUSP5 knockout MEFs, relative to wild-type. Therefore, we investigated whether 
SerpinB2 overexpression, induced by KRasG12D and DUSP5 loss, might also be involved in 
the increased initiation of ADM and PanINs observed in KCD5-/- pancreata, relative to KC 
counterparts. 
Before performing such experiments we initially examined whether SerpinB2 is expressed 
in the pancreas. SerpinB2 expression has not been reported in the murine pancreas in any 
previously published studies; however microarray and RNA-sequencing datasets show 
that low levels of SerpinB2 mRNA are present in the human pancreas 
(http://www.genecards.org/cgi-bin/carddisp.pl?gene=SerpinB2). Furthermore, multiple 
studies have detected SerpinB2 mRNA and protein in human pancreatic cancer tissue 
(Takeuchi et al., 1993; Wojtukiewicz et al., 2001; Xue et al., 2008), however in these 
studies high SerpinB2 expression correlated with improved survival. This might indicate 
that elevated SerpinB2 expression, induced following DUSP5 loss, is unlikely to promote 
the development of KRasG12D-driven pancreatic cancer. However, it is possible that 
SerpinB2 plays opposing roles in the initiation of tumours and their later maintenance, 
malignant growth and metastasis, in much the same manner in which TGFβ is known to 
switch between functioning either as a tumour suppressor or an oncogene during cancer 
development (Massagué, 2008, 2012).  
To confirm that SerpinB2 is expressed in the murine pancreas we isolated mRNA from 
wild-type, DUSP5-/- and SerpinB2-/- mice and compared the expression level of SerpinB2 
mRNA in the pancreas with that of the skin, which we already knew to express significant 
levels of SerpinB2 (Fig. 3.13B). This revealed that SerpinB2 mRNA is expressed in the 
murine pancreas, although at much lower levels than in the skin (Fig. 5.14A). 
Furthermore, pancreatic SerpinB2 expression is increased following DUSP5 loss (Fig. 
5.14A). Together this evidence suggests it might be formally possible for increased 
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SerpinB2 expression to promote the increased initiation of KRasG12D-driven pancreatic 
tumourigenesis observed following DUSP5 loss. To investigate this hypothesis, SerpinB2 
knockout mice were crossed with the KRasLSL-G12D/+; Ptf1α-Cre (KC) and KRasLSL-G12D/+; 
Ptf1α-Cre; DUSP5fl/fl (KCD5-/-) strains, resulting in the generation of additional KRasLSL-
G12D/+; Ptf1α-Cre; SerpinB2-/- (KCSB2-/-) and KRasLSL-G12D/+; Ptf1α-Cre; DUSP5fl/fl; SerpinB2-/- 
(KCDKO) strains. Age-matched cohorts of 56 day old mice of all genotypes were 
generated and the development of KRasG12D-driven pancreatic cancer assessed in each 
cohort. Both the KCSB2-/- and KCDKO cohorts displayed no significant change in their 
pancreas to body weight ratio relative to their respective SerpinB2 containing cohorts (KC 
and KCD5-/-) (Fig. 5.14B). Histologically KRasG12D-expressing, DUSP5 wild-type pancreata 
appeared very similar in the presence or absence of SerpinB2 (Fig. 5.15). Furthermore, a 
quantitative analysis of representative stained tissue sections revealed that deletion of 
SerpinB2 caused no significant changes in the amount of pancreatic tissue undergoing 
ADM (Fig. 5.16A), the numbers of pancreatic pre-neoplastic lesions (Fig. 5.16B-C) or the 
rate at which these progress (Fig. 5.16D-E). 
SerpinB2 ablation also had no effect on the initiation of ADM and PanINs following 
KRasG12D-driven tumourigenesis in the absence of DUSP5 (Fig. 5.15-16). KCDKO pancreata 
displayed the expected high levels of acinar atrophy, a high burden of ADM and numbers 
of PanINs that were directly comparable to those seen in our KCD5-/- pancreata, 
representing a significant increase over the KC and KCSB2-/- pancreata (Fig. 5.15 & 5.16A-
C). Furthermore, the rate of progression of ADM and PanIN lesions was not significantly 
different between the KCD5-/- and KCDKO pancreata. Overall, these experiments 
demonstrate that in contrast to our observations in the HRasQ61L-driven murine model of 
skin carcinogenesis (Fig. 3.14; Rushworth et al., 2014), SerpinB2 ablation has no effect on 
the initiation of KRasG12D-driven pancreatic tumourigenesis in either the presence or 
absence of DUSP5 and is therefore not responsible for mediating the effects of DUSP5 
loss in KRasG12D-driven pancreatic tumourigenesis. 
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Figure 5.14 SerpinB2 is expressed in the pancreas, yet its ablation has no effect on 
pancreatic weight following the initiation of KRas
G12D
-driven pancreatic tumourigenesis. A) 
Taqman qRT-PCR assay showing mRNA levels of SerpinB2, relative to β-actin, following RNA 
isolation from the skin and pancreas from mice of the indicated genotypes. Representative figure 
from age-matched littermate mice. Mean values ± SEM are shown, n=3. B) Pancreata from 56 day 
age-matched mice of the indicated cohorts were harvested and their pancreas to body weight 
ratios calculated. Cohorts consisted of the following genotypes: KRas
+/+
; Ptf1α-cre; DUSP
+/+
; 
SerpinB2
+/+ 
 (Ptf1α-cre), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP
+/+
; SerpinB2
+/+
 (KC), KRas
LSL-G12D/+
; Ptf1α-
cre; DUSP5
+/fl
; SerpinB2
+/+
 
 
(KCD5
+/-
), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
fl/fl
; SerpinB2
+/+ 
(KCD5
-/-
), 
KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
+/+
;
 
SerpinB2
-/- 
(KCSB2
-/-
) and KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
fl/fl
; 
SerpinB2
-/- 
(KCDKO). Mean shown, n = 5, 7, 7, 7, 7, 7. Ns = not significant, *P < 0.05, using one-
way ANOVA and Bonferroni post hoc test. 
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Figure 5.15 Co-ablation of SerpinB2 does not rescue the increased KRas
G12D
-driven PanIN 
initiation observed following DUSP5 loss. Representative images of H&E stained pancreata 
from 56 day age-matched mice of the indicated cohorts, with a 200μm (A) or 1mm (B) scale. 
Cohorts consisted of the following genotypes: KRas
+/+
; Ptf1α-cre; DUSP
+/+
; SerpinB2
+/+ 
 (Ptf1α-cre, 
n = 5), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP
+/+
; SerpinB2
+/+
 (KC, n = 7), KRas
LSL-G12D/+
; Ptf1α-cre; 
DUSP5
+/fl
; SerpinB2
+/+
 
 
(KCD5
+/-
, n = 7), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
fl/fl
; SerpinB2
+/+ 
(KCD5
-/-
, n 
= 7), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
+/+
;
 
SerpinB2
-/- 
(KCSB2
-/-
, n = 7) and KRas
LSL-G12D/+
; Ptf1α-cre; 
DUSP5
fl/fl
; SerpinB2
-/- 
(KCDKO, n = 7).  
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Figure 5.16 Co-ablation of SerpinB2 does not rescue the increased KRas
G12D
-driven PanIN 
initiation observed following DUSP5 loss. Quantification of the pancreatic precursor lesion 
development in 56 day age-matched pancreata of the indicated cohorts Cohorts consisted of the 
following genotypes: KRas
+/+
; Ptf1α-cre; DUSP
+/+
; SerpinB2
+/+ 
 (Ptf1α-cre), KRas
LSL-G12D/+
; Ptf1α-
cre; DUSP
+/+
; SerpinB2
+/+
 (KC), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
+/fl
; SerpinB2
+/+
 
 
(KCD5
+/-
), 
KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
fl/fl
; SerpinB2
+/+ 
(KCD5
-/-
), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
+/+
;
 
SerpinB2
-/- 
(KCSB2
-/-
) and KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
fl/fl
; SerpinB2
-/- 
(KCDKO). A) Percentage 
acinar tissue remaining in the pancreata of each cohort following KRas
G12D
-driven ADM and PanIN 
initiation. B) Total number of PanINs of all histological grades per mm
2
 in the indicated cohorts. C-
D) Quantification of the number of pancreatic cancer precursor lesions, divided into each 
histological grade, per mm
2
 in the indicated cohorts (C), and these expressed as a percentage of 
the total number of lesions (D). E) Percentage of mice of the indicated cohorts that displayed at 
least one of each PanIN grade. Quantification performed on one representative section per mouse, 
following serial sectioning of the pancreas. Mean values ± SEM are shown, n = 7. Ns = not 
significant, *P < 0.05, **P < 0.01, using one-way ANOVA and Bonferroni post hoc test.  
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5.2.3.3 Loss of DUSP5 or DUSP6/MKP-3 promotes increased pancreatic 
metaplasia, but does not influence either PanIN proliferation or 
senescence. 
So far we have demonstrated that the loss of either DUSP5 or DUSP6/MKP-3 increases 
KRasG12D-induced initiation of ADM and PanINs (Fig. 5.9A-C & 5.13A-C), and the loss of 
DUSP6/MKP-3 is able to promote accelerated PanIN progression (Fig. 5.13D-E). Therefore, 
to investigate the mechanism by which the loss of either DUSP5 or DUSP6/MKP-3 is able 
to promote these phenotypes, aged-matched tissue from each cohort was subjected to 
immunohistochemical analysis for established markers of KRas effector pathway 
activation and of cellular phenotypes, such as proliferation or senescence. 
Initially, we attempted to determine whether DUSP5 and/or DUSP6/MKP-3 expression is 
elevated in KRasG12D-driven PanINs. We hypothesised that this would be occurring as we 
have previously demonstrated that endogenous KRasG12D expression in MEFs induces a 
robust induction of DUSP5 and DUSP6/MKP-3 expression (Fig. 4.3-4 & 4.8-9). 
Furthermore, DUSP6/MKP-3 has been shown to be overexpressed in PanINs, before its 
subsequent downregulation in invasive carcinoma, in human pancreatic cancer tissue 
(Furukawa et al., 2003, 2005). However, unfortunately the most specific DUSP5 and 
DUSP6/MKP-3 antibodies available ( as determined by immunoblotting) produced strong, 
non-specific background staining in their respective DUSP knockout pancreatic tissues 
when utilised for IHC (Fig. 5.17A-B). Specific staining in DUSP wild-type tissue could not be 
observed for either antibody even following extensive titration and use of very low 
antibody concentrations for IHC. Consequently, in an attempt to identify potential 
changes in pancreatic DUSP5 and/or DUSP6/MKP-3 expression following KRasG12D 
expression and PanIN formation, RNA was isolated from 100 day KRas wild-type (Ptf1α-
Cre) and KRasG12D-expressing (KC) pancreata and analysed via qRT-PCR.  Pancreatic 
KRasG12D expression induced a significant increase in DUSP5 expression and a marginal 
increase in DUSP6/MKP-3 expression when compared to wild-type (Fig. 5.17C). The high 
variability of this experiment, and lack of a significant increase in DUSP6/MKP-3 
expression, is likely to be due to the imprecise nature of this experiment. RNA was 
isolated from multiple 100 day KRasG12D-expressing pancreata, however there is 
significant variability in the amount of pancreatic tumourigenesis initiated in these tissues 
(Fig. 5.17D). Therefore, as pancreatic samples taken for RNA extraction were isolated 
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from the whole pancreas, without histological examination and microdissection of the 
regions extracted, some samples could still contain a high proportion of normal acinar 
tissue and relatively few KRasG12D-expressing PanINs, potentially decreasing the levels of 
DUSP expression we could detect. 
DUSP5 and DUSP6/MKP-3 are ERK-specific MKPs (Groom et al., 1996; Mandl et al., 2005; 
Mourey et al., 1996), therefore it could be hypothesised that their loss could specifically 
modulate Ras-ERK pathway activity following expression of mutant KRasG12D, whereas 
other Ras effector pathways such as the PI3K-AKT pathway would be unaffected. To test 
this theory tissue sections from 56 day age-matched pancreata were 
immunohistochemically stained for both p-ERK (Fig. 5.18) and p-AKT (Fig. 5.19). IHC 
staining was quantified utilising the H-score system (Detre et al., 1995). In this system the 
percentage of cells displaying weak, medium or strong staining are quantified, then a H-
score out of 300 generated using the following formula: H-score = (% of cells stained at 
“weak” intensity x 1) + (% of cells stained at “medium” intensity x 2) + (% of cells stained 
at “strong” intensity x 3). DUSP5 loss induced a significant increase in nuclear p-ERK levels 
in KRasG12D-driven PanINs, yet had no effect on the relative levels of cytoplasmic p-ERK or 
nuclear/cytoplasmic p-AKT (Fig. 5.18A & 5.19A). This most likely reflects the role of DUSP5 
as a nuclear, ERK-specific MKP (Mandl et al., 2005). In contrast DUSP6/MKP-3 loss caused 
no significant changes in nuclear or cytoplasmic p-ERK or p-AKT levels in KRasG12D-driven 
PanINs (Fig. 5.18B & 5.19B). There was a slight trend towards increased cytoplasmic pERK 
levels following DUSP6/MKP-3 loss, which could be indicative of the loss of a cytoplasmic, 
ERK-specific MKP (Groom et al., 1996; Mourey et al., 1996). Overall, in KRasG12D-
expressing PanINs DUSP5 loss induces a clear increase in nuclear p-ERK levels and 
DUSP6/MKP-3 loss a marginal increase in cytoplasmic p-ERK, whereas loss of neither MKP 
affected levels of p-AKT. The more limited effect of DUSP6/MKP-3 loss on p-ERK levels 
could reflect an increased capacity for other cytoplasmic negative feedback regulators of 
ERK to compensate for DUSP6/MKP-3 loss, or the fact the cytoplasmic staining is more 
diffuse making the quantification of relatively small changes in level more difficult to 
observe. 
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Figure 5.17 Pancreatic KRas
G12D
 expression increases MKP expression. A) Representative 
images of IHC using a DUSP5 rabbit monoclonal or isotype control antibody on 56 day age-
matched pancreata of the indicated cohorts. B) Representative images of IHC using a 
DUSP6/MKP-3 rabbit monoclonal or isotype control antibody on 56 day age-matched pancreata of 
the indicated cohorts. C) Taqman qRT-PCR assays showing mRNA levels of DUSP5 or 
DUSP6/MKP-3, relative to β-actin, following RNA isolation from 100 day pancreata of the indicated 
cohorts. Mean shown, n = 6 ns = not significant, *P < 0.05, using an unpaired t-test. D) 
Representative images of H&E stained KRas
LSL-G12D/+
; Ptf1α-cre 100 day pancreata. Scale, 1mm. 
Cohorts consisted of the following genotypes: KRas
+/+
; Ptf1α-cre; DUSP
+/+
 (Ptf1α-cre), KRas
LSL-
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G12D/+
; Ptf1α-cre; DUSP
+/+ 
(KC), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
fl/fl 
(KCD5
-/-
) and KRas
LSL-G12D/+
; 
Ptf1α-cre; DUSP6
fl/fl 
(KCD6
-/-
). 
 
 
Figure 5.18 DUSP5 loss promotes elevated nuclear p-ERK levels in KRas
G12D
-driven PanINs. 
Representative images and H-score quantification of p-ERK IHC on 56 day age-matched 
pancreata of the indicated cohorts. All cohorts contained the KRas
LSL-G12D/+
 and Ptf1α-cre and only 
varied with respect to their DUSP5 (A) or DUSP6/MKP-3 (B) genotype: KRas
LSL-G12D/+
; Ptf1α-cre; 
DUSP
+/+ 
(KC), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
+/fl 
(KCD5
+/-
), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
fl/fl 
(KCD5
-/-
), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
+/fl 
(KCD6
+/-
) and KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
fl/fl 
(KCD6
-/-
). Mean values ± SEM are shown, n = 7. Ns = not significant, *P < 0.05, using one-way 
ANOVA and Bonferroni post hoc test. Scale, 200μm.  
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Figure 5.19 DUSP5 or DUSP6/MKP-3 loss has no effect on p-AKT level in KRas
G12D
-driven 
PanINs. Representative images and H-score quantification of p-AKT IHC on 56 day age-matched 
pancreata of the indicated cohorts. All cohorts contained the KRas
LSL-G12D/+
 and Ptf1α-cre alleles 
and only varied with respect to their DUSP5 (A) or DUSP6/MKP-3 (B) genotype: KRas
LSL-G12D/+
; 
Ptf1α-cre; DUSP
+/+ 
(KC), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
+/fl 
(KCD5
+/-
), KRas
LSL-G12D/+
; Ptf1α-cre; 
DUSP5
fl/fl 
(KCD5
-/-
), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
+/fl 
(KCD6
+/-
) and KRas
LSL-G12D/+
; Ptf1α-cre; 
DUSP6
fl/fl 
(KCD6
-/-
). Mean values ± SEM are shown, n = 7. Ns = not significant, *P < 0.05, using 
one-way ANOVA and Bonferroni post hoc test. Scale, 200μm. 
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Loss of either DUSP5 or DUSP6/MKP-3 promoted increased KRasG12D-driven metaplasia of 
pancreatic acinar tissue and the formation of ductal precursor lesions of pancreatic 
cancer (Fig. 5.9A-C & 5.13A-C). To explore this initiation phenotype in more detail we 
performed IHC for Sox9 on age-matched 56 day pancreata of all cohorts (Fig. 5.20). Sox9 
is a transcription factor, which in the pancreas specifies a ductal fate (Belo et al., 2013). 
Sox9 expression has been identified in acinar cells following KRasG12D expression prior to 
metaplasia to a duct-like state, as well as in developing ADM or PanIN lesions (Kopp et al., 
2012). Furthermore, Sox9 expression is essential for KRasG12D-mediated ADM and PanIN 
induction, with Sox9 knockout pancreata being completely refractory to KRasG12D-
mediated transformation. Additionally, the ectopic overexpression of Sox9 in the 
pancreas potentiates KRasG12D-mediated ADM and PanIN formation (Kopp et al., 2012). 
Sox9 expression was significantly elevated in the acinar tissue of both KCD5-/- and KCD6-/- 
pancreata, when compared to KC pancreata (Fig. 5.20). This is in addition to these KCD5-/- 
and KCD6-/- pancreata displaying an increased burden of ADM and PanIN lesions relative 
to KC pancreata at this age (Fig. 5.9), these lesions also stain positive for Sox9 due to their 
ductal differentiation, and thus were not included in this analysis. These data 
demonstrate that effects of DUSP5 or DUSP6/MKP-3 loss are occurring in the KRasG12D-
expressing acinar tissue prior to ADM or PanIN lesions forming. This indicates that the loss 
of DUSP5 or DUSP6/MKP-3 is able to potentiate KRasG12D-driven acinar metaplasia, which 
is then responsible for enabling the formation of the elevated burden of ADM and PanIN 
lesions observed. However, we have not yet determined whether DUSP5 or DUSP6/MKP-
3 loss are directly responsible for this increased acinar Sox9 expression and that this is the 
mechanism by which their loss is actually able to promote the increased initiation of 
KRasG12D-driven pancreatic cancer. Alternatively, Sox9 expression could be induced as a 
consequence of ADM, which could in theory be promoted through a quite distinct 
mechanism upon the loss of DUSP5 or DUSP6/MKP-3.  
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Figure 5.20 Loss of DUSP5 or DUSP6/MKP-3 promotes increased Sox9 expression in the 
pancreatic acinar tissue following KRas
G12D
-driven pancreatic tumourigenesis. 
Representative images and H-score quantification of Sox9 IHC on 56 day age-matched pancreata 
of the indicated cohorts. All cohorts contained the KRas
LSL-G12D/+
 and Ptf1α-cre alleles and only 
varied with respect to their DUSP5 (A) or DUSP6/MKP-3 (B) genotype: KRas
LSL-G12D/+
; Ptf1α-cre; 
DUSP
+/+ 
(KC), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
+/fl 
(KCD5
+/-
), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
fl/fl 
(KCD5
-/-
), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
+/fl 
(KCD6
+/-
) and KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
fl/fl 
(KCD6
-/-
).  Mean values ± SEM are shown, n = 7. Ns = not significant, *P < 0.05, using one-way 
ANOVA and Bonferroni post hoc test. Scale, 200μm.  
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DUSP6/MKP-3 loss promoted accelerated KRasG12D-driven PanIN progression, whereas 
loss of DUSP5 did not (Fig. 5.13D-E). To investigate potential cellular mechanisms 
mediating these phenotypes we performed immunohistochemical analysis for markers of 
proliferation (Ki67), senescence (p53 & p21) and apoptosis (cleaved Caspase 3) on age-
matched pancreatic tissue. Ki67 is a marker of cell proliferation which is expressed during 
G1, S, G2 and mitotic phases of the cell cycle and is only absent during either quiescence 
or in the G0 phase (Lopez et al., 1991; Scholzen and Gerdes, 2000). Quantification of the 
average number of Ki67-positive cells per PanIN revealed that loss of neither DUSP5 nor 
DUSP6/MKP-3 alters the proliferation rate of KRasG12D-driven PanINs in either 56 day (Fig. 
5.21A) or 100 day (Fig. 5.21B) pancreata. 
It has been established previously established that PanINs express many components of 
the senescence response including, p53, p21, p16INK4A and p19, and that either the loss 
or mutation of the genes encoding these tumour suppressors can result in accelerated 
PanIN progression and the development of invasive, metastatic PDAC (Aguirre et al., 
2003; Bardeesy et al., 2006; Guerra et al., 2007; Hingorani et al., 2005; Morton et al., 
2010). This suggests that the senescence system is activated in response to oncogenic 
activation of KRas, and this OIS response is constraining PanIN progression and tumour 
development. Consistent with these previous studies, we identified p53 (Fig. 5.22) and 
p21 (Fig. 5.23) expression in multiple cells across the majority of PanINs. However, H-
score quantification of the extent and intensity of p53 and p21 staining did not reveal any 
significant changes in the expression of these senescence markers following either DUSP5 
or DUSP6/MKP-3 loss in KRasG12D-expressing pancreata (Fig. 5.22-23).  
Finally, the induction of apoptosis in PanINs was assessed utilising cleaved-Caspase3 
expression as a marker. Cleaved-Caspase3 expression was very low across all genotypes, 
being very rarely observed in PanIN cells (Fig. 5.24). Only cells which had been released 
into the lumen of PanINs stained positively for cleaved-Caspase3, these cells are probably 
undergoing anoikis (von Figura et al., 2014), and therefore act as an internal control. This 
low level of apoptosis in KRasG12D-driven PanINs is consistent with previous studies 
(Rosenfeldt et al., 2013), and indicates that the lack of accelerated PanIN progression 
following DUSP5 loss, relative to DUSP6/MKP-3 loss, is not due to increased levels of 
apoptosis in DUSP5 knockout pancreata. Overall, we have been unable to identify any 
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changes in the proliferation rate or activation of the senescence and apoptotic 
programmes in KRasG12D-driven PanINs following the loss of DUSP5 or DUSP6/MKP-3. 
Therefore, so far we have been unable to dissect out any significant elements of the 
mechanism(s) by which loss of DUSP6/MKP-3, but not DUSP5, promotes accelerated 
PanIN progression. However, there are many other cellular mechanisms that have been 
shown to promote pancreatic cancer development by which this could be occurring, such 
as autophagy (Rosenfeldt et al., 2013), oxidative stress (Chio et al., 2016; DeNicola et al., 
2011) or the potentiation of an inflammatory response (Pylayeva-Gupta et al., 2012), that 
have not been investigated in this study to date. 
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Figure 5.21 Loss of DUSP5 or DUSP6/MKP-3 has no effect on Ki67 expression in KRas
G12D
-
driven PanINs. Representative images and quantification of Ki67 IHC on age-matched 56 day (A) 
or 100 day (B) pancreata of the indicated cohorts: KRas
LSL-G12D/+
; Ptf1α-cre; DUSP
+/+ 
(KC), KRas
LSL-
G12D/+
; Ptf1α-cre; DUSP5
+/fl 
(KCD5
+/-
), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
fl/fl 
(KCD5
-/-
), KRas
LSL-G12D/+
; 
Ptf1α-cre; DUSP6
+/fl 
(KCD6
+/-
) and KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
fl/fl 
(KCD6
-/-
). Staining was 
quantified as % Ki67 positive cells per PanIN, with up to 25 PanINs scored per section. Median ± 
IQR shown, n = 7 (A), n = 9, 7, 7, 4, 6 (B). Ns = not significant, using a Kruskal-Wallis test and 
Dunn’s post hoc test. Scale, 200μm.  
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Figure 5.22 DUSP5 or DUSP6/MKP-3 loss has no effect on p53 expression in KRas
G12D
-
driven PanINs. Representative images and H-score quantification of p53 IHC on age-matched 56 
day (A) or 100 day (B) pancreata of the indicated cohorts: KRas
LSL-G12D/+
; Ptf1α-cre; DUSP
+/+ 
(KC), 
KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
+/fl 
(KCD5
+/-
), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
fl/fl 
(KCD5
-/-
), 
KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
+/fl 
(KCD6
+/-
) and KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
fl/fl 
(KCD6
-/-
). 
Mean values ± SEM are shown, n = 7 (A), n = 9, 7, 7, 4, 6 (B). Ns = not significant, using one-way 
ANOVA and Bonferroni post hoc test. Scale, 200μm. 
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Figure 5.23 DUSP5 or DUSP6/MKP-3 loss has no effect on p21 expression in KRas
G12D
-
driven PanINs. Representative images and H-score quantification of p21 IHC on age-matched 56 
day (A) or 100 day (B) pancreata of the indicated cohorts: KRas
LSL-G12D/+
; Ptf1α-cre; DUSP
+/+ 
(KC), 
KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
+/fl 
(KCD5
+/-
), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
fl/fl 
(KCD5
-/-
), 
KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
+/fl 
(KCD6
+/-
) and KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
fl/fl 
(KCD6
-/-
). 
Mean values ± SEM are shown, n = 7 (A), n = 9, 7, 7, 4, 6 (B). Ns = not significant, using one-way 
ANOVA and Bonferroni post hoc test. Scale, 200μm. 
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Figure 5.24 Loss of DUSP5 or DUSP6/MKP-3 does not promote cleaved-Caspase3 
expression in KRas
G12D
-driven PanINs. Representative images of cleaved-caspase3 IHC on age-
matched 56 day (A) or 100 day (B) pancreata of the indicated cohorts: KRas
LSL-G12D/+
; Ptf1α-cre; 
DUSP
+/+ 
(KC), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
+/fl 
(KCD5
+/-
), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
fl/fl 
(KCD5
-/-
), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
+/fl 
(KCD6
+/-
) and KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
fl/fl 
(KCD6
-/-
). n = 7 (A), n = 9, 7, 7, 4, 6 (B). 
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5.2.3.4 DUSP5 or DUSP6/MKP-3 loss promotes accelerated mortality 
following KRasG12D-driven pancreatic tumourigenesis  
The loss of either DUSP5 or DUSP6/MKP-3 increases KRasG12D-induced ADM and the 
initiation of PanIN lesions (Fig. 5.9A-C & 5.13A-C), whereas only the loss of DUSP6/MKP-3 
is able to promote accelerated PanIN progression (Fig. 5.13D-E). Therefore, we 
hypothesised that the loss of either MKP could have different effects on the rate of PDAC 
development and associated mortality. To address this hypothesis we performed a 
survival study, whereby cohorts of KRasLSL-G12D/+; Ptf1α-Cre mice which were wild-type, 
heterozygous or homozygous for either DUSP5fl/fl or DUSP6fl/fl alleles were generated. 
These mice were monitored for signs of pancreatic cancer development and removed 
from the study once they became moribund or visibly unwell, generated visible ascites, 
lost over 20% of their maximal body-weight or reached a maximum age of 18 months. 
Consistent with previously published studies, KRasLSL-G12D/+; Ptf1α-Cre (KC) mice had a 
median survival of 467 days (Fig. 5.25A), with the vast majority of mice succumbing 
following the gradual development of invasive PDAC (Fig. 5.25B) (Eser et al., 2013; 
Hingorani et al., 2003). Cohorts, heterozygous for the expression of either DUSP5 or 
DUSP6/MKP-3, in the presence of KRasG12D, predominantly replicated this phenotype, 
with median survivals of 465 and 479 days respectively (Fig. 5.25A-B). In contrast, KRasLSL-
G12D/+; Ptf1α-Cre; DUSP6-/- (KCD6-/-) mice displayed a significant decrease in overall survival 
when compared with KC mice, with a median survival of only 148 days (Fig. 5.25A). The 
majority of KCD6-/- mice presented with PDAC when they showed any cardinal signs of 
having succumbed to illness (Fig. 5.25B), however a small number of mice which were 
removed from the study due to sustained weight loss (-20% of body weight) at a relatively 
young age did not present with PDAC (Fig. 5.26A). The median onset of PDAC in KCD6-/- 
mice was 237 days, relative to 501 days in KC mice, which represents a significant 
decrease in PDAC-free survival (Fig. 5.25B). 
KRasLSL-G12D/+; Ptf1α-Cre; DUSP5-/- (KCD5-/-) mice also displayed a significant decrease in 
total survival compared to KC mice, with the majority of mice succumbing before 150 
days of age and displaying a median survival of 107.5 days (Fig. 5.25A). However, in 
contrast to KC mice, the majority of KCD5-/- mice did not present with PDAC upon 
histological examination (Fig. 5.25B & 5.26A). Of the six KCD5-/- mice, which developed 
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PDAC, two did so at a significantly younger age than any KC mice, but the remaining four 
did not (Fig. 5.25B). Overall, the median survival of the KCD5-/- mice, which presented 
with PDAC was 333.5 days. However, due to the low sample size and lack of any 
prominent phenotype, it is not possible to conclusively determine whether DUSP5 loss is 
promoting the accelerated development of KRasG12D-driven PDAC and resulting in an 
increased mortality. 
The KCD5-/- mice which did not display PDAC succumbed following terminal weight loss at 
a young age, in a similar manner to a much smaller fraction of the KCD6-/- mice. However, 
the penetrance of this phenotype was significantly higher in KCD5-/- mice with around 
80% succumbing before the development of PDAC (Fig. 5.26A). These KCD5-/- “weight-
loss” pancreata characteristically displayed a decreased pancreatic size relative to KC 
pancreata, or even younger KCD5-/- pancreata (Fig. 26B), as well as a complete loss of 
acinar tissue and the majority of their islets of Langerhans (Fig. 5.26C). To determine 
whether this failure to generate PDAC and loss of pancreatic size is due to increased 
apoptosis of developing PanINs, cleaved-Caspase3 expression was assessed in KCD5-/- 
“weight-loss” pancreata. However, these pancreata expressed very low levels of cleaved-
Caspase3, and their PanINs were still proliferative, as demonstrated by Ki67 expression 
(Fig. 26D). Therefore, we hypothesise that due to the increased initiation of ADM and 
PanINs induced following DUSP5 loss in KRasG12D-expressing pancreata (Fig. 5.7-9 & 5.11-
13), a high proportion of KCD5-/- mice do not contain sufficient functional acinar and islet 
tissue to sustain normal homeostasis (Fig. 5.26C). Consequently, this loss of pancreatic 
function could result in the terminal weight loss observed in these mice due to a failure to 
produce digestive enzymes and therefore obtain necessary nutrition, as well as difficulties 
in controlling blood glucose levels. 
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Figure 5.25 Loss of DUSP5 or DUSP6/MKP-3 promotes accelerated KRas
G12D
-driven 
pancreatic tumourigenesis associated mortality. Kaplan-Meier curves showing the Total 
survival (A) and PDAC-free survival (B) of the indicated cohorts. Cohorts consisted of the following 
genotypes: KRas
+/+
; Ptf1α-cre; DUSP
+/+
 (Ptf1α-cre), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP
+/+ 
(KC), 
KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
+/fl 
(KCD5
+/-
), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
fl/fl 
(KCD5
-/-
), 
KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
+/fl 
(KCD6
+/-
) and KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
fl/fl 
(KCD6
-/-
). A) 
Total survival, n = 12, 21, 14, 24, 12, 15 respectively. Log-rank test: KC v KCD5
-/-
 p<0.0001, KC v 
KCD6
-/- 
p<0.0001. B) PDAC-free survival, n = 12, 19, 11, 5, 11, 9 respectively. Log-rank test: KC v 
KCD5
-/-
 p = 0.0033, KC v KCD6
-/- 
p = 0.0140. 
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Figure 5.26 DUSP5 loss, in the presence of KRas
G12D
, promotes complete loss of pancreatic 
acinar tissue and its replacement with pancreatic cancer precursor lesions. A) The 
percentage of mice of the indicated cohorts sacrificed due to ill health, which upon dissection did 
not present with PDAC. Cohorts consisted of the following genotypes: KRas
LSL-G12D/+
; Ptf1α-cre; 
DUSP
+/+ 
(KC, n = 21), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
+/fl 
(KCD5
+/-
, n = 14), KRas
LSL-G12D/+
; Ptf1α-
cre; DUSP5
fl/fl 
(KCD5
-/-
, n =24), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
+/fl 
(KCD6
+/-
, n = 12) and KRas
LSL-
G12D/+
; Ptf1α-cre; DUSP6
fl/fl 
(KCD6
-/-
, n =15). B) Representative images demonstrating the reduction 
in size of KCD5
-/- 
pancreata, relative to KC (Upper panel), and associated quantification of the 
pancreas to body weight ratio of the indicated cohorts (Lower panel). The KCD5
-/-
 WL cohort 
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represents all the DUSP5
-/-
 mice which were in the survival study, but which had to be removed 
following terminal weight-loss, but did not display with PDAC. KO WL cohort median age, 94 days. 
Mean shown, n = 5, 4, 7, 9, 7, 7, 7, 7, 10. C) A representative image of an H&E stained KCD5
-/- 
WL 
cohort pancreata (Upper panel - Scale, 2mm) and quantification of the percentage acinar tissue 
remaining in the pancreata of the indicated 100d age-matched cohorts alongside the KCD5
-/- 
WL 
cohort (Lower panel). Mean shown, n = 9, 7, 7, 10. Ns = not significant, **P < 0.01, ****P < 0.0001, 
using one-way ANOVA and Bonferroni post hoc test. D) Representative images of Ki67 or cleaved-
caspase3 IHC of KCD5
-/- 
WL cohort pancreata compared to positive control tissue. Scale, 200μm. 
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Histological analysis of PDAC tumours revealed a significant increase in the proportion of 
poorly-differentiated tumours in KCD6-/- mice relative all other genotypes (Fig. 5.27A-B). 
Approximately 80% of KCD6-/- tumours displayed a poorly differentiated morphology, 
whereas the majority of KC tumours were well-differentiated (Fig. 5.27B). This indicates 
that DUSP6/MKP-3 loss is highly likely to promote the poorly differentiated phenotype. 
However, DUSP6/MKP-3 loss, in the presence of KRasG12D, is not always sufficient to 
induce a poorly-differentiated phenotype (Fig. 5.27B), indicating that the spontaneous 
acquisition of additional mutations during tumourigenesis is likely to be required to 
generate this outcome. Poorly differentiated PDAC has been associated with a worse 
prognosis and increased proliferative capacity in human patients (Cleary et al., 2004; 
Hruban and Fukushima, 2007). These traits are apparent in our model with KCD6-/- mice, 
which predominantly displayed poorly-differentiated tumours (Fig. 5.27B), also 
demonstrating accelerated PDAC formation and associated mortality (Fig. 5.25B). In 
addition, poorly-differentiated tumours of all genotypes display increased proliferation 
relative to well-differentiated tumours (Fig. 5.27A & C).  
The KRasG12D-driven mouse models of pancreatic cancer display metastasis following a 
long latency, or more rapidly following the mutation of additional tumour suppressors 
including p53 or CDKN2A (Aguirre et al., 2003; Hingorani et al., 2003, 2005). Therefore, to 
determine whether loss of DUSP5 or DUSP6/MKP-3 promote increased metastatic 
potential of KRasG12D-expressing PDAC, liver metastases were identified via gross 
appearance or histological examination and were confirmed to be of pancreatic origin 
through PDX1 expression as determined by IHC (Fig. 5.27D). In contrast to liver 
metastasis, lung metastasis was observed very infrequently, with only two mice out of the 
whole study presenting with lung metastasis. KCD6-/- mice displayed a significant increase 
in the frequency of liver metastasis relative to KC mice, with KCD6+/- mice demonstrating 
an intermediate phenotype (Fig. 5.27D). KCD5-/- mice displayed a marginal increase in 
liver metastasis, relative to KC mice, but this is unlikely to be significant due to the low 
number of KCD5-/- mice, which developed PDAC (Fig. 5.25B & 5.27D). Therefore, loss of 
DUSP6/MKP-3, but not DUSP5, promotes an increased propensity for KRasG12D-driven 
pancreatic tumours to metastasise. 
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In summary, here we show that pancreas-specific DUSP6/MKP-3 loss, in the presence of 
KRasG12D, can promote accelerated PDAC development and mortality (Fig. 5.25B). KCD6-/- 
PDAC is characterised by a high frequency of highly proliferative, poorly-differentiated 
tumours (Fig. 5.27A-C), which display an elevated metastatic potential relative to KC 
tumours (Fig. 5.27D). In contrast, although KCD5-/- mice displayed decreased total survival 
relative to KC mice, this was primarily not due to PDAC development (Fig. 5.25). Instead, 
KCD5-/- mice developed a more extensive pancreatic atrophy and ADM with a very high 
burden of pre-neoplastic lesions, this most likely results in a loss of normal pancreatic 
function and consequently significant weight-loss (Fig. 5.26). KCD5-/- mice did not display 
an increased proportion of poorly-differentiated tumours or any evidence of increased 
metastatic potential relative to KC tumours (Fig. 5.27). 
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Figure 5.27 DUSP6/MKP-3 loss, in the presence of KRas
G12D
, promotes the development of 
poorly-differentiated, highly proliferative and frequently metastatic PDAC. A) Representative 
images of H&E staining and Cytokeratin-19 (CK19) or Ki67 IHC of either well-differentiated or 
poorly-differentiated PDAC tissue, taken from tumours arising from KRas
LSL-G12D/+
 and Ptf1α-cre 
(KC) expressing mice which were either DUSP6
+/+
 (KC) or DUSP6
fl/fl
 (KCD6
-/-
) respectively. Scale, 
500μm. B) Quantification of the percentage of mice which displayed poorly-differentiated PDAC of 
the indicated cohorts. Cohorts consisted of the following genotypes: KRas
LSL-G12D/+
; Ptf1α-cre; 
DUSP
+/+ 
(KC, n = 18), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP5
+/fl 
(KCD5
+/-
, n = 9), KRas
LSL-G12D/+
; Ptf1α-
cre; DUSP5
fl/fl 
(KCD5
-/-
, n =5), KRas
LSL-G12D/+
; Ptf1α-cre; DUSP6
+/fl 
(KCD6
+/-
, n = 7) and KRas
LSL-
G12D/+
; Ptf1α-cre; DUSP6
fl/fl 
(KCD6
-/-
, n =9). C) Quantification of the percentage Ki67-positive tumour 
cells in either well- or poorly-differentiated tumours of the indicated cohorts. Mean values ± SEM 
are shown, n = 6 tumours per cohort. D) Representative images of H&E staining and PDX1 IHC of 
liver metastases presented by KRas
LSL-G12D/+
 and Ptf1α-cre (KC) expressing mice (Left panel). 
Quantification of the percentage of mice presenting with PDAC which also displayed associated 
liver metastasis of the indicated cohorts, n = 18, 9, 5, 7, 8 respectively (Right panel).  
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5.3 Discussion 
DUSP5 and DUSP6/MKP-3 are ERK-specific MKPs, which are induced by ERK activity as 
negative feedback regulators (Ekerot et al., 2008; Groom et al., 1996; Kucharska et al., 
2009; Mandl et al., 2005; Mourey et al., 1996), therefore these proteins have the 
potential to modulate ERK activity following oncogenic activation of the Ras-ERK pathway. 
Furthermore, DUSP5 and DUSP6/MKP-3 display differential localisation, with DUSP5 
localised to the nucleus (Mandl et al., 2005) and DUSP6/MKP-3 to the cytoplasm (Groom 
et al., 1996; Mourey et al., 1996), therefore it is possible that loss of these MKPs could 
induce distinct changes in the spatial activity of ERK and consequently distinct 
phenotypes in cancers driven by oncogenic activation of the Ras-ERK pathway. Here we 
show that DUSP5 or DUSP6/MKP-3 ablation display differing abilities to modulate the 
oncogenic potential of mutant KRasG12D in mouse models of pancreatic cancer.  
Utilising the KRasLSL-G12D/+; Ptf1α-Cre (KC) model of pancreatic cancer (Hingorani et al., 
2003) we show that the loss of DUSP6/MKP-3 promotes the increased initiation of 
KRasG12D-driven ADM and PanIN lesions as well as the accelerated progression of PanINs 
towards higher more dysplastic grades (Fig. 5.7-9 & 5.11-13). Furthermore, KCD6-/- mice 
displayed accelerated mortality, compared to KC mice, due to the rapid formation of 
PDAC and a high frequency of liver metastasis (Fig. 5.25 & 5.27C). PDAC tumours arising 
from KCD6-/- mice are also characterised by a higher proportion of highly proliferative, 
poorly differentiated tumours than their KC counterparts (Fig. 5.27A-B).  
The loss of DUSP5 also promotes the increased initiation of KRasG12D-driven ADM and 
PanINs (Fig. 5.7-9 & 5.11-13). However, in contrast to the loss of DUSP6/MKP-3, DUSP5 
loss does not promote the accelerated progression of PanINs (Fig. 5.7-9 & 5.11-13), or a 
high frequency of poorly differentiated tumours or liver metastasis (Fig. 5.27). 
Furthermore, although some KCD5-/- mice developed PDAC at a significantly younger age 
than KC mice, we were unable to conclusively determine whether DUSP5 loss promotes 
accelerated PDAC development due to the low number of mice surviving until PDAC 
formation (Fig. 5.25). This was because KCD5-/- mice displayed accelerated mortality 
following to terminal weight-loss, but with the absence of PDAC formation (Fig. 5.25 & 
5.26A). Such mice displayed an extremely high burden of ADM and PanIN lesions, 
resulting in the complete loss of pancreatic acinar and islet tissue (Fig. 5.26C). Therefore, 
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we hypothesise that these mice became extremely ill due to a lack of normal pancreatic 
function induced by their high burden of benign neoplastic lesions. Some KCD6-/- mice 
also displayed this phenotype, however it occurred with a much lower penetrance than in 
KCD5-/- mice (Fig. 5.25 & 5.26A), perhaps reflecting a stronger promotion of tumour 
initiation following DUSP5 loss relative to DUSP6/MKP-3 loss in KRasG12D-expressing 
pancreata. 
These data demonstrating that the loss of DUSP6/MKP-3 promotes the accelerated 
initiation and development of invasive, metastatic PDAC in KRasG12D-driven mouse models 
of pancreatic cancer indicate that DUSP6/MKP-3 acts as a tumour suppressor in 
pancreatic cancer development (Fig. 5.7-13, 5.25 & 5.27). This conclusion is consistent 
with previous studies in human pancreatic tumour samples which have demonstrated 
that DUSP6/MKP-3 expression is selectively downregulated in invasive carcinomas, but 
not the PanIN precursors, via either aberrant hypermethylation or genomic LOH 
(Furukawa et al., 2003, 2005; Kimura et al., 1996; Xu et al., 2005). Therefore, these 
studies proposed that DUSP6/MKP-3 is tumour suppressor in pancreatic cancer as the 
downregulation of its expression is selected for during pancreatic tumourigenesis, 
implying that the loss of this protein confers a selective advantage to the tumour 
(Furukawa et al., 2003, 2005, 2006). Additionally, it was hypothesised that DUSP6/MKP-3 
loss might be a key determinant to enable the progression from PanIN to invasive 
carcinoma, as DUSP6/MKP-3 loss correlated with this aspect of tumour progression 
(Furukawa et al., 2003, 2005, 2006). Furthermore, these studies identified that in human 
PDAC tissue samples DUSP6/MKP-3 loss correlated with tumours displaying a poorly-
differentiated morphology (Furukawa et al., 2003, 2005; Xu et al., 2005). This is in 
agreement with our data, which demonstrates that DUSP6/MKP-3 loss in combination 
with KRasG12D expression promotes a significant increase in the proportion of poorly-
differentiated tumours relative to KRasG12D expression alone (Fig. 5.27A-B).  
It would be interesting to determine whether the KC tumours which displayed a poorly-
differentiated morphology had autonomously lost DUSP6/MKP-3 expression. If this was 
the case this would provide strong evidence that loss of DUSP6/MKP-3 expression is an 
important factor in the development of poorly-differentiated PDAC. However, 
unfortunately in our hands the most specific DUSP6/MKP-3 antibody available did not 
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specifically stain murine DUSP6/MKP-3 wild-type pancreatic tissue when used for IHC (Fig. 
5.17B). This technical issue also prevented the investigation into whether KRasG12D-
expressing PanINs display upregulated DUSP6/MKP-3 expression as previously 
demonstrated in human pancreatic cancer tissue (Furukawa et al., 2005) and indicated by 
our studies in KRasG12D-expressing MEFs (Fig. 4.3-4 & 4.8-9). In a similar manner to 
DUSP6/MKP-3, the activation of KRasG12D expression induced DUSP5 expression in MEFs. 
However, we encountered a similar problem attempting to utilise a DUSP5 antibody in 
IHC (Fig. 5.17A), so could not effectively investigate whether DUSP5 induction occurred in 
KRasG12D-driven PanINs. Analysis of DUSP5 and DUSP6/MKP-3 mRNA expression from 
KRasG12D expressing pancreata did demonstrate marginal increases in DUSP5 and 
DUSP6/MKP-3 expression (Fig. 5.17C). However, as mentioned previously this approach 
was very imprecise as it was not possible to determine what proportion of the tissue 
utilised for mRNA isolation had undergone pancreatic tumourigenesis. To resolve these 
problems and to investigate DUSP5 and DUSP6/MKP-3 expression in PanINs and tumour 
samples, we have formed a collaboration to have DUSP5 and DUSP6/MKP-3 mRNA 
expression levels investigated in pancreatic tissue utilising an in situ hybridisation based 
approach (RNAscope - Advanced Cell Diagnostics). 
DUSP5 ablation promoted the increased or accelerated initiation of ADM and PanIN 
lesions in KRasG12D-expressing pancreata (Fig. 5.7-9 & 5.11-13). This result mirrors the 
phenotype observed following DMBA/TPA-induced skin carcinogenesis, where the loss of 
DUSP5 induced an increased burden of skin papillomas, which are benign neoplasia’s like 
PanINs, relative to wild-type mice (Fig. 3.1) (Rushworth et al., 2014). However in contrast 
to skin carcinogenesis (Fig. 3.14), the increase in ADM and PanIN initiation observed 
following DUSP5 ablation is not mediated by increased SerpinB2 expression as this 
phenotype cannot be rescued by SerpinB2 ablation (Fig. 5.14-16). This is potentially due 
to the significantly lower level of SerpinB2 expression in the pancreas relative to the skin 
(Fig. 5.14A), meaning that although its expression is increased following the loss of 
DUSP5, SerpinB2 might not be expressed at a high enough level to have a significant role 
in modulating tumourigenesis. Alternatively, as different tissues are known to be 
predisposed to the development of cancer following the mutation of characteristic driver 
genes and processes (Greenman et al., 2007), SerpinB2 might not have a role in the 
processes which are deregulated during the development of pancreatic cancer. 
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The majority of KCD5-/- mice became ill prior to the development of PDAC (Fig. 5.25). We 
hypothesise this to be due to the extreme extent of pancreatic transformation and the 
high burden of ADM and PanIN lesions formed in KCD5-/- pancreata, resulting in a loss of 
pancreatic function and severe weight-loss due to malnutrition (Fig. 5.26). However, this 
phenotype prevented us from drawing reliable conclusions as to whether the loss of 
DUSP5 accelerates the development of PDAC tumours following KRasG12D-driven 
tumourigenesis or whether DUSP5 loss affects the tumour morphology or metastatic 
frequency, as observed following DUSP6/MKP-3 loss (Fig. 5.27). We hypothesise that 
DUSP5 loss would be likely to cause accelerated PDAC development in this KC model, as 
by increasing the initiation of ADM and PanINs DUSP5 loss would create a larger pool of 
precursor lesions, therefore increasing the probability that one of these lesions will 
acquire the additional mutational burden to develop into an invasive tumour. The 
occurrence of PDAC in two KCD5-/- mice at a significantly younger age than any KC mice is 
potential evidence supporting this hypothesis (Fig. 5.25B). However, alternatively DUSP5 
loss could be promoting the initiation of KRasG12D-driven pancreatic tumourigenesis, but 
subsequently delaying progression to invasive tumours. This could occur through the 
induction of cellular senescence, which has been shown to be a consequence of 
hyperactive ERK signalling in vitro and in vivo (Cisowski et al., 2015; Deschênes-Simard et 
al., 2013; Meloche and Pouysségur, 2007). In support of this theory KCD5-/- pancreata 
display elevated nuclear p-ERK expression (Fig. 5.18A), and although these pancreata did 
not display increased expression of senescence markers (Fig. 5.22A & 5.23A), only 
markers from the p53 pathway were investigated. Therefore, the increased induction of 
senescence in KCD5-/- pancreata via another mechanism cannot be discounted. 
To investigate whether the loss of DUSP5 accelerates the development of KRasG12D-driven 
pancreatic tumours we plan to have the KRasLSL-G12D/+; PDX1-Cre driven model repeated in 
a sterile animal facility. This should prevent the excessive penetrance of intussusceptions 
we observed with this model (Fig. 5.2). Furthermore, the PDX1-Cre allele has been shown 
to promote stochastic Cre expression across the pancreas, whereas the Ptf1α-Cre allele 
induces uniform expression throughout the pancreas (Hingorani et al., 2003). Therefore, 
use of the PDX1-Cre allele should ensure that KRasLSL-G12D/+; PDX1-Cre; DUSP5fl/fl mice do 
not demonstrate the total loss of acinar tissue apparent in the Ptf1α-Cre driven KCD5-/- 
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mice and therefore ensure that the majority of PDX1-Cre driven animals progress to 
develop PDAC. 
Recently, we have obtained and validated a new DUSP5fl/fl allele which is a true 
conditional allele (Fig. 4.19A), demonstrating wild-type levels of DUSP5 protein prior to 
Cre-mediated excision. Therefore, the second PDX1-Cre driven cohort will utilise this 
allele and a second Ptf1α-Cre driven 56 day age-matched cohort will be generated. This 
additional cohort containing the true conditional allele will be used to validate that the 
initiation phenotype observed following loss of DUSP5 (Fig. 5.7-5.9) is due to the cell 
autonomous effects of DUSP5 ablation in the pancreas, rather than the effects of 
effectively a whole body DUSP5 knockout. It is essential to validate whether the effects of 
DUSP5 loss on KRasG12D-driven pancreatic tumourigenesis are cell autonomous because 
pancreatic cancer development is well established to be strongly regulated by the 
inflammatory response (Guerra et al., 2007, 2011; Lee and Bar-Sagi, 2010; Pylayeva-
Gupta et al., 2012). The importance of the inflammatory response in pancreatic cancer 
development is highlighted by the fact that the induction of KRasG12D expression alone is 
not sufficient to induce pancreatic cancer development in adult mice, however KRasG12D 
expression coupled with caerulein-induced chronic pancreatitis results in widespread 
PanIN formation and the development of PDAC (Guerra et al., 2007). Furthermore, in 
humans chronic pancreatitis, often induced by excessive alcohol consumption, is a major 
risk factor of pancreatic cancer, increasing the risk by more than tenfold (Kleeff et al., 
2016). 
The genetic deletion of multiple MKPs has been shown to generate immune phenotypes 
(Jeffrey et al., 2007), with DUSP5 ablation resulting in prolonged eosinophil survival and 
increased effector function following helminth infection (Holmes et al., 2015). An earlier 
study utilising transgenic mice overexpressing DUSP5 demonstrated autoimmune 
symptoms, an inhibition of T-cell development and decreased T-cell proliferation 
(Kovanen et al., 2008). However, subsequent studies in DUSP5 knockout mice do not 
show any DUSP5-dependent effects on T-cell, B-cell, monocyte or natural killer cell 
development, or cytokine or chemokine synthesis in LPS-treated macrophages (Holmes et 
al., 2015; Rushworth et al., 2014). Furthermore, in the DMBA/TPA-induced model of skin 
carcinogenesis DUSP5 loss did not alter the infiltration of immune effector cells into skin 
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papillomas (Rushworth et al., 2014). These data indicate it is unlikely that the effects of 
DUSP5 loss on KRasG12D-driven pancreatic tumourigenesis could be driven by the potential 
effects of DUSP5 loss on the development or function of immune cells. However, this 
question should be conclusively addressed by the generation of KCD5-/- mice expressing 
the truly conditional DUSP5fl/fl allele. 
Cell autonomous effects of DUSP5 or DUSP6/MKP-3 loss in the pancreas could influence 
heterocellular signalling between KRasG12D-expressing tumour cells and either stromal 
cells or infiltrating immune cells (Tape et al., 2016). Such effects could modulate the 
inflammatory response following KRasG12D expression in the pancreas and thereby 
mediate the phenotypes observed following the loss of either DUSP5 or DUSP6/MKP-3. 
Therefore, to investigate whether the inflammatory response is altered in KRasG12D-driven 
pancreatic tumourigenesis following the loss of either DUSP5 or DUSP6/MKP-3 
expression, tissue sections from the age-matched cohorts generated have been sent to a 
collaborator for IHC staining for a panel of immune cell markers.  
As well as investigating whether inflammatory responses play a role in the phenotypes 
driven by loss of either DUSP5 or DUSP6/MKP-3 in KRasG12D-expressing pancreata, a range 
of further mechanistic studies are required to further characterise the development of 
these phenotypes. Such studies could involve, treating the KCD5-/- and KCD6-/- cohorts 
with a MEK inhibitor to enable confirmation that the effects of DUSP5 or DUSP6/MKP-3 
loss occur through the ERK pathway, as predicted by their known biochemical features 
(Ekerot et al., 2008; Groom et al., 1996; Kucharska et al., 2009; Mandl et al., 2005; 
Mourey et al., 1996). If the effects of DUSP5 or DUSP6/MKP-3 loss occur in an ERK-
dependent manner MEK inhibitor treatment would be expected to reverse the 
sensitisation of KCD5-/- and KCD6-/- mice to KRasG12D-driven pancreatic tumourigenesis. 
Multiple studies have proposed non-MAPK substrates for MKPs (Caunt and Keyse, 2013), 
including a potential role for DUSP6/MKP-3 in dephosphorylating the transcription factor 
forkhead box O1 (FOXO1) (Wu et al., 2010). These non-MAPK substrates and mechanisms 
of action for MKPs are fairly controversial, however it is still essential to validate that the 
phenotypic effects of DUSP5 or DUSP6/MKP-3 loss occur in an ERK-dependent manner. 
To investigate the mechanism enabling the increased initiation of KRasG12D-driven 
pancreatic tumourigenesis following DUSP5 or DUSP6/MKP-3 ablation acinar explant 
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experiments could be performed. Such experiments involve the 3D-culture of pancreatic 
acinar tissue followed by the induction of ADM via TGFα or EGF treatment of wild-type 
acinar tissue or through the culture of KRasG12D-expressing acinar tissue (Chen et al., 
2015; Shi et al., 2013). Alternatively, acinar tissue can be cultured containing the KRASLSL-
G12D/+ allele and any conditional genes of interest, then ADM can be induced through 
infection with adenoviral or lentiviral Cre systems (Liou et al., 2015). Such systems enable 
the quantification of duct formation via ADM in vitro, enabling examination of the effect 
of loss of a gene of interest, such as DUSP5 or DUSP6/MKP-3, on the propensity for ADM 
to occur. Furthermore, as in vitro systems, they allow simple manipulation via siRNA (Liou 
et al., 2015) or inhibitor treatment (Shi et al., 2013), making them an effective system to 
investigate the biochemical mechanism by which alteration of a gene of interest can 
induce changes in the propensity for ADM to occur. One potential avenue, which is 
worthy of further investigation using such an approach would be the potential 
upregulation of Sox9 following DUSP5 loss. Sox9 upregulation was detected following 
KRasG12D expression and DUSP5 ablation in MEFs (Fig. 4.13), and Sox9 is a transcription 
factor which induces a ductal fate in the pancreas which has been shown to be essential 
for KRasG12D-mediated ADM and PanIN induction (Kopp et al., 2012). 
PDAC tumour cell lines were generated and tumour mRNA isolated from mice that 
developed PDAC as part of the survival study during this project. These should form useful 
resources to investigate the mechanism by which the loss of DUSP6/MKP-3 promotes 
accelerated mortality due to PDAC (Fig. 5.25) and an increased metastatic propensity (Fig. 
5.27C) following KRasG12D-driven pancreatic tumourigenesis. KC and KCD6-/- tumour cell 
lines could be characterised and the migratory or invasive capacity of these cell lines 
investigated in vitro. If any phenotypes are observed these cell lines could then be utilised 
to elucidate the molecular mechanisms driving such processes. As we have yet to identify 
any ERK-target proteins which are specifically regulated upon the loss of DUSP6, 
proteomic and phospho-proteomic approaches might enable us to determine the 
proteins which are most strongly differentially regulated in this scenario. Furthermore, 
RNAseq or microarray analyses could be performed utilising the tumour mRNA or mRNA 
isolated from our pancreatic cancer cell lines to identify any significant differences in the 
activation of specific signalling networks or cellular processes across the KC, KCD5-/- and 
KCD6-/- cohorts. This might identify key processes, which are altered following the loss of 
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DUSP5 or DUSP6/MKP-3, thereby providing a starting point for more detailed mechanistic 
studies.   
These mechanistic studies could be further advanced through the generation of 3D 
organoid cultures of pancreatic tissue. Such approaches utilise culture conditions 
optimised to promote cells dissociated from primary tissue to self-organize into 
structures which mimic the 3D architecture of the organ from which they were derived 
(Baker et al., 2016). Organoid cultures have similar advantages over murine models to 2D 
cell culture approaches in that they allow simpler manipulation of the experimental 
system, and an increased experimental throughput. However, 2D cell culture approaches 
do not faithfully represent in vivo tumour biology. A striking demonstration of this being 
the fact that pancreatic cancer cell lines display a significant difference in gene expression 
in comparison to their parental primary PDAC following their isolation and culture in vitro 
(Gadaleta et al., 2011; Stein et al., 2004). In contrast, organoid cultures recapitulate many 
more features of the tumour environment including, a 3D organisation, continual cell-cell 
contact and interactions with stromal cells and the ECM (Baker et al., 2016). 
In summary, here we have shown that the loss of DUSP6/MKP-3 promotes the increased 
initiation and accelerated progression of KRasG12D-driven PanINs, resulting in the 
accelerated development PDAC, which displayed an increased propensity to metastasise. 
In contrast, although the loss of DUSP5 also promoted the increased initiation of 
KRasG12D-driven ADM and PanINs, it did not induce accelerated PanIN progression and 
had no influence on the frequency of metastasis. Furthermore, the rate of PDAC 
development could not be reliably assessed following loss of DUSP5 in the presence of 
KRasG12D expression because such mice carried an excessive burden of PanINs, resulting in 
the majority of these mice becoming ill prior to the development of PDAC. These 
phenotypic differences could be due to the differential subcellular localisation of DUSP5 
and DUSP6/MKP-3, enabling their loss to modulate the activity of ERK in unique ways. 
However, much of the mechanistic detail underpinning how loss of DUSP5 or 
DUSP6/MKP-3 promotes changes in KRasG12D-driven pancreatic tumourigenesis is still 
poorly understood and is the basis of ongoing work. 
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Chapter 6 Concluding Remarks 
The work presented in this thesis comprises some of the first evidence from in vivo 
genetic knockout studies that DUSP5 plays a functional role in cancer development. 
Following up our studies in the mouse model of DMBA/TPA-driven skin carcinogenesis we 
have analysed changes in nuclear ERK activation and gene expression, which give 
mechanistic insight into the increased tumour sensitivity of mice lacking DUSP5 in the 
latter model.  The potential role of DUSP5 as a tumour suppressor is also reinforced by 
our studies of KRasG12D-driven pancreatic cancer where DUSP5 acts as a tumour 
suppressor to restrain the initiation of benign pre-neoplastic lesions. In MEFs following 
acute Ras-ERK pathway stimulation DUSP5 performs a non-redundant role in the 
regulation of nuclear ERK activity and ERK-dependent gene expression. Therefore, despite 
the ability of ERK to shuttle rapidly between the cytoplasm and the nucleus, MKPs can 
mediate the precise control of ERK activity in specific subcellular compartments. 
In MEFs expressing endogenous levels of mutant KRasG12D many ERK-targeting MKPs 
including both DUSP5 and DUSP6/MKP-3 are upregulated, indicating that these proteins 
are involved in the negative feedback response which constrains ERK activity following 
constitutive pathway activation. Furthermore, in a mouse model of mutant KRas-driven 
pancreatic cancer we demonstrate that DUSP6/MKP-3 functions as a potent tumour 
suppressor, restraining the initiation, malignant progression and metastatic potential of 
these tumours. However, in contrast to the tumour suppressive role observed in 
KRasG12D-driven pancreatic cancer, the only other in vivo genetic model investigating the 
role of DUSP6/MKP-3 in cancer demonstrated that DUSP6/MKP-3 expression was 
essential for oncogenic transformation in NRasG12D-driven models for pre-B acute 
lymphoblastic leukemia (ALL) (Shojaee et al., 2015). Together these contrasting reports 
demonstrate that MKPs may exhibit differential roles in cancer development, indicating 
that the ways in which MKPs influence cancer-related endpoints are likely to be context-
dependent and influenced by factors including the tissue type and/or nature of the 
driving oncogene/s involved in the initiation and progression of particular cancer types.  
Together this work demonstrates that MKPs play an important role in modulating the 
oncogenic potential of ERK signalling in mutant Ras-driven cancers of different tissues, 
suggesting that these enzymes might have a wider role across tumours displaying Ras-ERK 
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pathway activation. Further studies are required to extend these findings into models of 
additional cancer types, driven by a variety of oncogenes and to elucidate the 
mechanisms by which the loss of individual MKPs are able to promote such distinct 
phenotypic consequences for cancer progression. 
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